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CHAPTER 1
General introduction and outline of thesis.
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Irresectable hepatic malignancy
Patients with irresectable hepatic malignancies remain an intriguing clinical
problem. Hepatocellular carcinoma (HCC) is the most common primary hepatic
malignancy and approximately one million individuals will develop this tumor
per year. The incidence of these tumors varies widely worldwide, being most
common in the Far East [1]. Recent advances in the early detection of these
tumors have improved the prognosis and long-term survival has been reported in
patients with small, encapsulated malignancy [2-4]. Nevertheless, the overall
prognosis of HCC remains poor and usually expressed in months rather than
years [5, 6]
Metastatic disease from colorectal cancer is the most common hepatic
malignancy in the Western countries. Most frequently, the liver is the site of
dissemination with many other sites in the body (lung, brain, bone). On the other
hand, in as many as 30 % of patients the liver is the sole site of initial cancer
recurrence [7]. If left untreated the mean survival rate in these patients is
approximately 6 to 9 months. In contrast, 5-year survival rates up to 35 % have
been reported for patients amendable to resection [8-11]. Unfortunately in the
majority (75 %) of the patients that have been diagnosed with colorectal cancer
metastases confined only to the liver, these metastases are considered
unresectable. These patients are eligible for other therapies.
Systemic chemotherapy
The effect of systemic chemotherapy on hepatic metastases depends on the
primary site of metastatic disease and the dose of agents used. Since certain
tumors (e.g. breast carcinoma) are responsive to chemotherapy, even when
hepatic metastases develop, systemic chemotherapy may be the appropriate
treatment. For patients with advanced colorectal carcinoma systemic
chemotherapy with 5-fluorouracil (5-FU) based protocols has been the standard
therapy. These therapies produce an average response rate of 20 to 30 % with
median survival times of 6.5 to 13.5 months, if 5-FU plus folic acid (FA) at
conventional doses is used for systemic (iv) therapy [12, 13]. Generally, with
systemic combination therapy for hepatic metastases it is not likely to obtain
response rates higher than 30 % with only minimal effect on survival and in most
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cases this is possible only with considerable systemic toxicity [14]. Most patients
eventually die due to intrahepatic progression and/or development and
progression of extrahepatic disease. In order to gain improved control of
intrahepatic disease and to reduce systemic toxicity of the applied therapy,
locoregional therapies have been developed.
Locoregional chemotherapy
Common causes for failure of systemic chemotherapy are low concentrations at
the tumor site and dose limiting systemic toxicity. The rationale behind regional
administration of chemotherapeutic agents is based on the concept of achieving
high local concentrations while minimizing systemic drug exposure and thus
reducing dose-limiting side effects. The importance of achieving high local drug
levels is based on the steep dose-response curves that have been demonstrated for
both sensitive as well as resistant cancer cells. For the latter even extremely high
levels are required in order to destroy them adequately [15, 16].
Although the best approach for regional infusion of the liver is still unknown,
hepatic artery infusion (HAI) is the single most widely applied form. The
rationale for the use of HAI is based on the fact that hepatic tumors obtain most
of their blood supply from the hepatic artery. [17, 18]. Furthermore, on first
passage through the liver, a significant amount of the anticancer drug could be
extracted with subsequent reduced systemic drug levels with reduced systemic
toxicity. This has indeed been firmly demonstrated in HAI with FUDR [19].
However, with high local drug levels, there is a greater risk of regional damage to
normal hepatic tissue, as well as cancer cells [20 ]. Only a few completed
randomized studies have been reported in patients with unresectable colorectal
metastases confined to the liver. Although response rates of 50 to 55 % of HAI
using either 5-FU, FUDR or fluoropyrimidines with or without other drug have
been demonstrated, the median survival time of 11 to 14 months in most of these
studies did not exceed the 11 months of 5-FU iv therapy that showed response
rates of 11 to 20 % [21].
Therefore, with HAI, compared to systemic chemotherapy, improved response
rates are achieved but convincing evidence of improved survival is lacking.
Despite high extraction ratios in HAI, systemic exposure and toxicity cannot be
fully eliminated and has been reported the dose-limiting factor. In order to further
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increase (maximize) locoregional drug concentrations in the liver and at the same
time completely shielding the patient from systemic toxicity isolated hepatic
perfusion has been developed.
Isolated Hepatic Perfusion
In isolated hepatic perfusion (IHP) the vascular bed of the liver is completely
isolated and perfused with a recirculating circuit. In short, an extracorporeal veno-
venous bypass (VVB) circuit (pump aided) is created to shunt mesenteric, renal,
and lower extremity blood around the liver to the heart. Next, inflow catheters are
placed in the portal vein and/or hepatic artery, and an outflow catheter in the
infrahepatic inferior caval vein. These catheters are connected to a heart-lung-
machine, and the vascular isolation is completed by clamping the suprahepatic
inferior caval vein and the suprarenal inferior caval vein. The liver is then perfused
with a normo- or hyperthermic (> 38 °C) perfusate consisting of a mixture of saline
and erythrocytes, to which drugs can be added.  After the perfusion, the liver is
washed thoroughly with a mixture of saline and Macrodex, decannulated, and the
vascular continuity restored.
Due to the complete vascular isolation extremely high local drug concentrations
can be achieved while on the same minimizing systemic exposure and thus
toxicity. IHP is a means to further improve selectivity of administration of
antitumor agents to the liver as compared with HAI. IHP with 5-FU in rats and
pigs resulted in significantly higher 5-FU concentrations in liver tissue of animals
in the higher dose groups [22]. When mitomycin C (MMC) was administered by
IHP a 400% higher dose could be safely administered and resulted in a five times
higher tumor tissue concentration as compared with HAI [23]. These data suggest
that five times the HAI dose can be administered with IHP in order to achieve
similar systemic drug levels. Therefore, IHP is a method to maximize selective
administration of antitumor agents to the liver while maintaining very low
systemic drug concentrations. As is true in HAI, it is clear from experimental data
that in the IHP setting hepatic rather than systemic toxicity is dose limiting [22,
23].
Successful clinical experience with IHP is limited but promising. Thus far,
several studies have been published with various chemotherapeutical or biological
agents e.g. Nitrogen Mustard, 5-FU, MMC, and melphalan. Reported hepatic
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toxicity is mild and transient. Furthermore, data thus far have made it clear that
IHP can bring about 3 - 5 years of disease-free survival [24, 25]. More recently,
tumor necrosis factor α (TNF) has come into focus as a result of the successes
achieved in isolated limb perfusions (ILP) with this cytokine in combination with
melphalan. Response rates greater than 80% have been observed in the treatment
of irresectable extremity soft tissue sarcomas by ILP with TNF plus melphalan.
This has recently led, in Europe, to the approval and registration of TNF for the
treatment of locally advanced extremity soft tissue sarcomas by ILP with high
dose TNF in combination with melphalan [26, 27].
Tumor Necrosis Factor α
TNF molecule
The structure of the human TNF protein is a homotrimeric complex of 52 kD that
is biologically active [28]. TNF is produced by many cells but mainly by activated
monocytes/macrophages [29-31]. Its expression and regulation is affected by a
variety of other cytokines, as interferon-γ (IFN), interleukines (IL-1, IL-2, IL-12),
GM-CSF, PAF as well as TNF itself [31]. TNF has pleiotropic effects that may
depend on its concentration. It has been shown to have vasculotoxic effects at
high concentrations while at low concentrations it may promote DNA synthesis
and angiogenesis [32, 33]. High concentrations of TNF have antitumor activity in
certain murine tumor models [34].
The effects of TNF are exerted by binding to two types of receptor, with
molecular weights of 55 kD (TNF-R1) and 75 kD (TNF-R2) respectively, which
are present on nearly all mammalian cells [29, 35, 36]. Apart from these two
distinct types of receptors, also soluble forms consisting of the extracellular
domain of the receptors have been described [37, 38]. The number of receptors on
the cell does not predict the magnitude of response to TNF but upregulation (IFN)
and downregulation (IL-1) of TNF receptors have been reported [39].
Clinical experience with TNF
The introduction of TNF in clinical trials commenced with systemic
administration. Phase I/II trials in cancer patients demonstrated that dose limiting
toxicity was already observed at dose levels too low to mediate anticancer effects.
[40-42]. Locoregional administration of TNF seemed the only option for
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successful application of TNF. Intralesional and intraperitoneal administration
were reported to increase response rates somewhat but proved no essential
improvement of the effective use of TNF [43-45]. This all changed when TNF
based isolated limb perfusions (ILP) in melanoma and in soft tissue sarcoma
patients were reported to yield impressive response rates [26, 27, 46]. This led to
the exploration of its use in the isolated organ perfusion setting. It was attempted
in lungs, kidneys as well as in livers [47-51].
TNF in combination with chemotherapeutics
TNF may potentate the effects of chemotherapy in various ways. The tumor
associated vasculature (TAV) responds to TNF with rounding of the endothelial
cells resulting in increased gaps, allowing easy passage of soluble materials and
even cells [52, 53]. Moreover, i.v. injection of TNF in human melanoma
xenograft-bearing mice resulted in significant reduction of the interstitial fluid
pressure of the tumors [54]. This phenomenon could increase localization of
cytotoxic drugs in the tumor interstitium and thus explain improved tumor
response. Secondly, experimental and clinical results demonstrating massive
destruction of the endothelial cells, as has been shown in vitro and on angiograms
in patients after ILP, suggest that the TAV is the primary target for TNF and
therefore that destruction of endothelial lining might be responsible for the
antitumor response [46, 55, 56]. This process is accompanied by inflammatory
responses and seemed to be dependent on infiltrating leucocytes [57]. Coagulative
and hemorrhagic necrosis and destruction of the endothelial lining was also seen
when TNF was used as a single agent in ILP, however without significant effect
on tumor growth in rats. This indicates hat direct effects of TNF are most likely
playing a minor role in its antitumor capacity [58, 59].
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Outline of the thesis
A large animal model for IHP was developed in pigs in which the technique could
be mastered and the toxicity of the combination TNF and melphalan evaluated.
For this purpose, a modification of the original IHP technique was developed.
The results of IHP in this model with the combination TNF and melphalan or
melphalan alone are described in chapter 2.
Following these experiments a phase I study of IHP with TNF and melphalan was
started in nine patients with colorectal metastases confined to the liver. In chapter
3, clinical and pharmacological results are presented of this phase I dose-
escalation study.
It could be speculated that intrahepatic administration of TNF induces significant
hepatotoxicity, as Kupffer cells are known to release various cytokines in
response to TNF exposure. Therefore, we were interested in the effects of IHP
with TNF on hepatic function, secondary cytokine production and hepatic acute
phase response (APR). In chapter 4 the APR in patients during and after IHP with
TNF and melphalan or melphalan alone was evaluated regarding the levels and
time dependency of TNF, IL-6, and the acute phase proteins C-reactive protein
(CRP), α1-acidglycoprotein, α1-antitrypsin, and transferrin. It could be
speculated that a similar TNF induced APR could be shown in patients with
systemic leakage of TNF during isolated limb perfusion with TNF and melphalan.
In chapter 5, we investigated the APR pattern during and after ILP in patients
with TNF leakage (> 10 %) and compared these results with patients who
underwent an uncomplicated ILP.
TNF mediates its multiple effects by binding to specific high-affinity cell surface
receptors. Two distinct TNF receptors (TNFR-p55 or type I and TNFR-p75 or
type II) have been identified. These receptors do not only exist as cell surface
membrane proteins but also as soluble proteins. Evidence indicates that these
soluble TNF receptors (sTNFRs) are derived by proteolytic cleavage from the cell
surface from a variety of cells. Since sTNFRs are known to influence the
bioavailability of TNF (or modulate the effects of TNF), and since sTNFRs are
known to be induced by TNF itself, we hypothesized that IHP with TNF and
Melphalan induces in-vivo formation of sTNFRs. In chapter 6 we present the
effect of the addition of rhTNF to IHP with melphalan on sTNFR-levels in
patients with irresectable colorectal metastases confined tot the liver.
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Experimental as well as clinical ILP with TNF and melphalan have demonstrated
that the tumor-associated vasculature (TAV) is the selective target for TNF. The
effects of high dose TNF on the TAV lead to an increased permeability and a
significant decrease of the interstitial pressure in the tumor. Both effects lead to a
better penetration of cytotoxic drugs into the tumor tissue. Indeed our group
demonstrated a 4 – 6 fold increase of intratumoral melphalan concentration when
TNF was added to the perfusate in ILP with melphalan in rats. We were interested
in the question whether the same holds true for TNF used in IHP. Therefore, we
examined the intratumoral melphalan concentrations after IHP with TNF and
melphalan in three different hepatic tumors in rats. The results of these
experiments are outlined in chapter 7.
In chapter 8, the experimental and clinical results of IHP reviewed from the
literature.
Finally, in chapter 9, the conclusions are summarized.
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ABSTRACT
Isolated limb perfusion with tumor necrosis factor α (TNF) and melphalan is
well tolerated and highly effective in irresectable sarcoma and melanoma. No
data are available on isolated hepatic perfusion (IHP) with these drugs for
irresectable hepatic malignancies. This study was undertaken to assess the
feasibility of such an approach by analyzing hepatic and systemic toxicity of
IHP with TNF with and without melphalan in pigs. Ten healthy pigs
underwent IHP. After vascular isolation of the liver, inflow catheters were
placed in the hepatic artery and the portal vein, and an outflow catheter was
placed in the infrahepatic inferior caval vein. An extracorporeal veno-venous
bypass was used to shunt blood from the lower body and intestines to the
heart. The liver was perfused for 60 min with (1) 50 µg kg-1 TNF (n=5), (2)
50 µg kg-1 TNF plus 1 mg kg-1 melphalan (n=3) or (3) no drugs (n=2). The
liver was washed with macrodex before restoring vascular continuity. All but
one pigs survived the procedure well. A stable perfusion was achieved in all
animals with median perfusate TNF levels of 5.1 ± 0.78 x 106 pg mL-1 (±
s.e.m.). Systemic leakage of TNF from the perfusate was consistently <
0.02%. Following IHP, a transient elevation of systemic TNF levels was
observed in groups 1 and 2 with a median peak-level of 23 ± 3 x 103 pg mL-1
at 10 min after washout, which normalized within 6 h. No significant systemic
toxicity was observed. Mild transient hepatic toxicity was seen to a similar
extent in all animals, including controls.
IHP with TNF with(out) melphalan in pigs is technically feasible, results in
minimal systemic drug exposure and causes minor transient disturbances of
hepatic biochemistry and histology.
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INTRODUCTION
The liver is the commonest site of dissemination in patients with colorectal
cancer [1-3]. Five-year survival rates up to 35% have been reported for
patients amenable for partial hepatic resection [4-8]. Unfortunately, the vast
majority of colorectal metastases confined to the liver are considered to be
unresectable [9-11]. In addition, systemic chemotherapy has so far failed t o
provide satisfactory results in these cases [12, 13]. Therefore, it is mandatory
to develop novel strategies in order to obtain tumor control in the liver.
The concept of locoregional administration of chemotherapy is aimed at
achieving high local concentrations while minimizing systemic drug levels in
an attempt to reduce dose-limiting side effects. This might enhance antitumor
efficacy as steep dose-response curves have been described for most
chemotherapeutic agents [14, 15]. Several techniques have been developed for
regional therapy of hepatic malignancies, of which hepatic artery infusion
(HAI) has become most widely used [16-19]. Although HAI has been shown t o
improve short-term tumor response rates over systemic chemotherapy, it
only slightly affects survival, while significant dose-limiting toxicity has been
encountered [13, 17-19]. Alternatively, isolated hepatic perfusion (IHP),
including total vascular isolation of the liver, has been reported t o
significantly increase intrahepatic drug concentrations when compared with
HAI, while maintaining sufficiently low systemic drug levels [20-27].
However, large animal studies have revealed systemic leakage of the perfused
antitumor agent owing to incomplete vascular isolation in up to 20% of
animals [22, 25, 27]. Although incidental clinical reports on IHP have
confirmed its potential use in humans, it is clear that optimization of the IHP
methodology is needed [20, 21, 26, 28]. In addition, a drug(s) that would
provide optimal antitumor activity in the IHP setting is (are) at present
unknown.
High dose tumor necrosis factor α (TNF) has been shown to be highly
tumorocidal both in vitro and in vivo [29-31]. Many phase I and II studies
have demonstrated that systemic administration of TNF in man results in
considerable dose-limiting toxicity at dose levels at which no antitumor
activity is observed [32-34]. On the other hand, isolated limb perfusion (ILP)
with high-dose TNF in combination with the alkylating agent melphalan has
recently been documented to be extremely effective in patients with
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irresectable soft tissue sarcomas and in patients with stage III melanoma [35-
37]. Although the exact mechanism of antitumor action by TNF is unknown,
endothelial injury of the tumor associated vascular bed (TAV) has been
suggested to play a pivotal role in inducing tumor necrosis [38, 39]. Thus,
TNF may be effective against any histological tumor variant, provided the
tumor has a well developed vascular bed.
It is not known whether intrahepatic administration of TNF via IHP is
feasible with a satisfactory degree of safety. It is possible that TNF might
induce significant hepatotoxicity, as Kupffer cells are known to release
various cytokines in response to TNF exposure [40, 41]. The present study in
healthy pigs was performed to determine the effects of IHP with TNF, with
and without melphalan with emphasis on hepatic, as well as systemic toxicity.
For this purpose, a modification of the previously reported IHP-techniques
was developed and tested.
MATERIALS AND METHODS
Isolated hepatic perfusion
Ten healthy pigs weighing 25 - 33 kg (median 30 kg) were used. All animals
received human care in compliance with the guidelines on animal welfare of
the Erasmus University, Rotterdam. General anesthesia was induced and
maintained with pavulon and fentanyl. Before surgery, all pigs received 0.1
mL kg-1 bodyweight depomycine consisting of 200.000 IU mL-1 of
procainepenicillin and 200 mg mL-1 of dihydrostreptomycin. In all animals an
arterial line was introduced into the right carotid artery; a tunneled double-
lumen central venous catheter and Swan-Ganz catheter were placed in the
right external and internal jugular veins respectively. In addition, the left
external jugular vein was dissected in preparation for the veno-venous bypass
shunt (see below). Via a midline abdominal incision, the liver was mobilized by
transecting all ligaments, and the supra- and infrahepatic inferior vena cava
(IVC) were dissected and encircled. All phrenic veins entering the suprahepatic
IVC were ligated. The hepatoduodenal ligament was meticulously dissected
preserving the portal vein (PV), celiac trunk, hepatic artery (HA) and the
common bile duct. Branches of the PV and HA, particularly those arterial
branches running towards duodenum and stomach, were ligated as needed t o
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obtain complete vascular isolation of the liver. The right common iliac vein
was dissected free. After heparinization with 2 mg kg-1 heparin, a veno-venous
bypass circuit (VVB) was established using an inverted Y-shaped cannula, t o
shunt mesenteric, renal and lower extremity blood around the liver back to the
heart. For this purpose, a 20F cannula was introduced into the right common
iliac vein, passed into the infrarenal IVC, and the free end was connected with
one of the two lower limbs of the inverted Y. Next, the left jugular vein was
cannulated (20F) and connected to the upper limb of the inverted Y. T o
complete the VVB, the distal PV was clamped, cannulated (20 French) and
connected with the remaining lower limb. Directly before opening the VVB, a
clamp was placed on the infrahepatic suprarenal IVC, proximal from the
cannula tip. The VVB flow was aided by a centrifugal pump (Medtronic,
Biomedics, USA) in a manner identical to the technique currently used during
liver transplantation procedures [42]. The liver perfusion circuit was
established by introducing a 20 French arterial cannula into the hepatic side of
the PV. A 24 French venous outflow catheter was placed into the suprarenal,
infrahepatic IVC via a longitudinal phlebotomy (including the pericaval
hepatic tissue) and passed into the retrohepatic IVC. These two catheters were
connected to the extracorporeal circuit (see below) and, after clamping of the
suprahepatic IVC and the HA, portal liver perfusion was allowed immediately
in an attempt to minimize anoxic liver damage (first anoxia time). Finally,
the HA was cannulated with an 8F catheter, which was subsequently connected
thus completing the isolated hepatic perfusion circuit. The extracorporeal
perfusion circuit consisted of a double head roller pump, VPCML membrane
oxygenator with integrated heatexchanger and reservoir, and arterial
bloodfilters, analogous to the extracorporeal circuit used during
cardiopulmonary bypass procedures. The circuit was primed with 500 mL of
colloid solution (Haemacel) and 500 mL porcine blood. In addition, sodium
hydrocarbonate 8.4 % was added to the priming solution (15 - 20 mL).  Portal
and arterial flow-rates and pressures, together with the oxygen saturation
levels in the perfusate, were recorded as indicated by the heart-lung machine.
The flow-rates in the VVB shunt were also documented. In addition, the portal
flow-rates were measured before and immediately after IHP using a 8 mm
35B548 flow-probe (Transonic Systems, Inc., Ithaca, NY, USA) connected t o
a Transonic T206X flowmeter (A.B. Medical B.V., Roermond, NL). Once
stable IHP was established, as judged by the reservoir level, absence of
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systemic leakage from the IHP circuit was confirmed by injection of 1 cm3 of
a 1:10 dilution of fluorescein into the arterial circuit, followed by illumination
with a UV (Woods) lamp. The perfusate was heated to 40 oC using a
cooler/heater device and was kept at ≥ 39 oC throughout the drug perfusion
period. After 60 minutes of perfusion the liver was washed with macrodex
(>1500 mL) until the fluid from the hepatic veins was clear. In order t o
restore physiological hepatic perfusion, the HA was decannulated and repaired
with Prolene 7-0 whereafter the HA and IVC clamps (second anoxia time)
were released. Next, the IVC and PV were decannulated and sutured (Prolene
5-0). The VVB was further dismantled by decannulating and ligating the left
internal jugular vein and right common iliac vein. Heparin was reversed by
injection of protamine. Pigs were sacrificed 4 to 6 weeks after IHP.
Drugs
Recombinant human tumor necrosis factor-α (rhTNF) (0.2 mg per ampoule)
was a kind gift from Boehringer Ingelheim, Germany. The cytostatic drug
melphalan (Alkeran) was obtained as a sterile powder (100 mg) that was
dissolved aseptically using solvent and diluent by Burroughs Wellcome
(London, UK).
Treatment schedule
In five pigs, a 60 min hyperthermic IHP was performed with rhTNF (50 µg
kg-1) alone, while three pigs were treated by IHP with rhTNF (50 µg kg-1) and
melphalan (1 mg kg-1). TNF was administered as a bolus in the arterial line of
the perfusion circuit; melphalan was given directly following the rhTNF bolus.
In 2 control pigs no drugs were added (sham group).
Sampling schedule
Perfusate was sampled at t = 0 (i.e., upon drug administration), 15, 30, 45 and
60 min. Systemic blood samples were collected at the day before IHP, during
IHP at t = 0, 15, 30, 45 and 60 min, and after perfusion at t = 1, 10, 30, 60,
120 and 480 min, day 1, 3, and 7, and weekly thereafter. Blood samples were
centrifuged at 5000 rpm for 5 minutes. Supernatants were stored at -70 oC
until analysis. Biliary samples (approximately 5-10 mL) were taken by direct
puncture of the gall bladder before IHP, immediately after IHP and upon
closure of the abdomen.
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TNF assay
TNF was measured by a sandwich-type ELISA using two monoclonal
antibodies (Department of Immune Reagents, Central Laboratory of Blood
Transfusion, Amsterdam, The Netherlands) raised against rhTNF (courtesy of
Dr. A. Creasey, Chiron Corp., Emeryville, CA, USA). One mAb (mAb CLB-
TNFα-7) was used for coating at a concentration of 2 µg mL-1. The second
mAb (mAb CLB-TNFα-5) was biotinylated and used in combination with
streptavidin poly-horseradish peroxidase conjugate to detect bound TNF.
Stimulated human mononuclear cell supernatant was used as a standard for
comparison with purified rhTNF. Results were expressed as pg mL-1 by
reference to this standard [43].
Histology
Multiple liver biopsies were taken before and directly after IHP and upon
sacrifice at 4 to 6 weeks post-operatively. The tissue samples were fixed in
formaldehyde and embedded in paraffin. Five-micrometer sections were
stained with haematoxylin and eosin (HE). In addition, samples were taken
from all animals in preparation for electron-microscopy (EM).
Statistics
Comparisons within and between groups were made by analysis of variance for
repeated measurements (ANOVA) or by the t-test where appropriate.
Correlations between maximum or minimum levels of parameters were
calculated as Spearmann’s rank correlations. The significance level was taken
as a probability (two-sided) of < 0.05.
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RESULTS
Operation
The duration of the operation ranged from 4 to 7 h (median 6 h). In all
animals a stable perfusion was attained with no apparent leakage as
demonstrated by the fluorescein dye injection. Further technical details are
summarized in table 1. As indicated by the oxygen saturation levels in the
perfusate, adequate tissue perfusion was attained in all cases. In addition, the
measured flow-rates in the PV did not differ significantly before and after IHP
in all groups. Median blood loss was 500 mL (range 300 - 1500 mL), including
blood lost in the perfusion circuit. All pigs survived the operation. One animal
in the TNF-alone group died on the first post-operative day. At necropsy
clear, serosanguinous fluid was demonstrated in the abdomen without evidence
of portal hypertension/thrombosis or surgical hemorrhage. One pig in the
TNF/melphalan group underwent relaparotomy for hernia cicatricalis 2 weeks
after IHP; one pig of the TNF alone group developed pneumonia with
elevated leukocyte counts at 4 weeks after perfusion. At the time of necropsy
all remaining animals were in good general condition, with weights ranging
from 30 to 40 kg. In fact, 4 weeks after IHP, all surviving animals had gained
weight. Weight gains did not differ significantly between groups. Macroscopic
post-mortem examination did not reveal any intra-abdominal or intra-
thoracic abnormalities.
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Control
(n=2)
TNF
(n=5)
TNF/Melphalan
(n=3)
Anoxic period (min)
1 st
2 nd
0 ± 0
6 ± 1.4
5 ± 8
13 ± 3
0 ± 0
13 ± 3
Flow rate VVB (mL min-1) 1125 ±
176
1053 ± 50 1117 ± 29
Perfusion pressure (mm Hg)
HA
PV
125 ± 35
33 ± 4
110 ± 46
38 ± 6
178 ± 54
43 ± 6
Perfusion flow rate (mL/min)
HA
PV
225 ± 14
470 ± 42
237 ± 121
350 ± 71
178 ± 21
407 ± 55
Perfusate O2 - saturation (%) 77.7 ± 0 73 ± 5 72 ± 1
Table 1. Technical data. Technical perfusion data as indicated by pump and H-L
machine. Data are presented as means ± s.e.m. First anoxic period is defined as time
between clamping and portal perfusion; second anoxic period as time between initiation
of washout and arterial recirculation.
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Hepatic enzymes
In all animals, IHP resulted in significant elevations of aspartate
aminotransferase (ASAT), alanine aminotransferase (ALAT), lactate
dehydrogenase (LDH) and alkaline phosphatase levels, with peak values
occurring at day 1 postoperatively (figure 1). Transaminase levels returned t o
normal within the first 7 to 10 postoperative days, wile alkaline phosphatase
and LDH remained slightly elevated throughout the follow-up period. Total
bilirubin values remained within the normal range, as did the serum values of
urea, γ-GT and creatinin (data not shown). There were no significant
differences in peak values or kinetics between the three groups. In all groups,
serum albumin levels decreased to a nadir of approximately 22 g L-1 on the
first postoperative day and returned to normal values within the following 7
to 14 days. Haemoglobin and haematocrit remained normal throughout the
follow-up period (data not shown). In contrast, platelet counts decreased
slightly, but not significantly, during the first postoperative day, and
normalized within 3 to 7 days.
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Figure 1. Course of liver biochemistry parameters as a function of time (days) following
hyperthermic isolated hepatic perfusion (IHP) in pigs on day 0. (a) ASAT, aspartate
aminotransferase; (b) ALAT, alanine aminotransferase; (c) LDH, lactate dehydrogenase;
(d) alkaline phosphatase. - -, control; -  -, TNF; -✴- , TNF + melphalan.
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TNF levels
TNF levels in the perfusate of the pigs in the TNF alone group increased to a
median of 5.0 x 106 pg mL-1 (range 4.9 - 6.3 x 106 pg mL-1); compared with
5.2 x 106 pg mL-1 (range 5.1 - 6.6 x 106 pg mL-1) in the TNF/melphalan
group. These perfusate TNF levels remained virtually stable throughout the 1
h perfusion period. Perfusate TNF levels in the control group remained
normal (i.e., < 5 pg mL-1) throughout IHP (figure 2). At t=0 (i.e. at the
beginning of the perfusion) all groups displayed normal systemic TNF levels.
During IHP, systemic TNF levels in the control group increased to a median
of 12 pg mL-1 (8.9 - 15 pg mL-1) at t=60 min, compared with 76 pg mL-1 (41
- 120 pg mL-1) in the TNF alone group, and 139 pg mL-1 (34 - 197 pg mL-1)
in the TNF/melphalan group. These figures indicate that, in both
experimental groups, systemic leakage of TNF from the perfusate was less
than 0.02% during the 60 min perfusion. However, following washout and
decannulation at the end of the perfusion, systemic TNF levels increased
significantly in the TNF alone group and the TNF/Melphalan group, with
median peak levels of 3.2 x 103 pg mL-1 and 17 x 103 pg mL-1 respectively
(figure 2). These peak levels occurred between 1 to 30 min (median 10 min)
after washout, and returned to normal within 480 minutes after IHP. Again,
there were no significant differences between the two experimental groups.
Systemic post-perfusion TNF levels in the control group rose slightly, but not
significantly, to a maximum value of 26 pg mL-1 at t=60 min after washout.
None of the evaluated biliary samples contained detectable levels of TNF.
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Figure 2. Perfusate (left panel) and systemic (right panel) TNF levels (pg mL-1).as a
function of  time before, during and after IHP in pigs. -  -, TNF; - ✴ -, TNF +
melphalan; -  -, control
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Histology
Compared with pre-perfusion histology, microscopic examination of HE
stained sections taken directly after perfusion showed mild sinusoidal
dilatation as well as septal edema with sporadic intraseptal polymorphonuclear
cell (PMN) infiltration. These findings were documented in all animals,
including controls. There was no apparent hepatocellular damage or
parenchymal necrosis. At 4 to 6 weeks after IHP, all microscopical sections
revealed normal pig liver histology (on both HE and EM) with the exception
of sporadic PMN infiltrates in the liver parenchyma. The septal oedema and
sporadic septal infiltration had disappeared in all specimens investigated.
Again, these findings were similar in all three groups.
DISCUSSION
The data presented here demonstrate that, in the pig model used,
hyperthermic isolated perfusion of the liver via both the HA and the PV is
technically feasible and safe. Nevertheless the current IHP technique still
involves a large operation, as illustrated by the median duration of 6 h and the
one postoperative death. Additional modifications, including the use of
balloon catheters are therefore being studied at present. Temporary exposure
of normal porcine liver parenchyma to high dose rhTNF with and without
melphalan, in combination with hyperthermia, is well accepted and results in
mild, transient hepatotoxicity. This was illustrated by early elevation of liver
enzyme levels, followed by spontaneous return to normal levels. On
histological analysis immediate post-perfusion changes included sinusoidal
dilatation and mild septal oedema, without any signs of hepatocellular injury.
Sections taken 4 to 6 weeks after IHP revealed sporadic, periportal infiltrates
in otherwise normal hepatic parenchyma. Most biochemical and histological
alterations following IHP were similar in both control and experimental
animals. This suggests that the mild hepatotoxicity phenomena observed were
primarily caused by the IHP procedure itself, and that the addition of the drugs
used, in particular rhTNF does not lead to additional hepatotoxicity. These
findings are in agreement with those reported on IHP with hyperthermia
and/or standard chemotherapeutics [25-27].
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Complete vascular isolation of the liver during IHP is essential to avoid
systemic exposure to high doses of antitumoral agents. Previous studies on
IHP in large animals, using somewhat different methodologies, have
mentioned technical difficulties resulting in incomplete vascular isolation and
systemic leakage of drugs. Van de Velde et al reported leakage in 3 out of 15
pigs with IHP, whereas Sindelar et al encountered incomplete vascular
isolation in 2 of 10 pigs resulting in severe systemic 5-FU toxicity and death
[25, 27]. In these studies either a passive external or an internal venous shunt
was employed to drain distal portal and lower body blood. In view of their
findings, we modified the IHP technique in an attempt to minimize leakage.
This modification involved the introduction of a separate, second active
circuit which consisted of a pump-aided, extracorporeal veno-venous bypass
shunt (VVB) connecting cannulas in the distal PV and infrarenal IVC with the
external jugular vein. Besides simplifying the hepatic perfusion circuit in this
manner (as opposed to internal venous shunts) the VVB has the additional
advantage of more efficiently shunting blood from the lower body and
intestines to the heart. As a result, the cardiac venous return increases,
thereby augmenting haemodynamic stability throughout the procedure. In
fact, we did not observe any haemodynamic instability during our experiments
in pigs, generally considered to be haemodynamically sensitive. Moreover, we
have been able to detect that there was no significant leakage from the liver
perfusion circuit to the systemic circulation. This was achieved using either of
two qualitative methods, i.e. observing fluorescent dye distribution or
monitoring perfusate reservoir levels. This was confirmed in a quantitative
manner by analyzing, during the vascular isolation period, systemic levels of
TNF, which remained about 4 orders of magnitude lower than perfusate levels.
In addition, all pigs survived the procedure and no animal demonstrated any of
the known side effects of rhTNF during and after IHP [44, 45].
However, following IHP and washout, an additional rise in systemic TNF
levels was seen upon restoration of vascular continuity. Although well below
toxic concentrations of rhTNF in the pig, this phenomenon still has to be
accounted for. It is possible that the washout procedure was not sufficiently
effective in removing all remaining TNF from the perfusate. This may be
particularly true in the non-tumor bearing pig liver, in which virtually no TNF
uptake was observed during IHP, as judged by perfusate TNF levels (figure 2).
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There is no consensus about the route of infusion (HA vs. PV vs. both).
Normal hepatic parenchyma receives most of its blood supply from branches
of the PV and to a much lesser extent from the HA. In contrast, the blood
supply of hepatic metastases is reported to rely almost entirely on the HA
[46]. Consequently, most regional approaches have been using the HA. More
recently, however, attention has been drawn to the PV as very small liver
tumors ( < 5 mm), as well as the outer rim of larger hepatic metastases, are fed
mainly by portal branches [46, 47]. In addition, most colorectal tumors are
drained via the PV suggesting that spreading tumor cells will first proliferate in
the portal system. Thus, by using the HA as well as the PV, drugs will reach
both established and newly formed (micro) metastases. Taking this into
consideration, we performed IHP via both the HA as well as the PV. However,
since most normal hepatic parenchyme tissue is supplied primarily by the PV,
it could be speculated that infusion via the PV might induce significant
hepatotoxicity. Indeed, Boddie et al performed IHP solely via the PV and
demonstrated significant hepatic damage [48]. In accordance with most other
reports on IHP, we have not been able to confirm these findings [25, 26, 49].
At present, it is unknown which drug, or combination of drugs, would provide
antitumoral efficacy in the IHP setting. TNF and melphalan were selected in
this study based on its clinical success (100 % limb salvage and a 90 % overall
response) in isolated limb perfusions for irresectable melanoma and sarcoma
[35-37]. As at least part of the antitumor effect of TNF relies on the
destruction of tumor associated vessels, irrespective of tumor histology, we
reasoned that this combination might well be effective against colorectal
hepatic metastases [38, 39, 50]. Indeed, Van der Schelling et al demonstrated
that intratumoral administration of rhTNF under ultrasonographic guidance,
was able to stabilize disease in eight patients with hepatic metastases at the
cost of minimal systemic symptoms [51]. As demonstrated by Mavligit et al,
HAI with rhTNF permits a more than sixfold dose increase of the maximum
tolerated systemic (i.v.) dose before adverse systemic side effects are noted. In
this setting, TNF was found to induce tumor regression in about 30% of
patients with irresectable colorectal liver metastases [52]. Because of the
synergy between melphalan and TNF as demonstrated in earlier reports,
melphalan was chosen over 5-FU, the drug most frequently used in
conventional regimens against colorectal (liver) metastases [35-37]. For
reasons of comprehensiveness, we also performed IHP with TNF and 5-FU in
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two pigs. No mortality was encountered, and (hepatic) response patterns were
identical to the ones described above (data not shown).
On the other hand, Kahky et al have shown that intraportal administration of
100 µg kg-1 day-1 rhTNF results in 100% mortality in rats. Histological
examination in their study revealed mild passive congestion of the liver
combined with severe pulmonary edema. As systemic administration of the
same dose of rhTNF did not result in death, it is unlikely that the high
mortality after intraportal injection was caused solely by TNF [53]. TNF has
been documented to induce the production of various cytokines (including IL-
1, IL-6 and TNF) by macrophages (i.e. Kupffer cells) [40, 41]. As the vast
majority of hepatic Kupffer cells are situated in the (peri) portal area, such a
secondary cytokine release might explain the observed mortality. As far as we
can judge, IHP with rhTNF and melphalan in the healthy pig does not lead t o
such dramatic cytokine-related side effects.
In conclusion, hyperthermic IHP with rhTNF and melphalan in pigs is
technically feasible, resulting in minimal systemic leakage of drugs and mild
hepatotoxicity. The addition of rhTNF and melphalan in the perfusate does
not lead to additional hepatotoxic side effects. As pig liver physiology is
similar to humans, IHP with rhTNF and melphalan should be considered for
phase I evaluation in patients with irresectable hepatic malignancy.
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ABSTRACT
We report our experience with isolated hepatic perfusion (IHP) with Tumor
Necrosis Factor α (TNF) and melphalan in a phase I study in humans. An
extracorporeal veno-venous bypass was used to shunt blood from the lower
body and intestines to the heart. IHP was performed with inflow catheters in
the hepatic artery and portal vein and an outflow catheter in the caval vein.
The liver was perfused for 60 min with 1 mg kg-1 melphalan plus 0.4 mg TNF
(n = 8) or 0.8 mg TNF (n = 1) with hyperthermia (> 41 °C). After the
perfusion the liver was washed with macrodex before vascular continuity was
restored. There was leakage in one patient (cumulative leakage 20%). There
were three perioperative deaths (one possibly drug related). All patients
demonstrated significant but transient hepatotoxicity. Survival ranged from 6
to 26 months (median 10.3 months). All patients demonstrated a tumor
response (5/6 partial response, 1/6 stable disease) with a median duration of 18
weeks.
In contrast to our experimental program in pigs, many problems were
encountered in the phase I study. By using both the hepatic artery and portal
vein for IHP we encountered more toxicity than expected based on data from
the pig program, resulting in fatal coagulative disturbances in one patient who
received the second rhTNF dose. Furthermore, local control after one IHP
with TNF and melphalan is only temporary.
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INTRODUCTION
The liver is the most common site of dissemination in patients with
colorectal cancer, and if left untreated the median survival in these patients is
approximately 6-9 months [1]. In contrast, 5-year survival rates as high as
35% have been reported for patients amenable to partial hepatic resection
[2]. Unfortunately, most colorectal metastases confined to the liver are not
resectable. Therefore it is mandatory to develop novel strategies to obtain
tumor control in the liver.
Several techniques have been developed for regional therapy of hepatic
malignancies, of which hepatic artery infusion (HAI) is most widely used [3].
Although HAI has been shown to improve short-term tumor response rates
compared to systemic chemotherapy, it hardly affects survival and significant
dose-limiting toxicity has been encountered [3].
Alternatively, isolated hepatic perfusion (IHP), with total vascular isolation
of the liver, significantly increased intrahepatic drug concentrations when
compared with HAI while maintaining sufficiently low systemic drug levels [4-
7]. With IHP hepatic rather than systemic toxicity may prove to be dose-
limiting. Incidental clinical reports on IHP are promising, indicating the
potential use of this technique in humans [4, 8-10]. It is clear that
optimization of the IHP methodology is needed. In addition, it is presently
unknown which drug(s) would provide optimal TNF activity in the IHP
setting.
A promising drug with important in vitro and in vivo is tumor necrosis factor
α (TNF), a cytokine produced mainly by activated macrophages [11]. In
humans systemic administration of TNF in many phase I and II studies has
resulted in considerable dose-limiting toxicity with dose levels at which no
TNF activity was observed [12, 13]. Multicenter studies have now shown that
high-dose TNF, in combination with the alkylating drug melphalan, can be
used safely in isolated limb perfusion (ILP), where complete vascular isolation
of the extremity involved ensures minimal systemic exposure to the drug [14-
16]. Although the exact mechanism of antitumor action by TNF is unknown,
endothelial injury of the tumor associated vascular bed (TAV) after ILP was
ascribed to be essential in the genesis of tumor necrosis [17]. Thus TNF may
be expected to prove effective against any histological tumor variant,
provided the tumor has a well developed vascular bed [18].
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It could be speculated that intrahepatic administration of TNF induces
significant hepatotoxicity, as Kupffer cells are known to release various
cytokines in response to TNF exposure [19]. On the other hand, based on the
synergy between TNF and melphalan, considerable tumor responses could be
anticipated. Following this step, we started a phase I clinical study in nine
patients with colorectal metastases confined to the liver. For this purpose, a
modification of the original IHP technique was developed and tested.
MATERIALS AND METHODS
Study Design
The study was designed as a dose escalation study to assess the toxicity and
maximal tolerated dose (MTD) of recombinant human TNF (rhTNF) in
combination with melphalan 1 mg kg-1 body weight in a hyperthermic,
isolated hepatic perfusion (IHP). The study was performed in two centers: the
Erasmus Medical Center Rotterdam - Daniel den Hoed Cancer Center and the
Leiden University Medical Center. Inclusion criteria for IHP with TNF and
melphalan were: (1) histological evidence of unresectable metastases of
colorectal origin confined to the liver; (2) age between 18 and 70 years; (3)
Karnofsky performance status of > 80%. The exclusion criteria (summary)
included: (1) extrahepatic malignant disease; (2) > 50% hepatic tissue
replacement by tumor; (3) liver cirrhosis; (4) signs of significant hepatic
dysfunction (abnormal levels of aspartate aminotransferase (ASAT), alanine
aminotransferase (ALAT) or alkaline phosphatase more than two times
normal), and (5) ascites or portal hypertension.
From January to June 1995, nine patients underwent IHP with TNF and
melphalan. All gave informed consent prior to treatment. The protocols were
approved by the hospitals' ethics committees. There were six men and three
women with a mean age of 59.8 years (range 49 - 65 years). The median
replaced hepatic volume (RHV) was 20% (3.5 - 45%). Patient characteristics
are outlined in table 1.
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Operative procedure and leakage monitoring
The procedure of IHP has been described elsewhere [20]. Briefly, following
systemic heparinization (200 U kg-1), an extracorporeal veno-venous bypass
(VVB) circuit  (pump aided) was created to shunt mesenteric, renal, and lower
extremity blood around the liver to the heart. Next, inflow catheters were
placed in the portal vein and hepatic artery, and an outflow catheter in the
infrahepatic inferior caval vein. These catheters were connected to a heart-
lung-machine, and the vascular isolation was completed by clamping the
suprahepatic inferior caval vein and the suprarenal inferior caval vein. The liver
was then perfused with a hyperthermic (> 38 °C) perfusate consisting of a
mixture of saline and erythrocytes. Once a stable counter-per-minute (cpm)
baseline was obtained from scintillation probes placed over the perfusate
reservoir and VVB, 200 µCi I131 - albumin was injected into the perfusate.
Based on the systemic baseline count and the perfusion circuit volume, the
percentage of leakage can be accurately calculated. If there was more than 1%
leakage over 10 min, adjustments were made in the perfusion flow rates and
cannula position in an attempt to identify the source of the leak prior t o
administering the rhTNFα and melphalan. The leak rate was monitored for
the duration of the perfusion; and if the cumulative leak was more than 15%,
the perfusion was halted and the perfusate flushed from the circuit. After the
absence of leakage was confirmed, rhTNF (0.4 mg in eight patients, 0.8 mg in
one.) was administered as a bolus in the arterial line of the perfusion circuit;
melphalan (1 mg kg-1) was given directly following the rhTNF bolus. After a
60 min perfusion, the liver was washed thoroughly with a mixture of saline
and macrodex, decannulated, and the vascular continuity restored. Heparin was
reversed with 1 mg kg-1 protamine sulphate (Novo-Nordisk AS, Rud, Norway)
injection.
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Postoperative Care
Postoperatively, the patients were monitored in the intensive care unit (ICU)
for at least 48 h, primarily to evaluate for evidence of systemic toxicity due
to rhTNF.
Routine laboratory tests were performed once a day for the first week, at days
10, 14, 21 and 28, and every 2 months thereafter. True-cut biopsies of the
liver and tumor tissues were performed before and during operation, and 4 - 6
weeks after IHP. Tumor measurement was performed by computed
tomography (CT) scan pre-operative, 2 and 4 weeks after IHP and every 2
months thereafter.
Drugs
RhTNF (0.2 mg per ampoule) was a kind gift from Boehringer Ingelheim,
Germany. The cytostatic drug melphalan (Alkeran) came as a sterile powder
(100 mg) that was dissolved aseptically using solvent and diluent obtained
from Burroughs Wellcome (London, UK).
Sampling schedule
Blood samples were collected from a peripheral vein in siliconized 5 mL
Vacutainer tubes (Becton Dickinson, Plymouth, UK) containing EDTA 10
nmol L-1, soybean trypsin inhibitor 100 mg L-1, and benzamidine 10 nmol L-1
(Sigma Chemicals, Detroit, USA) to prevent any in vitro activation. Samples
were centrifuged immediately after collection, at 5000 rpm. for 5 minutes.
Supernatant was stored at minus 70 oC until analysis. Perfusate was sampled at
t = 0 (i.e., upon drug administration), 10, 20, 30, 40, 50, and 60 min.
Systemic plasma samples were collected at the day before ILP, during ILP at t
= 0, 30, and 60 min., and post-perfusion (after release of the VCI clamp) at t
= 1, 5, 10, 20, 30, 60, 120, and 180 min., at 21:00 h, day 1, 3, 5, and 7, and
weekly thereafter.
Assays
Tumor Necrosis Factor-α (TNF) levels were measured by a sandwich-type
enzyme linked immunosorbent assay (ELISA) using two monoclonal
antibodies (Dept. Immune Reagents, Central Laboratory of Bloodtransfusion,
Amsterdam, Netherlands) raised against recombinant human TNF (courtesy of
Dr. A. Creasey, Chiron Corp., Emeryville, CA, USA). One mAb (mAb CLB-
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TNFα-7) was used for coating at a concentration of 2 µg mL-1. The other
mAb (mAb CLB-TNFα-5) was biotinylated and used in combination with
streptavidin poly-horseradish peroxidase conjugate (CLB, Dept. Immune
Reagent) to detect bound TNF. Stimulated human mononuclear cell
supernatant was used as a standard for comparison with purified rhTNF.
Results were expressed as pg mL-1 by reference to this standard [21].
Histology  
Multiple liver biopsies were performed before and directly following IHP and 4
- 6 weeks after IHP. The tissue samples were prepared for hematoxylin and
eosin (H-E) staining and electronmicroscopy (EM).
Toxicity
Toxicity and adverse events were assessed and recorded according to the
World Health Organization (WHO) grading system (WHO Adverse Event
Coding Thesaurus) [22].
Assessment of tumor response
Responses were defined by computed tomography. Radiologic findings were
differentiated as follows (WHO response criteria): complete response (CR) as
complete disappearance of all measurable tumor in the liver for more than 4
weeks, partial response (PR) as regression of tumor volume (the sum of the
product of the perpendicular diameters of all measurable lesions) by > 50 %
for more than 4 weeks, no change (NC) as regression < 50 % of the tumor
volume or progression > 25 %, and progressive disease (PD) as progression >
25 % of the tumor volume. The primary efficacy endpoints in the study were
best tumor response observed and duration of the best response, calculated
from the date the best response was observed until the date of progression.
Statistics
Results are expressed as the mean ± standard error of the mean (SEM).
Comparisons within groups were made by means of the Friedman
nonparametric repeated measures test or by the Mann-Whitney test, where
appropriate. The significance level was taken as a probability (two-sided) of <
0.05.
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RESULTS
Operative Procedure
The median duration of the operation was 8 h (range 6 - 10h). Median blood
loss was 5250 mL (range 4700 - 25000 mL), including blood lost in the
perfusion circuit. A stable perfusion was attained in all patients. Mean flow-
rates in the portal and arterial line were 480 mL (range 400 - 600) resp 293
mL (range 250 - 400). The mean veno-venous bypass flow-rate of the portal
vein and infrahepatic IVC to the axillary vein during perfusion was 2425 mL
(range 1750 - 3000). Systemic leakage was demonstrated in only one patient
during the IHP procedure. In this patient this resulted in discontinuing the IHP
after 43 min (cumulative leakage 20 %).
Three patients died during the perioperative period. One patient died from
sepsis with multiple organ failure (MOF) due to biliary tract necrosis that was
a result of common hepatic artery thrombosis following iatrogenic hepatic
artery injury. In the second patient there was an unacceptably large blood loss
prior to drug administration, possibly caused by preoperative abuse of aspirin
(unknown to the physician), which caused severe coagulopathy leading t o
exsanguination. The third patient (given 0.8 mg rhTNF) was reoperated
because of hypotension and shock about 25 min after a completely normal
IHP procedure. Uncontrollable, diffuse intraperitoneal hemorrhage was
demonstrated, probably caused by a coagulation disorder; it led t o
exsanguination. This adverse event was reported as probably drug related
(rhTNF) and the phase I study was discontinued. The remaining six patients
(five men, one woman) survived the operation and were evaluable for tumor
response.
Toxicity
Toxicity within the first 30 days after IHP is summarized in table 1. A number
of haemodynamic parameters were evaluated. In all patients slight fever,
hypotension, pulmonary hypertension, and sinus tachycardia were
demonstrated and was reported as drug related (figure 1). Most disturbances
normalized within the first 3 days and did not appear to be of major clinical
importance. Some degree of pulmonary hypertension was demonstrated in
almost all patients, with two patients developing adult respiratory distress
syndrome (ARDS). All patients demonstrated an anemia (nadir at day 3) and
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thrombocytopenia (nadir 69.2 ± 14 x109 L-1 at day 3), returning to normal 10
days after IHP. Furthermore, all patients demonstrated initial significantly
elevated serum levels of LDH, ASAT and ALAT, normalizing within the first
7 - 10 postoperative days (figure 2). No correlation could be demonstrated
between IHP parameters nor TNF levels and the peak levels of LDH, ASAT,
ALAT and bilirubin. Two patients had grade III and three grade IV
hepatotoxicity. No significant renal toxicity could be demonstrated.
Blood Pressure
Pre 3 6 12 18 24 30 36 42 48
50
75
100
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175
mm Hg
Hours
Pulse Rate
Pre 3 6 1 2 18 24 30 36 42 48
0
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5 0
7 5
100
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Figure 1. Pattern of blood pressure (left panel) and pulse rate (right panel) before and
after IHP. On the y-axis, blood pressure is expressed as mm Hg and pulse rate as beats
per minute (bpm). Time is expressed on the x-axis. Pre = day prior to IHP; 3, 6, 12, 24,
30, 36, 42, 48 = hours after IHP.
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Figure 2. Course of ASAT, (aspartate aminotransferase); ALAT, (alanine
aminotransferase); AFS, (alkaline phosphatase; and LDH, (lactate dehydrogenase)
before and after IHP. Concentration is expressed on the y-axis in IU L-1. Time is
expressed on the x-axis. Pre = the day prior to IHP; 1, 2, 3, 4, 5, 6, 7, 10, 14 = days
after IHP
Patient survival and Tumor response
Among the six evaluable patients the survival time ranged from 6 to 26
months. The median survival time was 10.3 months (mean 13.3 months).
This best response was confirmed objectively in five patients by a true-cut
biopsy and in the other patient by CT scan only. Among the six evaluable
patients, five had partial responses and one had stable disease. In one patient,
a complete response was observed at autopsy 26 days after IHP. The duration
of best response ranged from 17.5 to 32.5 weeks (median 18 weeks). The first
sites of progression were the lung (n = 2) and the brain (n = 1). In one other
patient local recurrence of the primary tumor (rectal carcinoma) was
observed. Two patients demonstrated local progression in the liver.
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TNF levels
In the perfusate the initial TNF levels of 1.8 ± 0.5 pg mL-1 increased rapidly
to 6.0 ± 2.0 x 104 pg mL-1 at 10 min, followed by a decrease to 2.8 ± 0.9 x
104 pg mL-1 at the end of IHP (figure 3). Systemic levels of TNF remained
virtually unchanged during the IHP. After the washout, systemic TNF levels
increased rapidly to a peak value of 169 ± 38 pg mL-1 at 1 min, and
normalized within the next 2 h.
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0
20
40
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100
x 103 pg mL-1
Time (min)
0 D-1 0 30 60 61 120 9h D1 D3 D5 D7
0
50
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200
250
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( a) (b)
Figure 3. Course of TNFα levels before, during and after IHP. Left panel (a) shows
perfusate levels, right panel (b) systemic levels. Time is expressed on the x-axis; left
panel: minutes during perfusion; right panel: D-1 = the day prior to IHP; 0, 30, 60, 61,
120 = 0, 30, 60, 61, 120, 240 minutes after start of IHP (61 min represents the time just
after vascular restoration; 9h = 9h after IHP; D1, D3, D5, D7 = first, third, fifth and
seventh day after IHP.
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Table 1. Patient characteristics.
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DISCUSSION
Several IHP methods were employed in the past [5, 8, 23] that initially
encountered technical difficulties resulting in incomplete vascular isolation
and systemic leakage of drugs. In view of these findings, we modified the IHP
technique in an attempt to minimize leakage. The first modification consisted
of the development of a pump-aided, extracorporeal veno-venous bypass
shunt (VVB) as a second circuit during IHP. The VVB has the additional
advantage of sufficiently shunting the blood from the lower body and
intestines, resulting in better haemodynamic control during IHP. In fact, no
haemodynamic instability was observed during the perfusions. During IHP,
complete vascular isolation of the liver is essential to avoid systemic exposure
to chemotherapeutic agents. Vascular isolation was complete in all but one
patient. In this patient the IHP had to be stopped after 43 min because of
progressive systemic leakage (cumulative leakage 20%). Despite the leakage,
with higher systemic TNF levels during IHP this patient did not exhibit
additional toxicity, demonstrated by clinical and biochemical parameters,
compared to the other patients studied.
In contrast to our experimental animal studies in the pig, protracted (hepatic)
toxicity was encountered in five out of nine patients. It might therefore be
speculated that the effects of rhTNF on the porcine liver are different than
those in the human liver. Furthermore, three patients died during the
postoperative period. Two of these deaths demonstrated protracted bleeding
with one of these possibly drug related, after which the study was discontinued.
Unfortunately, we were not able to evaluate coagulation and fibrinolysis in
this patient by analyzing TAT, PAP, PAI, and t-PA levels. In the six
evaluable patients, measurement of these parameters indicated significant
activation of both coagulation and fibrinolysis. Apart from a direct TNF
effect the extent of the surgical procedure with subsequent bloodloss may have
contributed.
All surviving patients developed some degree of pulmonary hypertension,
with two patients developing ARDS. Kahky et al. demonstrated that
intraportal administration of rhTNF 100 µg kg-1 per day resulted in 100%
mortality in rats. Histological examination demonstrated significant gastric
and small intestinal mucosal injury, mild passive congestion of the liver, and
severe pulmonary edema. Animals that had received rhTNFα systemically
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followed a relatively benign course with only mild pulmonary edema and no
renal or gastrointestinal injury [29]. Furthermore, Boddie et al showed
significant hepatic damage after IHP via the portal vein only [30]. Most
hepatic Kupffer cells are situated in the (peri) portal area, and TNF is known
to induce production of various cytokines (including IL-1, IL-6, and TNF) by
macrophages (i.e. Kupffer cells). Therefore, this could be an explanation for
the toxicity we encountered, as we performed IHP via both hepatic artery and
portal vein [19]. Indeed high IL-6 and IL-8 levels were seen in our patients;
and they were significantly higher when compared with levels in the ILP
setting [31, 32]. Paradoxically, we could not demonstrate a significant
correlation between peak levels of TNF, IL-6 or IL-8 and clinical parameters
such as fever or hypotension. Furthermore, cytokine levels in the two
patients with ARDS were not different from those measured in the other
patients. The investigated acute phase proteins demonstrated the same course
as in the ILP setting, with CRP reaching peak levels 48 h after IHP, with no
significant differences between patients [33].
The second modification of the IHP technique involved the use of both
hepatic artery (HA) and portal vein (PV) as inflow routes. Normal hepatic
parenchyma receives most of its blood supply from branches of the PV and t o
a much lesser extent from the HA. In contrast, the blood supply of hepatic
metastases has been ascribed to rely almost entirely on the HA, although very
small (< 5 mm) liver tumors and the outer rim of large hepatic metastases
have been shown to be fed mainly by portal branches [27, 28]. Most
colorectal tumors drain via the PV, suggesting that spreading tumor cells first
proliferate in the portal system. Thus by using the HA and PV drugs reach
both established and newly formed (micro) metastases. It could therefore be
speculated that an improvement of response could be achieved. In our study,
almost all surviving patients demonstrated a partial response or stable disease
with only one of the non-surviving patients showing a complete response. In
contrast, other groups demonstrated a higher complete response rate by
performing IHP via the hepatic artery only. A possible explanation for this
difference might be the mechanism by which TNF exerts its anti-tumor effect
in isolated perfusion setting (ILP/IHP). TNF without melphalan or any other
chemotherapeutic agent does not appear to have any significant antitumor
activity when administered in IHP. Fraker et al demonstrated a response rate
of only 20% in 17 patients treated in a study with IFN and escalating doses of
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TNF administered in IHP [36]. Similar results have been demonstrated in ILP
with TNF only. Therefore, as was concluded from the ILP experiments in
rats, TNF needs a chemotherapeutic agent to in order to be effective. The
antitumor effects of TNF in the Isolated Perfusion setting are based on
synergism with a cytostatic drug [18, 37, 38]. Probably, TNF is suggested t o
be responsible for the disruption and subsequent leakage of the TAV whereas
melphalan (or in theory any other chemotherapeutic drug) causes a non-
specific necrosis of the tumor cells [39]. The effects of high dose TNF on the
TAV lead to an increased permeability and a significant decrease of the
interstitial pressure in the tumor. Both effects lead to a better penetration of
cytotoxic drugs into the tumor tissue [40-42]. Indeed our group demonstrated
a 4 – 6 fold increase of intratumoral melphalan concentration when TNF was
added to the perfusate in ILP with melphalan [43]. Similarly, an increased
uptake of doxorubicin in tumor tissue was shown after TNF based ILP [44].
Probably these findings are one of the most important mechanisms behind the
successes demonstrated by ILP with TNF and melphalan. In contrast,
Alexander et al showed an increased capillary leakage during IHP and an
increased uptake of I131 albumin in tumor tissue compared to liver tissue.
However, the addition of TNF did not affect melphalan concentrations in the
tumor tissue compared to liver tissue [45]. Several reasons for the discrepancy
are possible such as concentrations of TNF used, sampling method and
duration of perfusion. Of more importance however, might be the type of
tumor with associated difference in tumor vasculature since colorectal
metastases are hypovascular and largely necrotic, whereas soft tissue sarcoma
are usually hypervascular. The results of Van der Veen et al and De Wilt et al
implicate that the better the vascularisation of a specific tumor, the more
explicit the effects of TNF on the TAV and the better the overall response of
the tumor to the treatment [43, 44]. This has been proven from experimental
as well as clinical results. In the rat, best response rates after ILP with TNF
and melphalan have been demonstrated by our group for the highly
vascularised BN soft tissue sarcoma bearing rats whereas the less vascularised
rat osteosarcoma (ROS) showed subsequent lower responses [46, 47]. Similar
results have been shown by Van IJken et al in an IHP model in rats using the
same tumors (BN, ROS) but now localized in the liver. In case a
coloncarcinoma was used, only few responses had been shown [48]. In
accordance with these results, best clinical responses have been demonstrated
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after ILP with TNF and melphalan in patients with unresectable soft tissue
sarcoma of the extremities [15, 16]. The same holds true for the clinical
result of IHP. Therefore, the vascularisation of the tumor seems to be of
utmost importance in the treatment with TNF, independent of its
localization.
Two goals of IHP are an increase in response rate and a prolongation of
duration of response. The technique of IHP as presented here is not
repeatable. Furthermore, IHP is a technically demanding procedure. One way
to overcome these two problems could be the development of the balloon
catheter technique in combination with IHP (IHHP) [53]. With this
technique, the procedure is simplified and can be repeated. Van IJken et al
performed IHHP with TNF, melphalan and mytomicinC (MMC) in pigs. They
demonstrated that a leakage free isolated IHHP can be performed with a small
surgical procedure and is well tolerated in pigs. Regional drug levels were 20 t o
40 times higher than after systemic drug injection. Because of the leakage free
quality of this procedure in combination with the efficacy of the washout
procedure, TNF may be used in this setting [53]. After the promising results in
pigs, our group started a phase I-II study on IHHP with melphalan in patients
with irresectable hepatic metastases of colorectal origin [54]. In our first six
patients we have had no serious adverse events. Moreover, antitumor activity
has been demonstrated at the dose level of 1 mg kg-1 melphalan. With further
experience with this technique, TNF may be introduced in order to further
increase antitumor activity.
Despite the very promising experiences with our IHP experiments in pigs,
many problems were encountered during the phase I study. Contributing
factors were the magnitude of the surgical procedure of IHP, and the overall
blood loss (median 5500 mL). By using both the hepatic artery and portal
vein in the IHP we encountered more toxicity than expected from the pig
program, resulting in fatal coagulative disturbances in one patient who
received the second rhTNF dose. Furthermore, local control after one IHP
with TNF and melphalan is only temporary. Taking into account the current
aims and indications for IHP it is clear that simplification and further
optimization of the IHP technique is necessary to render it a smaller,
preferably less invasive as well as repeatable technique. One possibility that
may be explored is the employment of multiple balloon catheters to achieve
vascular isolation.
IHP in patients with hepatic metastases
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ABSTRACT
In this study, we have evaluated hepatotoxicity, secondary cytokine production
and hepatic acute-phase response (APR) in patients who underwent isolated
hepatic perfusion (IHP) with tumor necrosis factor α (TNF) and melphalan for
irresectable colorectal liver metastases.
An extracorporeal veno-venous bypass was used to shunt blood from the lower
body and intestines to the heart. Inflow catheters were placed in the hepatic artery
and portal vein, and an outflow catheter in the infrahepatic, inferior caval vein.
The liver was perfused for 60 min with 1.0 mg kg-1 melphalan and TNF (0.4 mg
(n=8) or 0.8 mg (n=1)), IHPTM group or 1 mg kg
-1 melphalan (n=3), IHPM group.
The liver was washed with macrodex before restoring vascular continuity.
After the washout procedure, a TNF peak (169 ± 38 pg mL-1) was demonstrated in
the IHPTM group only. Both groups demonstrated peak levels of IL-6 in perfusate
as well as systemically. These were significantly higher in the IHPTM group. Acute
phase protein (APP) levels followed a similar pattern as has been demonstrated
after major surgery, with no significant differences between both groups. The
addition of TNF to the perfusate did not lead to a significant difference in APP
levels as well as time course between groups.
IHP with TNF and melphalan is followed by a transient systemic peak of TNF
directly after liver washout. Secondary IL-6 induction was seen in the present
study after IHP with and without TNF, which was highest when TNF was added.
This phenomenon cannot be extrapolated to APP induction, which appeared
unaffected by the addition of TNF, presumably because the surgical procedure
itself already causes maximal stimulation of APP production.
APR in IHP with TNF and melphalan
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INTRODUCTION
The acute phase response (APR) is a general systemic reaction induced by injury
or various kinds of inflammatory states such as burns, infection or surgical
procedures. As part of this reaction, the liver responds to several mediators by the
increased synthesis of a series of glycoproteins called acute phase proteins (APP).
The function of the APPs is pleiotropic: they may both mediate and inhibit
inflammation, scavenge free oxygen radicals, act as transport proteins for
products of the inflammatory process, or have an active role in tissue repair and
remodeling.
Both tumor necrosis factor α (TNF) and interleukin 6 (IL-6) have been shown to
induce the APP synthesis of the liver, of which the latter seems to be the major
inducer and mediator of this APP production [1-4]. TNF derives its name from
the observation that it can cause hemorrhagic necrosis of tumors. However, TNF
is also known to be an important mediator in shock. Systemic administration of
small amounts of TNF leads to influenza-like symptoms; at higher dose levels a
septic shock syndrome develops, characterized by pulmonary edema, adult
respiratory distress syndrome (ARDS) and severe inflammatory response
syndrome (SIRS). For this reason, many phase I and II trials studying the
systemic administration of TNF have failed to reproduce the experimental
successes because the severe, systemic toxic side effects of TNF limited the
usable dose of TNF to a level at which no effective antitumor activity could be
seen [5-7].
It has been shown recently that this concentration gap can be overcome by the
application of cytostatic drugs in isolated perfusion systems. These allow safe
increase of doses to > 20 x the systemic maximum tolerated dose (MTD) [8]. This
also holds true for the application of TNF in such systems. It has become firmly
established that TNF can be applied safely and successfully in isolated limb
perfusion (ILP) both in melanoma patients and in patients with irresectable soft
tissue sarcomas [9-11]. Furthermore, this remarkable antitumor effectivity of TNF
in combination with melphalan, proved to be effective against a wide range of
histologies [5].
The results of the ILP studies led to the development of isolated perfusion of
other organs, such as isolated hepatic perfusion (IHP) [12, 13]. With this
technique, the liver circulation is completely separated from the systemic
circulation, thus allowing high drug levels within the liver while keeping systemic
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exposure low. However, unlike limbs, the liver is a metabolically active organ
that contains a large amount of tissue macrophages, the Kupffer cells. As Kupffer
cells are known to release various cytokines in response to TNF, it could
therefore be speculated that IHP with TNF might induce considerable
(hepato)toxicity. Therefore, we were interested in the effects of IHP with TNF on
secondary cytokine production and hepatic APR. To obtain further insight, we
evaluated patients who underwent IHP with TNF and melphalan for colorectal
metastases confined to the liver. The APR was evaluated regarding the levels and
time dependency of TNF, IL-6, and the APP C-reactive protein (CRP), α1-
acidglycoprotein, α1-antitrypsin, and transferrin.
PATIENTS AND METHODS
IHP patient groups
Twelve patients with colorectal metastatic liver disease gave informed consent for
undergoing isolated hepatic perfusion (IHP) with TNF and melphalan (IHPTM
group, n = 9) or melphalan alone (IHPM group, n = 3). There were 9 men and 3
women with a mean age of 59.8 years (range, 49 – 65). All gave informed consent
before treatment in protocols approved by the hospitals' ethical committees. The
study was carried out in accordance with the principles of the Declaration of
Helsinki, as revised in Hong Kong 1989. Inclusion criteria for IHP with TNF and
melphalan included histological evidence of irresectable metastases of colorectal
origin confined to the liver, Karnovsky performance status of > 80%. Exclusion
criteria included extra-hepatic malignant disease, > 50% hepatic tissue replacement
by tumor, liver cirrhosis, signs of significant hepatic dysfunction (abnormal levels
of ASAT, ALAT or Alkaline Phosphatase > 2 x norm), and ascites or portal
hypertension.
IHP technique
The procedure of IHP has been described elsewhere [12]. Briefly, the vasculature of
the liver was dissected free and isolated. After systemic heparinization (200 IU kg-
1), an extracorporeal veno-venous bypass (VVB) circuit (aided by a passive
centrifugal pump) was created to shunt mesenteric, renal, and lower extremity
blood around the liver to the heart. Next, inflow catheters were placed in the portal
vein and hepatic artery, and an outflow catheter in the infrahepatic inferior caval
APR in IHP with TNF and melphalan
69
vein. These catheters were connected to a heart-lung machine, and the vascular
isolation was completed by clamping the suprahepatic inferior caval vein and the
suprarenal inferior caval vein. The liver was then perfused with a hyperthermic (>
38 °C) perfusate consisting of a mixture of saline and erythrocytes. Once a stable
perfusion was attained, leakage from the perfusion circuit into the systemic
circulation was measured by the addition of 200 µci I131 -albumin into the perfusate
and the continuous monitoring of radioactivity scintillation probes placed over the
perfusate reservoir and VVB. The leak rate was monitored for the duration of the
perfusion and if the cumulative leak was greater than 15%, the perfusion would be
halted and the perfusate flushed from the circuit. After the absence of leakage was
confirmed, drugs (see treatment schedule) were administered as a bolus into the
arterial line of the perfusion circuit. After a 60 min perfusion, the liver was washed
thoroughly with a mixture of saline and macrodex, decannulated, and vascular
continuity restored. Heparin was reversed with 1 mg kg-1 protamine sulphate
(Novo-Nordisk AS, Rud, Norway) injection. Postoperatively, the patients were
monitored at the ICU for at least 48 hours, primarily to evaluate for evidence of
systemic toxicity due to rhTNF.
Drugs
Recombinant human TNF (0.2 mg per ampoule) was a kind gift from Boehringer
Ingelheim GmbH, Ingelheim am Rhein, Germany. The cytostatic drug melphalan
(Alkeran) was obtained as a sterile powder (100 mg) that was dissolved aseptically
using solvent and diluent by Burroughs Wellcome, London, UK.
Treatment schedule
In nine patients (IHPTM group), rhTNF (0.4 mg (n=8), 0.8 mg (n=1)) was
administered as a bolus; melphalan (1 mg kg-1) was given directly following the
rhTNF bolus. In 3 patients (IHPM group) only melphalan (1 mg kg
-1) was
administered.
Sampling schedule
Blood samples were collected from a peripheral vein in siliconized 5 mL
Vacutainer tubes (Becton Dickinson, Plymouth, UK) containing EDTA (10 nmol
L-1) and soybean trypsin inhibitor (100 mg L-1), and benzamidine (10 nmol L-1)
(Sigma Chemicals, Detroit, Michigan). Samples were centrifuged immediately
after collection, at 5000 rpm. for 5 minutes. Supernatants were stored at -70 oC
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until analysis. Perfusate was sampled at t = 0 (i.e., upon drug administration), 10,
20, 30, 40, 50 and 60 min. Systemic plasma samples were collected the day
before IHP, during IHP at t = 0, 30 and 60 min., and post-perfusion (after release
of the inferior caval vein clamp) at t = 1, 5, 10, 20, 30, 60, 120 and 240 min., day
1, 3, and 7, and weekly  thereafter, until 3 weeks post-operatively.
Assays
TNF levels were measured by a sandwich-type enzyme linked immunosorbent
assay (ELISA) using two monoclonal antibodies (Dept. Immune Reagents, Central
Laboratory of Blood transfusion, Amsterdam, Netherlands) raised against
recombinant human TNF (courtesy of Dr. A. Creasey, Chiron Corp., Emeryville,
CA, USA). One mAb (mAb CLB- TNFα-7) was used for coating at a
concentration of 2 µg mL-1. The other mAb (mAb CLB-TNFα-5) was biotinylated
and used in combination with streptavidin poly-horseradish peroxidase conjugate
(CLB, Dept. Immune Reagent) to detect bound TNF. Stimulated human
mononuclear cell supernatant was used as a standard for comparison with purified
recombinant human TNF. Results were expressed as pg mL-1 by reference to this
standard [14]. The detection limit of this essay was 10 pg mL-1.
IL-6 was measured by an ELISA modified from that described in detail before [15].
Briefly, purified monoclonal anti-human-IL-6 antibody (mAb CLB-IL-6-16) was
used as a capture antibody, and biotinylated sheep antibodies in combination with
streptavidin poly-horseradish peroxidase conjugate were used to detect bound IL-6.
Results were expressed as pg mL-1 by reference to a standard consisting of
recombinant human IL-6. Normal healthy control subjects values were < 10 pg mL-
1 and the limit of detection was 5 pg mL-1.
Acute-phase proteins
C-reactive protein (CRP), α1-antitrypsin (α1-AT), α1-acidglycoprotein (α1-AG)
and transferrin (TRF) levels were measured by means of a nephelometric assay
[16]. The antisera used were obtained from the Central Laboratory of the Blood
Transfusion Service (CLB), Amsterdam, The Netherlands. Normal values (obtained
from 100 blood donors) were: CRP < 5 mg L-1, α1-AT 1.4 - 3.2 g L-1, α1-AG 0.4 -
1.3 g L-1, and TRF 2.3 - 4.3 g L-1.
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Statistics
Results are expressed as means ± standard error of the mean (SEM). Comparisons
within groups were made by means of the Friedman Nonparametric Repeated
Measures Test or by the Mann-Whitney Test, where appropriate. Correlations
between maximum levels of parameters were calculated as Spearman’s rank
correlations. A two-side P-value < 0.05 was regarded as significant.
RESULTS
Operative procedure
The median duration of the operation was 8 h (range 6 - 10 h). In all patients a
stable perfusion was attained. In one patient, progressive systemic leakage
resulted in discontinuation of the IHP after 43 minutes (cumulative leakage 20%).
In all other patients no leakage was demonstrated. Three patients in the IHPTM
group died in the immediate postoperative period as a result of surgical
complications of the operation. As the purpose of this study was to describe APR
in uncomplicated IHP, these patients were excluded for this study.
Survival
In the six evaluable patients the survival time ranged from 6 to 26 months. The
median survival time was 10.3 months (mean 13.3 months).
Tumor response
The primary efficacy end points in the study were best tumor response observed
[WHO response criteria: complete response (CR), partial response (PR), stable
disease (SD), or progressive disease (PD)] and duration of the best response,
calculated from the date the best response was observed until the date of
progression. True-cut hepatic tissue samples and/or computerized tomography
(CT) scan evaluations were used to describe the best tumor response. In the
IHPTM group 5 out of 6 patients demonstrated CR or PR and one patient
demonstrated SD. Patients treated with melphalan alone demonstrated PR or SD.
The duration of best response ranged from 17.5 to 32.5 weeks (median 18 weeks).
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Toxicity
Toxicity and adverse events were assessed and recorded according to the WHO
grading system (WHO Adverse Event Coding Thesaurus) [17].
General toxicity
In the IHPTM group, all patients developed slight fever, hypotension, pulmonary
toxicity, and sinus tachycardia that was reported as drug related. All patients
demonstrated anemia and thrombocytopenia (nadirs at day 3), returning to normal
after 10 days post IHP (p>0.05 between groups).
Hepatotoxicity
All patients demonstrated significant initial elevations in liver enzyme levels,
normalizing within the first two postoperative weeks (p>0.05 between groups). In
contrast, bilirubin and alkaline phosphatase levels increased more slowly after IHP
but remained elevated over a longer period. Overall, two (IHPTM group) patients
demonstrated grade III and three (IHPTM group) patients grade IV according to the
WHO classification (figure 1).
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Figure 1. Course of liver enzyme levels as a function of time following IHP. Time is
expressed  in days on the x-axis, where D–1 represents the day prior to the operation. Left
panel (a): ASAT, aspartate aminotransferase; right panel (b):  ALAT, alanine
aminotransferase.  Note: since liver enzyme levels were virtually equal in both groups, the
IHPM group levels are not shown for reasons of clarity.
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Cytokine levels
TNF levels
In the perfusate, TNF levels in the IHPTM group were 1.8 ± 0.5 pg mL
-1 at t = 0 min
and increased rapidly to 6.0 ± 2.0 x 104 pg mL-1 at t = 10 min. Thereafter, TNF
levels decreased to 2.8 ± 0.9 x 104 pg mL-1 at the end of IHP (t = 60 min). In the
IHPM group TNF levels did not demonstrate any significant changes. (figure 2)
Baseline serum TNF levels were similar in both groups, although these levels were
higher than normal (4.3 ± 0.5 pg mL-1 and 4.5 ± 1 pg mL-1 in the IHPTM and IHPM
group resp.). During IHP TNF levels did not change significantly, indicating that
vascular isolation was effective. However, after washout, TNF levels increased
rapidly to a peak value of 169 ± 38 pg mL-1 at t = 1 min in the IHPTM group, and
normalized within the next 3 hours. In the IHPM group, TNF levels demonstrated a
slight increase to 7.2 ± 5 pg mL-1 within the first 30 minutes after IHP. However,
this elevation of TNF levels in the IHPM group was not statistically significant
(figure 2).
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Figure 2. Course of tumor necrosis factor α (TNF) levels before, during and after IHP.
Left panel (a) shows perfusate levels, right panel (b) shows systemic levels. Time is
expressed on the x-axis; left panel: minutes during perfusion; right panel: D-1, the day
prior to IHP; 0, 30, 60, 61, 120,  0, 30, 60, 61, 120 minutes after start of IHP (61
represents the time just after vascular restoration, not shown in following panels); 9h, 9
hours after IHP; D1, D3, D5, D7, first, third, fifth and seventh day after IHP. (--),
represents the group of patients receiving TNF and melphalan; (--), the group of
patients receiving melphalan alone.
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Interleukin-6 levels
In the perfusate, baseline IL-6 levels were elevated in both the IHPTM and IHPM
group (91 ± 45 pg mL-1 resp 94 ± 58 pg mL-1). During IHP, IL-6 levels increased
over time to  2.1 ± 0.7 x 103 pg mL-1 in the IHPTM group (p<0.01) and to 227 ± 128
pg mL-1 (p>0.05) in the IHPM group (p<0.01 between groups, figure 3).
Serum IL-6 levels at the start of the IHP procedure were elevated in both groups
and rose slightly during IHP (p>0.05 between groups). However, after the washout
procedure IL-6 levels increased significantly, reaching the highest levels, 1 hour
after washout, in the IHPTM group (p<0.01 between groups). Respective maximum
IL-6 levels were 9.8 ± 0.8 x 103 pg mL-1 and 2.4 ± 1 x 103 pg mL-1 in the IHPTM and
IHPM group. Thereafter levels dropped, and returned to pre-operative levels within
the first post-operative day (figure 3).
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Figure 3. Course of IL-6 levels before, during and after IHP. Left panel (a) shows
perfusate levels, right panel (b) shows systemic levels. Time is expressed on the x-axis;
(a): minutes during perfusion; (b): D-1, the day prior to IHP; 0, 30, 60, 120, 0, 30, 60,
120 minutes after start of  IHP; 9h, 9 hours after IHP; D1, D3, D5, D7, first, third, fifth
and seventh day after IHP. (--), represents the group of patients receiving TNF and
melphalan; (--), the group of patients receiving melphalan alone.
Acute-phase protein response
C-reactive protein levels started to rise 9 hours after washout and maximum levels
(143 ± 3 mg L-1 and 129 ± 4 mg L-1 in the IHPTM and IHPM group respectively)
were reached at the fifth postoperative day. Thereafter, levels dropped and
normalized slowly within the next two weeks (p>0.05 between groups, figure 4).
From the start of the IHP procedure α1-antitrypsin and α1-acidglycoprotein levels
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first decreased in both groups. At 60 min after washout, levels increased gradually
(p<0.01), and they were still elevated at day 10 (p>0.05 between groups, figure 4)
The “negative” acute phase protein transferrin levels in both groups decreased until
30 - 60 min after washout, where after levels increased to normal values within the
first postoperative days (p>0.05 between groups, figure 4)
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Figure 4. Course of (a) C-reactive protein (CRP), (b) α1-antitrypsin (a1-AT), (c) α1-
acidglycoprotein (a1-AG) and (d) Transferrin (TRF) levels before, during and after IHP.
Time is expressed on the x-axis as follows: D-1, the day prior to IHP; 0, 30, 60, 120, 0,
30, 60, 120 minutes after start of IHP; 9h, 9 hours after IHP; D1, D3, D5, D7, first, third,
fifth and seventh day after IHP. (--), represents the group of patients receiving TNF
and melphalan; (--), the group of patients receiving melphalan alone.
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DISCUSSION
In this study, we describe the effects of IHP with TNF and melphalan, or
melphalan alone, on secondary cytokine and APP production. After the washout
procedure, IHP was followed by a TNF peak in the IHPTM group only,
normalizing within 2h. TNF levels in the melphalan alone group remained
virtually unchanged. In both groups, peak levels of IL-6 were observed 1h after
the washout, although levels were significantly higher in those patients with TNF
added to the perfusate. IL-6 levels normalized at day 1 post-operatively. The APP
production, followed a pattern similar to that demonstrated after various kinds of
surgery, including major hepatic surgery, with no differences between both
groups.
Despite its promising in vitro antitumor effects, the in vivo administration of TNF
has been demonstrated to be accompanied with dose limiting systemic toxicity at
dose levels at which no antitumor effect could be seen. Furthermore, phase I and
II studies demonstrated specific organ toxicity with increasing dosages of TNF [6,
7]. We were particularly interested in the potential hepatotoxicity caused by IHP
with TNF and melphalan. All our patients displayed moderate transient
hepatotoxicity as demonstrated by transient elevated hepatic enzymes (figure 1).
Since similar elevations were also observed in the IHPM group, we believe that
the addition of TNF did not lead to additional hepatotoxicity. These findings are
in accordance with the results of our experimental IHP program in pigs [12].
Therefore, more likely, we think that the hepatotoxicity encountered in our
patients is the result, at least in part, of the IHP procedure itself.
To avoid systemic exposure to chemotherapeutic agents or cytokines, the main
goal of the isolation perfusion technique is the complete vascular isolation of the
limb or organ. In our study vascular isolation of the liver was complete in all
patients but one. In this patient progressive systemic leakage (cumulative leakage:
20%) led to premature termination of the IHP procedure after 43 min. However,
despite this leakage, this patient did not demonstrate additional toxicity as
demonstrated by clinical as well as biochemical parameters, compared with the
other patients studied. The same observation has been demonstrated by Pinsky
and co-workers, who showed that the outcome of patients with septic shock did
not correlate with peak levels but with the persistence of both TNF and IL-6
levels [18]. In our eight patients without leakage, systemic TNF levels did not
change significantly during IHP, indicating that vascular isolation was complete.
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After the washout procedure, however, systemic TNF levels in the IHPTM group
peaked rapidly and normalized within the next two to three hours (figure 2). A
possible explanation for this TNF peak in the IHPTM group could be the release of
remnant TNF in the liver after the washout procedure, a phenomenon also
described in isolated limb perfusions (ILP) with TNF and melphalan [16, 19, 20].
However, peak TNF levels in our study were much lower than those levels in
ILP, indicating a more efficient washout procedure [19, 21]. Furthermore,
endogenous TNF production may have attributed to this peak, since surgery, extra
corporeal circulation circuits, and intravascular plastic catheters are known to
induce TNF [22, 23]. However, the latter explanation may be of less importance
since only mild elevation of systemic TNF levels could be demonstrated in the
IHPM group (figure 2).
TNF is also know as a proinflammatory cytokine being able to stimulate the
production of several interleukines like IL-6. In this study, perfusate IL-6 levels
increased significantly in all patients during IHP, with highest levels in the IHPTM
group (figure 3). The same pattern has been demonstrated in the perfusate of ILP
circuits in patients with melanoma stage III/IV or irresectable sarcoma of the limbs,
although perfusate IL-6 levels in our patients (IHPTM group) were much higher at a
lower TNF dose [20]. Macrophages are known to produce various cytokines, e.g.
IL-6, in response to TNF. As the liver contains the largest amount of fixed tissue
macrophages, Kupffer cells, this induction of IL-6 production by the Kupffer cells
could be an explanation not only for the difference in IL-6 levels between our study
groups, but also between IHP and ILP. Furthermore, all patients demonstrated
elevated systemic IL-6 levels at the start of the actual perfusion, which further
increased, with perfusing time. Several studies have demonstrated increased IL-6
levels after various surgical procedures, including hepatic surgery [24-29].
Cruickshank et al. described elevated IL-6 levels in patients undergoing elective
surgery of varying severity. Levels of IL-6 were shown to increase with the extent
of surgery [29]. Several other studies confirmed this finding but peak IL-6 levels
were usually less than 500 pg mL-1 [24-29]. In this context, it should be borne in
mind that, at the beginning of the perfusion, patients already had undergone a major
surgical procedure, with subsequent increased IL-6 concentrations resembling
levels described in other surgical procedures (figure 3, t = 0 min). The slow initial
increase, during IHP was followed by a further steep increase after IHP to a peak at
1 hour after the washout procedure (figure 3). Although this peak occurred in both
groups, it was significantly higher in those patients perfused with TNF and
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melphalan. Since both groups underwent the same surgical procedure with
melphalan, the significant difference between groups can only be explained by the
addition of TNF to the perfusate of the IHPTM group. The same observation was
reported by Thom et al. In their study serum IL-6 levels in patients with ILP with
TNF, interferon-γ, and melphalan were significantly higher compared to ILP with
melphalan alone, with a trend toward higher IL-6 levels with increased exposure to
TNF [20]. Taking into account the aforementioned Kupffer cell response to TNF,
both the TNF peak after washout in the IHPTM group as well as the hepatic IL-6
production could be an explanation for the difference in systemic peak IL-6 levels.
An important function of the liver is the production of so called APPs in response
to various stimuli. In all our patients a clear APR could be observed. Levels of all
proteins first decreased, probably caused by haemodilution in combination with
extravasation after the washout procedure. Thereafter the negative APPs
normalized, whereas the positive APPs started to increase and remained elevated
for at least two weeks with the exception of CRP which normalized within this
period (figure 4). Furthermore, there were no significant differences in APP levels
between both groups. Several in vitro and in vivo studies demonstrated that IL-6 is
secreted in the early stages of the APR, and is the main mediator of the hepatic
production of APPs like α1-AG, α1-AT and CRP [1, 2]. To emphasize the central
role of IL-6, in vivo studies have revealed clear correlations between IL-6 and
several APP levels [3, 30-33]. Since in our study significant differences in systemic
IL-6 levels were demonstrated, we speculated that this might lead to a different
APP production profile between groups. In contrast, in our study, there were no
significant differences in APP profiles or peak levels between groups. Moreover,
we could not demonstrate a significant correlation between peak IL-6 and CRP
levels. Instead, the APP pattern, including peak levels, as described here is similar
to patterns demonstrated after elective surgery of various extent, including ILP [16,
31, 32]. A possible explanation for the identical profile in both groups could be that
the IHP, as a major surgical procedure (and identical in both groups), already
caused a maximal induction of the APPs by the liver. Consequently, the addition of
TNF to the perfusate, with subsequent short-lived systemic TNF peak and resulting
IL-6 peak, could not further influence the APR. Thus, the conditions under which
TNF  induced IL-6 production occurs may be essential to the extent in which the
hepatic APR is induced [34].
In conclusion, IHP with TNF and melphalan is followed by a transient systemic
peak of TNF directly following liver washout. Secondary IL-6 induction was seen
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in the present study after IHP with and without TNF, which was highest when
TNF was added. This phenomenon cannot be extrapolated to APP induction,
which appeared unaffected by the addition of TNF, presumably because the
surgical procedure itself already causes maximal stimulation of APP production.
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ABSTRACT
Since the introduction of high dose tumor necrosis factor α (TNF) in the setting
of isolated limb perfusion (ILP) in the clinic prevention of leakage to the body of
the patient is monitored with great precision for fear of TNF-mediated toxicity.
The fact that we observed remarkably little toxicity in patients with and without
leakage prompted us to determine patterns of cytokines and acute phase proteins
(APPs) in patients with high leakage and in patients without any leakage.
TNF, IL-6, IL-8, CRP and sPLA2 were measured at several time-points during
and after (till 7 days) ILP in 10 patients with a leakage to the systemic circulation
varying in percentage from 12 to 65%. As a control the same measurements, both
in peripheral blood and in perfusate, were done in 9 patients without systemic
leakage.
In patients with systemic leakage levels of TNF increased during ILP reaching
values up to 277 ng mL-1 . IL-6 and IL-8 peaked 3 hours after ILP with values
significantly higher compared with patients without systemic leakage. CRP and
sPLA2 peaked at day 1 in both patient groups. sPLA2 with significant higher
levels and CRP, in contrast, with lower levels in the leakage-patients.
High leakage of TNFα to the systemic circulation caused by a complicated ILP
led to a ten- to more than hundredfold increased levels of TNF, IL-6 and IL-8 in
comparison to patients without leakage. The increase of the APPs was limited.
Even when high leakage occurs, this procedure should not lead to fatal
complications. The most prominent clinical toxicity was hypotension (grade III in
4 patients), which was easily corrected. No pulmonary or renal toxicity was
observed in any patient. It is our experience that even in the rare event of
significant leakage during a TNF-based ILP postoperative toxicity is usually mild
and can be easily managed by use of fluid and in some case vasopressors.
Systemic toxicity after complicated ILP with TNFα and melphalan
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INTRODUCTION
The technique of regional isolated limb perfusion (ILP) utilizing an
extracorporeal circuit was pioneered by Creech and coworkers [1]. The advantage
of this treatment modality is that high dose of cytostatic drug can be delivered to
the tumor bearing extremity without producing systemic side effects. ILP permits
regional cytostatic concentrations 15 to 20 times higher than those reached after
systemic administration [2]. The standard drug in this setting is melphalan (L-
phenyl-alaninemustard). In patients with multiple melanoma in-transit metastases
an ILP with melphalan results in a complete remission in about 50% of the
patients [3]. Addition of Tumor Necrosis Factor α  (TNF) to melphalan has
proven most effective in terms of response rate, yielding a 80-90% complete
response rate, and an overall response of about 100% [4, 5]. In locally advanced
soft tissue sarcomas the use of TNF in combination with melphalan has proven
remarkably effective in rendering irresectable tumors resectable and thereby
preventing amputations [4, 5]. The efficacy of TNF against the drug-resistant soft
tissue sarcomas has led to the approval of TNF by the EMEA (European
Medicine Evaluation Agency) for its use in combination with melphalan [6].
In the ILP system, TNF is administered in a 10-fold higher dose compared with
the maximum tolerable dose (MTD) in systemic administration. The MTD of
TNF in single dose intravenous (i.v.) or intramuscular (i.m.) administration is
limited by toxicity at 400 µg m-2 [7, 8]. Toxicity consists of fever, hypotension,
chills and transient leucopenia. Hardly any tumor response has been reported after
systemic administration of TNF [8-10].
Despite careful precautions systemic leakage of more than 10% appeared in 10
patients during the last 8 years in our hospital. These patients had a remarkably
mild clinical course. To get more insight in the cause of this discrepancy between
the high systemic concentration of TNF and the mild clinical symptoms, we
studied cytokine levels and the acute phase response.
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PATIENTS AND METHODS
Patients
From the 212 patients who underwent an ILP with TNF and melphalan in the past
8 years in our hospital, 10 patients were selected because of very high systemic
levels of TNF, caused by leakage from the perfusate. These patients were treated
because of an irresectable sarcoma (n=6) or melanoma with multiple in transit
metastases (n=4). Demographic and treatment characteristics are summarized in
table 1. As a control group we studied 9 comparable patients undergoing ILP
without systemic leakage. These patients were all sarcoma-patients, who
underwent a 90-minutes long ILP with 3 to 4 mg TNF. Mean age was 48 years
(range, 21 to 77).
Patient
no.
age sex Diagnosis Arm/
leg
Duration
of
perfusion
dose
(mgTNF)
%
leak
max
systTNF
(ng mL-1 )
1 55 F Sarcoma leg 90 min 2 23% 169
2 52 F Melanoma leg 90 min 4 20% 178
3 66 M sarcoma arm 90 min 3 12% 30
4 61 F sarcoma arm 30 min 3 65% 277
5 71 F melanoma leg 90 min 2 24% 112
6 56 M sarcoma leg 90 min 2 15% 77
7 65 M melanoma leg 90 min 2 32% 108
8 64 F melanoma leg 90 min 4 13% 104
9 83 M sarcoma leg 75 min 4 19% 174
10 55 F sarcoma leg 90 min 4 16% 90
Table 1. Patient characteristics
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Treatment schedule
The procedure of ILP has been described previously [5]. Briefly, ILP consisted of
a 90 minutes long perfusion with 3 to 4 mg of recombinant-human-TNF
(Boehringer Ingelheim, Germany) and 10 to 13 mg L-1 perfusion tissue of
melphalan (Alkeran) (Burroughs Wellcome, London, UK) at mild hyperthermia
(39 to 40°C). Composition of the perfusate was as follows: priming volume of
700 to 850 mL consisted of 400 to 500 mL blood (50% red blood cells, 50%
plasma), 200 to 400 ml 5% dextran-40 in glucose 5% (Isodex, Pharmacia,
Uppsala, Sweden), 10 to 30 ml 8.4% sodium bicarbonate and 0.5 mL 2500 to
5000 IU heparin. TNF was injected as a bolus into the arterial line provided limb
tissue temperature was > 38°C. Melphalan was administered 30 minutes later at
limb temperatures between 39-40°C. At the end of perfusion, the limb was
washed with at least 2 liters of 6% dextran-70 (Macrodex, Pharmacia, Uppsala,
Sweden). During and after ILP vital signs of the patients, including body
temperature, heart rate, blood pressure and fluid balance were recorded. Toxicity
was registered according to the World Health Organization criteria [11].
Leakage monitoring
During ILP, there was a dynamic balance between two pressure compartments,
the systemic vasculature and the isolated circuit, which could be influenced by
adjusting the systemic blood pressure and/or the extracorporeal flow rate.
Throughout the perfusion period any potential leakage of the drugs was
monitored using a radioactive tracer. A small calibration dose of human serum
albumin radiolabeled with iodine 131 or technetium 99m was injected into the
systemic circulation and a 10-fold higher dose of the same isotope into the
isolated extremity. Continuous monitoring was performed with a precordial
scintillation probe. Systemic leakage was expressed quantitatively as a percentage
such that 100% leakage represented a homogeneous distribution of the isotope in
the body.
Blood sampling procedure
Venous blood samples were collected at several time-points, i.e., the day before
ILP, just before administration of TNF in the perfusate, halfway perfusion, just
before release of the tourniquet (after completion of the washout procedure at the
end of the perfusion). Then after ILP, 5, 10, 30 minutes, 3 and 7 hours after
release of the tourniquet and once a day until 7 days after ILP. Samples from the
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perfusate were obtained at time-points: 0 (just before administration of TNF) and
10, 30, 60 and 90 minutes after administration of TNF. Blood samples were
immediately centrifuged; plasma was collected and stored at -70°C until tested.
Assays for cytokine and acute phase protein analysis
Cytokine and acute phase protein levels were measured using enzyme-linked
immunosorbent assay (ELISA). Used antibodies were obtained from the Central
Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). For
measuring TNF, as described previously, flat-bottomed micro titer plates (Nunc,
Kamstrup, Denmark) were coated overnight with purified monoclonal antibody
(mAb) against TNF (CLB-TNF/7) [12]. After washing, serial dilutions of TNF-
containing samples were added. Bound TNF was detected by biotinylated sheep
anti-TNF. The detection limit of the assay was 5 pg mL-1 . Healthy controls were at
less than 5 pg mL-1 .
The IL-6 specific ELISA has been described previously [13]. A coat of CLB-IL-6/16
was applied overnight and bound IL-6 was detected by biotinylated affinity-purified
polyclonal sheep anti-IL-6. Lower detection limit was 1 pg mL-1 and normal healthy
control subjects were at less than 10 pg mL-1.
For IL-8 a coat of CLB-IL-8/1 MAb was applied overnight and bound IL-8 was
detected by biotinylated affinity-purified polyclonal sheep anti-IL-8. The lower
detection limit of this assay was 8 pg mL-1. Normal values were at less than 20 pg
mL-1 [14].
C-reactive protein (CRP) levels were measured by a sandwich ELISA using
polyclonal rabbit anti-human CRP Abs as catching Abs and biotinylated mAb anti-
CRP (CLB anti-CRP-2) as a detecting Ab. Results were referred to a standard
(Behringwerke AG, Marburg, Germany) and expressed in mg L-1. The detection
limit was 10 ng L-1 [15].
The ELISA used for measuring secretory phospholipase A2 (sPLA2) has been
described before [16]. Two different mAbs against human sPLA2 were used as
coating and catching antibodies respectively. The lower limit of detection was 0.1 ng
mL-1. Normal healthy volunteers were at less than 5 ng mL-1.
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Statistics
Median values are expressed with range. Comparison between the cytokine and
acute phase protein levels in the 2 groups (with and without leakage) were made
by the Mann-Whitney test. Values of p ≤ 0.05 were considered to be statistically
significant.
RESULTS
Systemic toxicity
Ten patients with a systemic leakage percentage of more than 10% were entered
in this study. Leakage varied from 12 to 65% (mean 24%, table 1). Because of
expected toxicity all patients were well monitored at our intensive care unit post-
operatively. Systemic toxicity is summarized in table 2.
During ILP blood pressure and pulse rate remained stable with adequate fluid
management. The body-temperature did not increase above 38°C. After ILP, all
patients received indomethacin to suppress flu-like symptoms. Eight out of 10
patients developed fever grade II (range, 38 to 40°C) within a few hours after ILP
(mean maximal temperature 38.9°C). In the patients without detectable leakage
the mean maximal temperature was 38.1°C. In 4 leakage-patients the heart rate
increased to more than 110 beats per minute (range, 120 to 132). Four patients
had a hypotension, which was not quickly restored to normal values by fluid
administration alone, requiring additional treatment with dopamine (3 to 6 µg kg-1
min -1) during 2 to 3 days. From start of surgery a mean of 8 liters was
administered to the leakage-patients over the first 16 hours versus 5 liters for non-
leakage patients. Leucopenia and thrombocytopenia was absent or mild. Grade IV
leucopenia and thrombocytopenia in one patient was induced by leakage of
melphalan. No transfusion was required. Patients without leakage did not develop
hematological toxicity. All leakage-patients had a hyperbilirubinemia after 2 days
and the transaminases increased (grade I-II). In the no leakage group only 1
patient had a mild hyperbilirubinemia. No pulmonary or renal toxicity was
observed in any patient.
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Toxicity WHO grade
LEAKAGE Grade 0-I Grade II Grade III Grade IV
Fever 2 8 0 0
Hypotension 3 3 4 0
Leukocytes a 8 0 1 1
Platelets b 6 3 0 1
Bilirubin c 3 3 4 0
OT/PT d 7 3 0 0
Nausea 8 2 0 0
NON-
LEAKAGE
Grade 0-I Grade II Grade III Grade IV
Fever 6 3 0 0
Hypotension 9 0 0 0
Leukocytes 9 0 0 0
Platelets 9 0 0 0
Bilirubin 9 0 0 0
OT/PT 9 0 0 0
Nausea 8 1 0 0
a gr. III: 0-1.9 x 109 L-1iter; gr.IV: < 1.0 x 109 L-1iter
b gr. II: 50-74 x 109 L-1iter; gr.IV: < 25 x 109 L-1iter
c gr. II: 2.6-5 x N; gr. III: 5.1-10 x N (N = upper limit of normal value)
d gr. II: 2.6-5 x N
Table 2. Systemic toxicity following ILP in the 10 patients with leakage to the systemic
circulation compared to 9 patients without leakage.
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Plasma cytokine and acute phase protein levels
In figure 1, median values with range are represented for the cytokines TNF and
IL-6 and the acute phase proteins (APPs) CRP and sPLA2. Median peak levels of
all measured cytokines and APPs in both patient groups, depicted in table 3, were
significantly different (p-values in table 3). Because we know the curves of IL-8
and sPLA2 from previous published experiments we restricted the determinations
to the pre-operative and the maximum level time points [17, 18].
In the leakage group very high circulating concentrations of TNF are found
during perfusion (at – 45 minutes) in contrast to the non-detectable TNF levels in
patients without leakage. Plateau circulating concentrations are measured at the
end of the perfusion lasting up to 30 minutes after ILP. The small amount of TNF
that remains in the limb after the washout procedure does not increase the
colossal systemic levels any further in these patients in contrast to what is
observed in patients without leakage. There we observed a brief peak of systemic
levels more than hundredfold less than in leakage patients. Moreover the peak
occurs typically at 5-10 minutes after ILP and represents the TNF that was left
behind in the limb after the washout. TNF-levels decreased already after 30
minutes, because rapid clearance of this cytokine with a short half-life time of 17
minutes is operational. Thus, in leakage-patients very high TNF-concentrations
are present for about 4 hours, whereas a very short peak of 20-30 minutes of
“moderate” increased TNF-levels is present in leakage free patients. There was a
strict correlation between the degree of leakage estimated by isotope monitoring,
the (adjusted) dose of TNF and the measured maximum systemic levels of TNF,
depicted in table 1.
IL-6 increased already during perfusion in leakage-patients, immediately induced
by TNF. In the non-leak patients IL-6 increased 5 to 10 minutes after ILP, i.e.,
after TNF from the washed out limb appeared in the systemic circulation.
Maximum values of IL-6 were reached 3 hours after ILP. IL-8 showed the same
pattern as IL-6 (data not shown). In the control group, values of IL-6 and IL-8
were 10-60 times lower than in the leakage-patients.
The acute phase protein CRP was increased from 3 hours after ILP until over 7
days after ILP. Peak levels occurred at day 1. The CRP curve in patients without
leakage was comparable, but the peak-value was higher. Levels of sPLA2 were
very different for each patient. However, the pattern was consistent, with the start
of increase at 3 hours after ILP and the peak at day 1. Levels were still increased
after 7 days. Levels in the non-leakage patients were factor 6 lower.
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Levels of cytokines and acute phase proteins in perfusate
No significant difference was observed in perfusate-levels of cytokines and acute
phase proteins in patients who underwent ILP with systemic leakage and without
leakage. From the ILP-patients with systemic leakage, only 5 series of perfusate
samples were available. Curves are presented in figure 2. TNF levels remained
stable around 7.5 µg mL-1. IL-6 increased after 10 minutes of perfusion, to 4.3 ng
mL-1 at the end of perfusion. IL-8 increased from 65 pg mL-1 to 1600 pg mL-1
during perfusion. CRP did not change during perfusion, with values hardly
detectable or at less than the detection limit. In 3 out of 5 patients sPLA2
increased during perfusion; the median value at the end of perfusion was 14 ng
mL-1, range 8.5 to 266 ng mL-1.
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Figure 1. Median (with range) levels of TNF (a), IL-6 (b), CRP (c) and sPLA2 (d) in
plasma from 10 patients who underwent an ILP complicated by high leakage (> 12%) to
the systemic blood circulation (). For TNF (a), IL-6 (b) and CRP (c) the curves of the
non-leakage group () are also depicted, for sPLA2 only two control levels (pre and day
1) are shown. Time-points were as follows: pre, pre-operative; 0’, just before perfusion; -
45’, half-way perfusion; -1’, just before release of the tourniquet; 5’ (10’, 30’), 5 (10, 30)
minutes after release of the tourniquet; 3h and 7h, 3 and 7 hours after ILP; d1 to d7:
number of days after ILP
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Cytokine/acute
phase protein
time-point Leakage-patients
median (range)
no leakage
median (range)
p-value
TNFα ng mL-1 10 min after
ILP
108 (26-277)  1.4 (0.3-3.4) p<0.001
IL-6 ng mL-1 3 hours after
ILP
49 (13-257)  0.8 (0.3-3.3) p<0.001
IL-8 ng mL-1 3 hours after
ILP
14 (1.3-49) 0.2 (0.01-1.7) p<0.001
CRP mg L-1 day 1 76 (34-419) 166 (93-350) p<0.01
SPLA2 ng mL
-1 day 1 568 (123-986)   84 (20-390) p<0.01
Table 3. Median and range of peak-levels of cytokines and acute phase proteins in 10
patients who underwent ILP with >10% leakage compared with 9 patients without
leakage in the systemic circulation
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Figure 2. Median (with range) of cytokine (a) and acute phase protein (b) profile in
perfusate from 5 patients who underwent an ILP complicated by high leakage (> 12%) to
the systemic blood circulation. Time-points: 0’, just before administration of TNF in the
perfusate; 10’ (30’, 60’), 10 (30,60) minutes after start of perfusion; 90’, end of perfusion,
just before release of the tourniquet.
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DISCUSSION
The aim of our study was to quantify cytokine levels and acute phase response in
patients who underwent an ILP with high dose TNF complicated by high leakage
compared with the same variables in patients without leakage, and correlate
findings with clinical toxicity. In this study, we measured TNF plasma-levels up
to 277 ng mL-1. Nevertheless, most of the patients needed only extra intravenous
fluid administration. Systemic levels of this magnitude have been described
before in the same setting and once after a 30-min intravenous infusion of
recombinant TNF [19-21].
In our patients the necessity for dopamine administration was not related to the
highest levels of TNF in the systemic circulation. This finding is in accordance
with previous studies in which no correlation between maximum TNF
concentrations in the peripheral blood of an individual and the side effects could
be found, which indicates that patients vary in their sensitivity to TNF [19, 22].
Systemic toxicity seems to be determined by the duration of exposure to high
levels of TNF. Our data demonstrate this clearly with levels of 1000 to more than
100.000 pg mL-1 for 4 hours in high leakage patients, and only “moderate” levels
(~ 1000 pg mL-1 for 20 minutes) in non-leakage patients. In non-leakage patients,
20 minutes of “moderate” TNF-levels were not enough to cause hypotension.
This is in accordance with the findings reported previously in this journal by
Vrouenraets et al., who described minimal toxicity after leakage-controlled ILP in
20 patients [23]. The IL-6 curves demonstrate the effect of prolonged exposure to
high TNF levels even more pungently. Even at 24 hours after ILP, IL-6 levels are
still higher in the leakage-patients than the peak IL-6 levels observed in ILP-
patients without leakage. IL-6 levels remained elevated for at least 3 whole days.
In the 10 patients with high leakage, 4 hours of exposure to very high levels of
TNF resulted in 3 patients with grade II and 4 patients with grade III hypotension.
Four patients required dopamine support temporally with good response. In phase
I-II studies on the systemic administration of TNF dose-limiting toxicity was
observed at TNF-concentrations similar to those observed in our 10 patients
described here. For instance Schaadt et al. reported dose-limiting hypotension in
32% of the patients after administration of 650 µg m-2 intravenously resulting in a
systemic TNF peak concentration of approximately 270 ng mL-1. Moreover grade
II hepatotoxicity was observed in 80% of the patients. This is quite different from
the relative lack of toxicity observed in our 10 ILP-patients who had similar
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systemic TNF peak concentrations. In other studies hypotension was dose
limiting at lower doses, with serum TNF levels of 10 ng mL-1 [7, 8].
In comparison with septic shock the duration of exposure to elevated levels of
TNF in the leakage-patients is relatively short. The prolonged exposure in septic
shock, despite of concentrations many times lower than the short peak levels after
ILP, results in the typically unresponsiveness of the hypotension to fluid
challenge in the septic shock patients [24-27]. Adequate diuresis plays a key-role
to keep the period of high circulating TNF-levels as short as possible to prevent a
septic shock like state in perfusion patients. That patients are well hydrated at the
time of exposure to TNF, and that their blood pressure is optimally maintained by
fluid challenge, and only if necessary also the use of dopamine, prevents septic
shock like situation. This explains why these patients have little toxicity in view
of the very high circulating TNF-levels. It is a fundamental difference with often
poorly hydrated patients with metastatic cancer who received intravenous TNF in
phase I-II studies in the past. Moreover, septic patients are infected and have
significant levels of endotoxin, which has been shown to be synergistic with TNF
for toxicity (in rats) [28, 29]. In addition, Feelders et al. have shown in patients
who underwent ILP,  cortisol is already increased prior to the TNF-peak as a
result of surgery and anesthesia [30]. The cortisol response may have a down-
regulatory effect on TNF.
The increased TNF-levels in the patients with systemic leakage were followed by
significant higher levels of IL-6 and IL-8. This is in accordance with previous
studies [17, 21, 31]. In our study, we also determined CRP and sPLA2 as
parameters of the acute phase response. sPLA2 levels were more increased in the
leakage-patients; CRP, in contrast, had significantly lower levels in these patients
at the time points of maximum values. Lower levels of CRP than expected were
also observed in patients who underwent an isolated hepatic perfusion (IHP) [32].
That CRP had even lower levels in leakage-patients could be ascribed to a higher
expenditure of CRP in the neutralization of the effects of exposure to higher
levels of TNFα [33-35].
In conclusion, ILP complicated by high leakage to the systemic circulation
resulted in high systemic levels of TNF up to 277 ng mL-1. IL-6 and IL-8
followed with significantly higher levels compared with values measured in
patients without leakage. The pattern of the acute phase proteins CRP and sPLA2
resembled each other, except that CRP levels had significantly lower maximum
levels in leakage-patients compared with patients without leakage. Overall the
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patients with high systemic leakage had a marked mild clinical course. It is our
experience that even in patients with very high leakage life-threatening reactions
have not occurred and that temporary hypotension can be easily dealt with by
fluid challenge and sometimes by temporary vasopressor support. Our
observations support the need for further study regarding potential use of TNF
systemically.
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ABSTRACT
In this study we have evaluated soluble tumor necrosis factor α receptor
(sTNFR) p55 and p75 levels in patients who underwent Isolated Hepatic
Perfusion (IHP) with tumor necrosis factor α (TNF) and melphalan for
irresectable colorectal liver metastases.
An extracorporeal veno-venous bypass was used to shunt blood from the lower
body and intestines to the heart. Inflow catheters were placed in the hepatic
artery and portal vein, and an outflow catheter in the infrahepatic inferior
caval vein. The liver was perfused for 60 min with TNF (0.4 mg (n=8), 0.8
mg (n=1)) plus 1 mg kg-1 melphalan (IHPTM group) or 1 mg kg
-1 melphalan
alone (IHPM group, n = 3). The liver was washed with macrodex (washout)
before restoring vascular continuity. After the washout procedure, a TNF peak
(169 ± 38 pg mL-1) was demonstrated in the IHPTM group only. In both groups
levels of both sTNFR increased after the IHP and were still higher than pre-
operative values after two weeks. In the patients with TNF added, sTNFR-p55
levels were higher than sTNFR-p75 levels, whereas patients in the melphalan
alone group demonstrated the reverse. Furthermore, sTNFR-p55
concentrations were significantly higher in the IHPTM group, and remained so
during the following 2 weeks. In contrast, there were no significant differences
in sTNFR-p75 levels between groups.
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INTRODUCTION
Tumor Necrosis Factor-α (TNF) is a 17 kD trimeric polypeptide cytokine,
produced mainly by activated mononuclear phagocytes. It was originally
recognized for its cytotoxic effect on tumor cells in vitro and for its capacity
to cause necrosis of solid tumors in vivo. TNF has diverse biological activities,
of which this antitumor effect has clinical desirability and great therapeutic
potential. However, TNF cannot be administered systemically in cancer
patients at effective doses because of prohibitive toxicity as was experienced
in phase I-II studies [1, 2]. In fact, it is estimated that only 1/20 to 1/50 of
doses with consistent antitumor effectivity in murine tumor models can be
administered in humans [3]. This concentration gap is unlikely to be
overcome in any mode of systemic administration. Thusfar only isolated
perfusion systems have been shown to increase cytostatic drug concentrations
more than 20-fold the maximum tolerated dose (MTD) when given
systemically [4]. It has become firmly established that TNF can indeed be
successfully applied in isolated limb perfusion (ILP) in melanoma patients as
well as in patients with very large tumors such as irresectable soft tissue
sarcomas [5-7]. ILP with TNF and melphalan resulted in a 30% complete
response (CR) and a 50% partial response rate (PR) in the latter patient
category and resulted in the approval of TNF by the EMEA (European
Medicine Evaluation Agency) for its clinical use in the setting of ILP [8].
Furthermore, this remarkable antitumor effectivity of TNF in combination
with melphalan proved to be effective against a wide range of histologies. 
TNF mediates its multiple effects on cell function by binding to specific high-
affinity cell surface receptors. Two distinct species of TNF receptors, one of
55 kD (TNFR-p55 or type I) and one 75 kD (TNFR-p75 or type II) have
been identified and purified [9, 10]. These receptors do not only exist as cell
surface membrane proteins but also as soluble proteins. Evidence indicates that
these soluble TNF receptors (sTNFRs) are derived by proteolytic cleavage
from the extracellular domain of the corresponding cell surface from a variety
of cells, mostly neutrophils, activated T-cells and monocytes. The formation
of sTNFRs in vitro is triggered by certain immune-stimulating agents and is
enhanced by a number of cytokines, including TNF itself [11, 12]. Elevated
levels of sTNFRs have been described in patients with cancer, HIV infection,
sepsis and malaria [13-15]. The exact function of sTNFRs is not known yet.
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The loss of cell surface TNF receptors may lead to a temporary decrease in
sensitivity of the cell to TNF. Furthermore, by binding to the TNF molecule,
soluble receptors could antagonize TNF function. On the other hand, the same
sTNFRs are proposed to augment TNF activity by the formation of so called
‘slow-release’ complexes, depending of the relative concentrations of sTNFRs
and TNF [16].
Recently, the technique of isolated perfusion of the liver has been developed
for the treatment of patients with irresectable hepatic malignancy. With this
technique, the liver circulation is completely separated from the systemic
circulation, thus allowing high drug levels within the liver whilst keeping
systemic exposure low [17]. Since sTNFRs are known to influence the
bioavailability of TNF (or modulate the effects of TNF), and since sTNFRs
are known to be induced by TNF itself, we hypothesized that Isolated Hepatic
Perfusion (IHP) with TNF and melphalan induces in-vivo formation of
sTNFRs. In the present study we therefore evaluated the effect of IHP with
recombinant human TNF (rhTNF) and melphalan on sTNFR-levels in
patients with irresectable colorectal metastases confined tot the liver.
PATIENTS AND METHODS
Patients
Twelve patients with colorectal metastatic liver disease gave informed
consent for undergoing Isolated Hepatic Perfusion (IHP) with TNF and
melphalan (IHPTM group, n = 9) or melphalan alone (IHPM group, n = 3).
There were 9 men and 3 women with a mean age of 59.8 years (range, 49 -
65). Inclusion criteria for IHP with TNF and melphalan included: histological
evidence of (irresectable) metastases of colorectal origin confined to the liver,
Karnofsky performance status of > 80%. Exclusion criteria included: extra-
hepatic malignant disease, > 50% hepatic tissue replacement by tumor, liver
cirrhosis, signs of significant hepatic dysfunction (abnormal levels of ASAT,
ALAT or Alkaline Phosphatase > 2 x Norm), and ascites or portal
hypertension. The protocol was approved by the hospitals' ethical
committees. The Study was carried out in accordance with the principles of
the Declaration of Helsinki, as revised in Hong Kong in 1989.
Soluble TNF receptor levels
105
Isolated Hepatic Perfusion Technique
The procedure of IHP has been described elsewhere [17]. Briefly, following
systemic heparinization (200 U kg-1), an extracorporeal veno-venous bypass
(VVB) circuit (pump aided) was created to shunt mesenteric, renal, and lower
extremity blood around the liver to the heart. Next, inflow catheters were
placed in the portal vein and hepatic artery, and an outflow catheter in the
infrahepatic inferior caval vein. These catheters were connected to a heart-
lung-machine, and the vascular isolation was completed by clamping the
suprahepatic inferior caval vein and the suprarenal inferior caval vein. The
liver was then perfused with a hyperthermic (> 38 °C) perfusate consisting of
a mixture of saline and erythrocytes. Once a stable perfusion was attained,
leakage from the perfusion circuit into the systemic circulation was measured
by the addition of 200 µci I131 -albumin into the perfusate and the continuous
monitoring of radioactivity scintillation probes placed over the perfusate
reservoir and VVB. The leak rate was monitored for the duration of the
perfusion and if the cumulative leak was greater than 15%, the perfusion
would be halted and the perfusate flushed from the circuit. After the absence
of leakage was confirmed, rhTNF (0.4 mg in eight patients, 0.8 mg in one)
was added as a bolus in the arterial line of the perfusion system (IHPTM group);
melphalan (1 mg kg-1) was given directly following the TNF bolus. In 3
patients (IHPM group), serving as a control group with regards to this study,
only melphalan (1 mg kg-1) was administered. After a 60 min perfusion, the
liver was washed thoroughly with a mixture of saline and macrodex,
decannulated, and vascular continuity restored. Heparin was reversed with 1
mg kg-1 protamine sulphate (Novo-Nordisk AS, Rud, Norway) injection.
Postoperatively, the patients were monitored in the ICU for at least 48 hours,
primarily to evaluate for evidence of systemic toxicity due to rhTNF.
Drugs
Recombinant human TNF (0.2 mg per ampoule) was a gift from Boehringer
Ingelheim GmbH, Ingelheim am Rhein, Germany. The cytostatic drug
melphalan (Alkeran) came as a sterile powder (100 mg) that was dissolved
aseptically using solvent and diluent obtained from Burroughs Wellcome,
London, UK.
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Sampling schedule
Blood samples were collected from a peripheral vein in siliconized 5 ml
Vacutainer tubes (Becton Dickinson, Plymouth, UK) containing EDTA 10
nmol L-1, soybean trypsin inhibitor 100 mg L-1, and benzamidine 10 nmol L-1
(Sigma Chemicals, Detroit, USA) to prevent any in vitro activation. Samples
were centrifuged immediately after collection, at 5000 rpm. for 5 minutes.
Supernatant was stored at minus 70 oC until analysis. Perfusate was sampled at
t = 0 (i.e., upon drug administration), 10, 20, 30, 40, 50, and 60 min.
Systemic plasma samples were collected at the day before IHP, during ILP at t
= 0, 30, and 60 min., and post-perfusion (after release of the VCI clamp) at t
= 1, 5, 10, 20, 30, 60, 120, and 180 min., at 21:00 h, day 1, 3, 5, and 7, and
weekly thereafter.
Assays
Tumor Necrosis Factor-α (TNF) levels were measured by a sandwich-type
enzyme linked immunosorbent assay (ELISA) using two monoclonal
antibodies (Dept. Immune Reagents, Central Laboratory of Blood
Transfusion, Amsterdam, Netherlands) raised against recombinant human
TNF (courtesy of Dr. A. Creasey, Chiron Corp., Emeryville, CA, USA). One
mAb (mAb CLB-TNFα-7) was used for coating at a concentration of 2 µg mL-
1. The other mAb (mAb CLB-TNFα-5) was biotinylated and used in
combination with streptavidin poly-horseradish peroxidase conjugate (CLB,
Dept. Immune Reagent) to detect bound TNF. Stimulated human mononuclear
cell supernatant was used as a standard for comparison with purified
recombinant human TNF. Results were expressed as pg mL-1 by reference t o
this standard [18].
Soluble TNFα receptor p55 (sTNF-R55) and soluble TNFα receptor p75
(sTNF-R75) levels were measured by an ELISA as described previously [12].
Briefly, polyclonal anti-sTNF-R55 (anti-sTNF-R75) antibody was used as a
capture antibody, and biotinylated, polyclonal rabbit antibodies in
combination with streptavidin conjugate were used to detect bound sTNF-R55
(sTNF-R75). Results were expressed as ng mL-1 by reference to a standard
consisting of human sTNF-R55 (sTNF-R75). The ELISA was shown to be not
affected by TNF concentrations as high as 1 µg mL-1. Normal values are < 2
ng mL-1 for both sTNFRs.
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Statistics
Results are expressed as means ± standard error of the mean (SEM).
Comparison within groups was made by means of the Friedman
Nonparametric Repeated Measures Test or by the Mann-Whitney Test, where
appropriate. Correlations between maximum levels of parameters were
calculated as Spearmann’s rank correlations. The significance level was taken
as a probability (two-sided) of < 0.05.
RESULTS
Operative procedure
The median operation time was 8 hours (range, 6 to 10). In all patients a
stable perfusion was attained. In one patient progressive systemic leakage
resulted in discontinuation of the IHP after 43 minutes (cumulative leakage:
20%). In all other patients no leakage could be demonstrated. Three patients
in the IHPTM group died peroperatively (n = 1) or in the direct postoperative
period (n = 2) due to complications of the operation. As the purpose of this
study is the description of the sTNFR levels in uncomplicated IHP, these
patients were excluded for this study.
Tumor Response and Survival
The primary efficacy endpoints in this study were the best tumor response
observed (WHO response criteria: complete response (CR), partial response
(PR), stable disease (SD), or progressive disease (PD)) and duration of the best
response, calculated from the date the best response was observed until the
date of progression. True-cut hepatic tissue samples and/or CT-scan-
evaluations were used to describe the best tumor response. In the IHPTM group
five out of six patients demonstrated CR or PR, one patient SD. Patients
treated with melphalan alone demonstrated PR or SD. The duration of best
response ranged from 17.5 to 32.5 weeks (median 18 weeks). In the evaluable
patients the survival time ranged from 6 to 26 months. The median survival
time was 10.3 months (mean: 13.3).
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TNF levels
In the perfusate, TNF levels in the IHPTM group were 1.8 ± 0.5 pg mL
-1 at t  = 0
min and increased rapidly to 6.0 ± 2.0 x 104 pg mL-1 at t  = 10 min. Thereafter,
TNF levels decreased to 2.8 ± 0.9 x 104 pg mL-1 at the end of IHP (t  = 60 min).
In the IHPM group TNF levels did not demonstrate any significant changes.
(figure 1, left panel)
Baseline serum TNF levels were similar in both groups, although these levels
were higher than normal (4.3 ± 0.5 pg mL-1 and 4.5 ± 1 pg mL-1 in the IHPTM
and IHPM group resp.). During IHP TNF levels did not change significantly,
indicating that vascular isolation was effective. However, after washout, TNF
levels increased rapidly to a peak value of 169 ± 38 pg mL-1 at t  = 1 min in the
IHPTM group, and normalized within the next 3 hours. In the IHPM group, TNF
levels demonstrated a slight increase to 7.2 ± 5 pg mL-1 within the first 30
minutes after IHP. However, this elevation of TNF levels in the IHPM group
was not statistically significant  (figure 1, right panel)
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Figure 1. Course of TNF levels before, during and after IHP. Left hand panels show
perfusate levels,  right panels show systemic levels. Time is expressed on the x-axis; left
panel: minutes during perfusion; right panel: D-1 = the day prior to IHP; 0, 30, 60, 61,
120 = 0, 30, 60, 61, 120, 240 minutes after start of IHP (61m represents the time just
after vascular restoration, not shown in following panels); 9h=9h after IHP; D1, D3, D5,
D7 = first, third, fifth and seventh day after IHP. (--), represents the group of patients
receiving TNF and melphalan; (--), the group of patients receiving melphalan alone.
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Soluble TNF receptor levels
sTNFR-p55 levels
In the perfusate, baseline sTNFR-p55 levels were mildly elevated in both the
IHPTM and IHPM group (5.4 ± 0.7 ng mL
-1 resp 2.66 ± 0.62 ng mL-1). During
IHP, sTNFR-p55 levels increased over time to 9.9 ± 0.7 ng mL-1 in the IHPTM
group (p<0.01) and to 4.57 ± 1 ng mL-1 (n.s.) in the IHPM group. The
difference between groups was significant (p<0.01) (figure 2, left panel).
Serum sTNFR-p55 levels before and during the IHP did not change
significantly in both groups. After the washout procedure, the sTNFR-p55
levels rose significantly in all patients, reaching the highest levels in the
IHPTM group (p<0.01 between groups). Maximum sTNFR-p55 levels were
12.7 ± 2.7 ng mL-1 and 3.0 ± 0.6 ng mL-1 in the IHPTM and IHPM group
respectively. Furthermore, after 2 weeks, sTNFR-p55 levels were still elevated
in the IHPTM group (9.1 ± 2.9 ng mL
-1), whereas levels in the IHPM group had
normalized (figure 2, right panel).
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Figure 2. Course of soluble TNF receptor p55 (sTNFRp55) levels before, during and after
IHP. Left panel show perfusate levels, right panel show systemic levels. Concentration is
expressed on the y-axis in ng mL-1. Time is expressed on the x-axis; left panel: minutes
during perfusion; right panel: D-1 = the day prior to IHP; 0, 30, end, 120, 180 = 0, 30,
60, 120, 180 minutes after start of IHP; 21h = 9 hours after IHP; D1, D3, D5, D7, D14
= first, third, fifth, seventh and fourteenth day after IHP. (--), represents the group of
patients receiving TNF and melphalan; (--), the group of patients receiving melphalan
alone.
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sTNFR-p75 levels
Perfusate baseline sTNFR-p75 levels were also slightly elevated in both the
IHPTM and IHPM group (1.4 ± 0.3 ng mL
-1 and 1.96 ± 0.26 ng mL-1,
respectively). During IHP, sTNFR-p75 levels rose in both groups, to  4.1 ±
0.9 ng mL-1 in the IHPTM group (p<0.05) and to 2.52 ± 0.08 ng mL
-1 in the
IHPM group (n.s.). (figure 3, left panel).
Serum sTNFR-p75 levels during the IHP did not change significantly in both
groups. After the washout procedure, sTNFR-p75 levels rose significantly in
all patients. In contrast with sTNFR-p55 levels there was no significant
difference between groups. Maximum sTNFR-p75 levels were 6.9 ± 2.0 ng
mL-1 and 6.3 ± 3.0 ng mL-1 in the IHPTM resp IHPM group. Although not as
high as sTNFR-p55 levels, sTNFR-p75 levels remained elevated in the both
the IHPTM group (3.6 ± 0.7 ng mL
-1) and IHPM group (3.9  ± 0.8 ng mL
-1)
after 2 weeks (n.s. between groups). (figure 3, right panel)
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Figure 3. Course of soluble TNF receptor p75 (sTNFRp75) levels before, during and after
IHP. Left panel show perfusate levels, right panel show systemic levels. Concentration is
expressed on the y-axis in ng mL-1. Time is expressed on the x-axis; left panel: minutes
during perfusion; right panel: D-1 = the day prior to IHP; 0, 30, end, 120, 180 = 0, 30,
60, 120, 180 minutes after start of IHP; 21h = 9 hours after IHP; D1, D3, D5, D7, D14
= first, third, fifth, seventh and fourteenth day after IHP. (--), represents the group of
patients receiving TNF and melphalan; (--), the group of patients receiving melphalan
alone.
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DISCUSSION
In this study, we describe the effects of Isolated Hepatic Perfusion (IHP) with
TNF and melphalan, or melphalan alone, on the patterns of TNF and its p55
and p75 soluble receptor levels in patients with unresectable colorectal
malignancy confined to the liver. After the washout procedure, the rapid and
transient appearance of TNF could be demonstrated in the serum of patients
in the IHPTM group, which was absent in the IHPM group. In all patients, levels
of both sTNFRs increased significantly after IHP demonstrating a different
pattern. In the patients with TNF added, sTNFR-p55 levels were higher than
sTNFR-p75 levels, whereas patients in the melphalan alone group
demonstrated the reverse. Furthermore, sTNFR-p55 concentrations were
significantly higher in the IHPTM group, and remained so during the following
2 weeks. In contrast, there were no significant differences in sTNFR-p75
levels between groups.
In order to avoid systemic exposure to chemotherapeutic agents or cytokines,
the main goal of the isolation perfusion technique is complete vascular
isolation of the limb or organ. In our study vascular isolation of the liver was
complete in all patients but one (IHPTM-group). In this patient progressive
systemic leakage (cumulative leakage: 20%) led to premature termination of
the IHP procedure after 43 min. However, despite this leakage, this patient
did not demonstrate additional toxicity as demonstrated by clinical as well as
biochemical parameters, compared to the other patients studied [19].
Furthermore, this patient did not demonstrate any significant differences in
sTNFRs levels. In our eight patients without discernable leakage, systemic
TNF levels did not change significantly during IHP, indicating that vascular
isolation was complete. After the washout procedure, however, systemic TNF
levels in the IHPTM group peaked rapidly and normalized within the next two
to three hours (figure 1, right panel). A possible explanation for this TNF
peak in the IHPTM group could be the release of remnant TNF in the liver
after the washout procedure, a phenomenon also described in Isolated Limb
Perfusions (ILP) with TNF and melphalan [20, 21]. Furthermore, endogenous
TNF production may have attributed to this peak, since surgery, extra
corporeal circulation circuits, and intravascular plastic catheters are known t o
induce TNF [22, 23]. However, the latter explanation may be of less
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importance since only mild elevation of systemic TNF levels could be
demonstrated in the IHPM group (figure 1).
Our finding of elevated pre-operative sTNFR levels is in contrast with the
normal levels described in Isolated Limb Perfusion [21, 24]. Several other
studies however reported elevated sTNFR levels in patients with various
malignancies, with highest levels in disseminated disease and lower to normal
levels in patients with more localized cancer [16, 25]. This could well be the
explanation of the virtually normal preoperative sTNFRs levels in patients
undergoing Isolated Limb Perfusion (ILP) for irresectable sarcomas of the
extremities (localized cancer) compared to the patients described in this study
[21, 24].
After IHP, levels of both sTNFRs increased significantly. Elevated sTNFR
levels have also been demonstrated in patients with chronic renal failure or
dialysis, and a positive correlation with plasma creatinine was demonstrated in
patients with different degrees of chronic renal failure [26-29]. Indeed, recent
studies indicate that soluble TNF receptor levels are influenced by renal
function. Furthermore, a central role of the kidney in the clearance of TNF
and TNF - sTNFR complexes has been demonstrated by Bemelmans et al. in
mice [30]. Therefore, renal function has to be monitored, in order to evaluate
sTNFR levels. Since one of the systemic side effects of TNF is (acute) renal
failure/renal impairment, it could be suggested that the elevation in sTNFR
levels after the IHP procedure are the result of a decrease in renal clearance.
None of the patients presented here demonstrated renal failure as indicated by
serum creatinine and urea levels (data not shown). Therefore, in our study, the
increased sTNFR levels before, during and after IHP cannot be explained by a
decrease in renal clearance.
Our finding of sTNFRs induction after IHP with TNF and melphalan confirms
previous studies by others on the systemic administration of TNF. Lantz et al
showed a rapid and transient release of TNF binding protein (TNF-BP,
sTNFR) in five patients with various malignancies [11]. Furthermore, an
inductive role of TNF on the release of sTNFRs has been suggested by Jansen
et al, who demonstrated that blocking TNF with neutralizing antibodies,
strongly inhibited sTNFR induction in chimpanzees [31]. More recently,
elevated sTNFR levels have been demonstrated after ILP with TNF and
melphalan, with higher sTNFR concentrations in those patients with leakage
of TNF from the circuit during the perfusion [32]. Since elevated sTNFR
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levels were also demonstrated in our patients without TNF added, there must
be an inductive role for the IHP procedure (with melphalan) itself. Indeed,
several reports describe elevated sTNFR levels after major surgical procedures,
including liver surgery [33, 34]. Schroder et al demonstrated prolonged
elevated sTNFR concentrations after gastrectomy and liver resection,
whereby  levels after liver surgery remained elevated for a longer (up to one
week) period [34]. Similar results have been described in ILP with TNF and
melphalan for irresectable sarcomas of the limb, with higher sTNFR levels in
those patients with leakage of TNF.
Several hypotheses about the in vivo function of sTNFRs have been postulated
with evidence of both antagonistic and carrier (buffer) effects. There are
indications that the soluble forms of TNF receptors are derived by proteolytic
cleavage from the extracellular domain of the corresponding cell surface form
(shedding) [35]. The result of this cleavage of sTNFRs from the cell surface
might result in a down regulation of the number of cell surface receptors, with
a subsequent decreased responsiveness of the cell to circulating TNF [36].
Since both sTNFRs are still capable of binding TNF, they can compete for
TNF with the cell surface form. In vitro the shedding of the sTNFR-p75 is
triggered with TNF-mimetic antibodies. The shedding of the sTNFR-p75,
leading to the above mentioned down regulation of this receptor on the cell-
surface, can reduce the cell-associated TNFR-p75 passing of TNF to the p55
receptor, and thus acting as a desensitization mechanism [16]. This
mechanism has been confirmed in vivo, and could explain the observation that
in most studies, sTNFR-p75 levels are higher than p55 levels. In accordance
with these reports are the sTNFR patterns and maximal concentrations
demonstrated here in IHP with melphalan alone. In contrast, patients with
TNF added to the perfusate showed a reverse pattern with higher sTNFR-p55
concentrations. Possibly, in IHP with TNF and melphalan different shedding
mechanisms are responsible for the induction of sTNFR-p55 and –p75, which
might lead to excessive shedding of the TNFR-p55 instead of p75. The reason
for this is unclear, but other factors than TNF, e.g. interleukin-6 (IL-6) might
be involved in the induction of sTNFR-p55 as has been demonstrated by Tilg
et al [37]. This alternative (p55 mediated) desensitization mechanism has also
been demonstrated by Leist et al who showed that extensive for induction of
hepatocyte apoptosis and liver failure [38]. Arguing that the increased
sTNFR-p55 levels indicate a down regulation of the membrane bound
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receptor, this process might make the hepatocyte less prone to the induction
of TNF mediated apoptosis. In this light, an interesting question would be
whether the down regulation of membrane bound TNF receptors, with
subsequent (possible) protection against TNF, may have implications for the
antitumor effects of TNF treatment. Further research is mandatory in order
to evaluate this putative sTNFR-mediated antitumor effect of TNF.
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ABSTRACT
Clinical trials of isolated limb perfusion (ILP) with recombinant human tumor
necrosis factor alpha (TNF) and melphalan resulted in high complete response
rates of 75 to 90 % in patients with in transit melanoma and unresectable sarcoma
of the extremities. Recently we demonstrated, what we consider a key explanation
for the potent synergy between TNF and chemotherapy, an up to six-fold
increased intratumoral melphalan or doxorubicin concentration in rat sarcomas
after ILP when high dose TNF was co-administrated. Moreover in our pre-clinical
ILP model we observed drastic alterations in tumor microvasculature integrity.
These findings led to the hypothesis that TNF causes specific destruction of
tumor endothelial cells and thereby induces an increased permeability of tumor
vasculature. Isolated hepatic perfusion (IHP) with melphalan with or without TNF
is currently performed in clinical trials in patients with hepatic metastases.
However, whether TNF contributes to the therapeutic efficacy in IHP still
remains unclear. In an in vivo rat liver metastases model we studied three
different tumors: colon carcinoma CC531, ROS-1 osteosarcoma and BN-175 soft
tissue sarcoma which exhibit different degrees of vascularisation. IHP was
performed with melphalan with or without addition of TNF. IHP with melphalan
alone resulted in all tumor types in a decreased growth rate. However in the BN-
175 tumor addition of TNF resulted in a strong synergistic effect. In the majority
of the BN-175 tumor bearing rats a complete response was achieved. In vitro
cytoxicity studies showed no sensitivity (CC531 and BN-175) or only minor
sensitivity (ROS-1) to TNF, ruling out a direct interaction of TNF with tumor
cells. The response rate in BN-175 tumor bearing rats when TNF was co-
administrated with melphalan was strongly correlated with drug accumulation in
tumor tissue, as only in these rats a 5-fold increased melphalan concentration was
observed. Secondly, immunohistochemical analysis of microvascular density
(MVD) of the tumor showed a significantly higher MVD for BN-175 tumor
compared to CC531 and ROS-1. These results indicate a direct relationship
between vascularity of the tumor and TNF-mediated effects. Assessment of the
tumor vasculature of liver metastases would be a way of establishing an
indication for the utility of TNF in this setting.
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INTRODUCTION
Tumor necrosis factor α (TNF) is a cytokine with an interesting potential in the
treatment of cancer [1]. However when administered systemically it is
accompanied with severe toxicity, but when TNF is used locoregionally in
combination with chemotherapy  without systemic exposure it has very potent
antitumor effects. Clinical trials of isolated limb perfusion (ILP) with
recombinant human TNF (rhTNF) and melphalan resulted in high complete
response rates of 75-90 % in patients with in-transit melanoma and unresectable
sarcoma of the extremities [2-7]. This is in contrast to ILP with melphalan alone
which is relatively effective against small in transit melanoma metastases but
achieves very poor results against large tumors such as soft tissue sarcomas  [8-
10].
In order to elucidate the mechanism of TNF several studies have been performed.
In our pre-clinical ILP model we observed drastic alterations in tumor
microvasculature integrity [11]. Rüegg et al. demonstrated elegantly that TNF in
combination with IFN-γ induced functional down regulation of αvβ3, resulting in
detachment of the endothelial cells of the tumor vasculature [12]. In patients,
angiographic studies performed pre and post TNF perfusion showed selective
destruction of tumor associated vasculature and histologic studies demonstrated
hemorrhagic necrosis of the tumor [2, 6]. Recently we demonstrated, what we
consider a key explanation for the potent synergy between TNF and
chemotherapy, an up to six-fold increased intratumoral melphalan or doxorubicin
concentration in rat sarcomas after ILP when high dose TNF was co-
administrated [13, 14]. These findings led to the hypothesis that TNF causes
specific destruction of tumor endothelial cells and thereby induces an increased
permeability of tumor vasculature.
As a result of the favorable experience with the ILP system, other isolated
perfusion settings have been developed [15, 16].  Especially the liver offers
superb opportunities for isolated perfusion. Irresectable liver metastases are a
significant clinical problem. Isolated hepatic perfusion (IHP) with melphalan with
or without TNF is technically feasible and is currently performed in clinical trials
in patients with hepatic metastases [17, 18]. Whether TNF contributes to the
therapeutic efficacy in IHP still remains unclear.
Based on our findings in the ILP studies, it is indicated to study whether TNF can
improve tumor response in different tumors after IHP and, if so, to investigate the
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capability of TNF to augment drug accumulation in this perfusion setting. By
addressing this issue, the usefulness of TNF in IHP might be become clear. Since
the tumor associated vasculature is the target of TNF, we expect that tumor
microvessel density (MVD) is a predictor of the potentiating effect of TNF during
isolated perfusions. Here we present data that indicate that the antitumor effect of
TNF is strongly correlated with the tumor microvessel density.
MATERIALS AND METHODS
Rat Liver Metastases Model
We used male inbred WAG/RIJ or Brown-Norway (BN) strain rats, weighing
250-300 g, obtained from Harlan-CPB (Austerlitz, The Netherlands). The rats
were fed a standard laboratory diet.
Three different tumors were used in this study. The weakly immunogenic colon
carcinoma CC531 is an 1,2-dimethylhydrazine-induced, moderately differentiated
adenocarcinoma transplantable in syngeneic WAG/RIJ rats. The estimated
doubling in vivo is about 6-8 days. The spontaneously originated
nonimmunogenic osteosarcoma ROS-1 is also transplantable in the WAG-RIJ rat
and in the liver metastases model it has a mean doubling time of about 4-5 days.
The spontaneously originated nonimmunogenic soft tissue sarcoma BN-175 is the
fastest growing tumor of the tumors tested, with an estimated doubling time in
vivo of about 2 days and is transplantable in syngeneic BN rats. Following a
standardized protocol, small viable tumor fragments of CC531, ROS-1 or BN-175
tumor fragments of 1 by 2 mm were implanted under the liver capsule, one in the
left and one in the right side of the left liver lobe, using a 19 G Luerlock needle.
Experiments started at a fixed tumor diameter between 5 and 6 mm. When tumors
reached a size of 20 mm in diameter or animals showed obvious signs of
discomfort the animals were sacrificed.
Drugs
Recombinant human TNF α (TNF, 4.9-5.8 x 107 units mg-1) was provided as a
kind gift by Boehringer Ingelheim GmbH, Ingelheim/Rhein, Germany. Melphalan
(L-pam, Alkeran, Wellcome Ltd., London, United Kingdom) was obtained as a
sterile powder (100 mg) that was dissolved aseptically using solvent and diluent
provided by Burroughs Wellcome (London, United Kingdom).
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Isolated Hepatic Perfusion
This rat isolated liver perfusion model has been described in detail earlier by van
IJken et al [15]. A schematic representation is shown in figure 1. Anesthesia was
induced and maintained with ether (Merck, Darmstadt, Germany). During the
surgical procedure, with an average duration of 60-75 minutes, rats were kept at a
constant temperature using a warmed mattress. A mid-line laparotomy was
performed and the hepatic ligament exposed. The gastroduodenal side branch of
the common hepatic artery was cannulated, positioning the tips of the cannula
(0.025 outer diameter (OD), 0.012 inch inner diameter (ID), (Dow Corning,
Michigan, USA)) in the proper hepatic artery. Through a small inguinal incision
the femoral vein was exposed. To collect hepatic venous outflow a silicon
cannula (0.047 OD, 0.025 inch ID), (Dow Corning, Michigan, USA) was
introduced in the femoral vein and moved up into the caval vein positioning the
tip of the cannula at the level of the hepatic veins.
Isolation of the hepatic vascular bed was obtained by temporarily ligating the
common hepatic artery and the portal vein. The venous outflow limb was isolated
by temporarily clamping the supra hepatic caval vein and by applying a
temporary ligature around the infra-hepatic caval vein containing the cannule,
cranial to the right adrenal vein. The mesenteric artery was temporarily clamped
in order to reduce splanchnic blood pressure. The circuit was primed with 10 mL
Haemaccel (Behring Pharma, Amsterdam, Netherlands). Arterial flow of 5 mL
min-1 was maintained with a low-flow roller pump (Watson Marlow type 505 U,
Falmouth, UK). Rats were perfused for ten minutes with oxygenated Haemaccel
in which melphalan and/or TNF was dissolved. Afterwards a washout was
performed by perfusing with 10 mL of oxygenated Haemaccel. 50 IU of Heparin
(Heparine Leo, The Netherlands) was added to the perfusate. The perfusate was
oxygenated in a reservoir with a mixture of O2/CO2  (95%:5%) and was kept at
38-39 °C by means of a heat exchanger and a warm water bath. A temperature
probe was positioned in the lumen of the arterial catheter, 5 cm from the catheter
tip. Following the washout-procedure, the clamps on caval vein, portal vein,
hepatic artery and mesenteric artery were released. The gastroduodenal artery and
femoral vein were ligated and the gastroduodenal and femoral cannulas were
removed.
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Figure 1. Schematic representation of an isolated hepatic perfusion (IHP).
In vivo Antitumor Efficacy Study
Treatment started at a fixed tumor size of 5-6 mm in diameter. Rats were perfused
in random order. In a pilot dose finding study performed for each tumor type the
melphalan dose inflicting a partial tumor response was chosen for this study. So
in case of additive or synergistic effect of TNF on melphalan this could still be
demonstrated in the growth curves of the tumors. CC531 bearing rats were treated
with 50 mg  melphalan (n=6), 20 µg TNF (n=6), or a combination of  50 mg
melphalan and 20 µg TNF (n=6). ROS-1 bearing rats were perfused with 50 mg
melphalan (n=6), 20 µg TNF (n=8), or a combination of  50 mg melphalan and 20
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µg TNF (n=6). In the BN-175 bearing rats perfusions were carried out with 200
mg  melphalan (n=6), 20 µg TNF (n=6), or a combination of  200 mg melphalan
and 20 µg TNF (n=6). After IHP tumor size was measured via a small midline
laparotomy every fourth day. Tumor volume was calculated by using the
following formula: tumor volume = A2 x B x 0.4. In which B is the largest
diameter and A the diameter perpendicular to B, measured with a standardized
calliper. In every treatment group, sham perfused rats (n=6) and untreated control
rats (n=5) were included.
In vitro Cytotoxicity Assay
CC531 and BN-175 cells were grown in RPMI 1640 and ROS-1 cells in modified
Eagle’s medium (Gibco BRL, Paisley, UK) supplemented with 10% fetal calf
serum (Harlan/Sera-Lab, UK), 1% penicillin (5000 IU mL-1), 1% streptomycin
(5000 IU mL-1) and 1% L-glutamine (200mM) (all Gibco BRL) in a humidified
incubator at 37 °C and 5% CO2. Before usage, the cells were trypsinised (1 min,
37 °C), centrifuged (5 min, 700 g), resuspended and the viability measured by
trypan blue exclusion. For in vitro testing of proliferation inhibition, 1.0 x 104
viable cells were seeded in flat bottomed 96-well microtiter plates (Costar, USA).
After 24 hours the cells were incubated with different concentrations of TNF for
72 hours ranging from 0 to 10 µg mL-1 . Afterwards, cells were washed with PBS
and fixed for 1 hour with 10% trichloro-acetic acid at 4 °C . Growth of tumor
cells was measured using the sulpharhodamine-B assay according to the method
of Skehan et al [19]. Tumor cell proliferation was measured using the formula:
tumor growth = (test well/control) x 100%. Five independent tests were
performed for each point on the line.
Measurement of Melphalan in Tissue
Five minutes after the restoration of the circulation the perfused tumor and part of
the liver were excised. The tissues were immediately frozen in liquid nitrogen to
stop metabolism of melphalan and stored at –80 °C. Tumor and liver tissues were
homogenized in 2 mL acetonitrile (Pro 200 homogenizer, Pro scientific, CT,
USA) and centrifuged at 2500g. Melphalan was measured in the supernatant by
gas chromatography-mass spectrometry (GC-MS). P-[Bis(2-chloroethyl)amino]-
phenylacetic acid methyl ester was used as an internal standard. Samples were
extracted over trifunctional C18 silica columns. After elution with methanol and
evaporation, the compounds were derivatized with trifluoroacetic anhydride and
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diazomethane in ether. The stable derivates were separated on a methyl phenyl
siloxane GC capillary column and measured selectively by single ion monitoring
GC-MS in the positive EI mode described earlier by Tjaden et al [20].
Assessment of Tumor Microvessel Density by Immunohistochemistry
Cryosections of tumors were fixed for 15 minutes with 4% formaldehyde. After
rinsing with PBS, sections were incubated for 1 hour with 1:10 PBS diluted,
mouse-anti-rat-endothelial cell antibody (RECA-1, Instruchemie, Hilversum, The
Netherlands). For the negative control an aspecific mouse IgG was used
(SantaCruz Biotechnology, Santa Cruz, California, USA). Thereafter sections
were rinsed with PBS and incubated for 1 hour with 1:100 diluted, in 5% normal
rat serum in PBS, goat-anti-mouse peroxidase labeled antibody (DAKO,
Carpinteria, CA, USA). After rinsing with PBS, positive cells were revealed by
immunoperoxidase reaction with DAB solution (DAB-kit, DAKO) and
counterstained with hematoxylin. For microvessel quantification two independent
persons performed a blinded analysis. Positive cells were counted in 3 different
high power fields (magnification 160x) in each slide according to the method of
Bosari et al [21]. In total 3 slides per tumor and 3 tumors per tumor type were
evaluated.
Statistical Analysis
In vitro bioassays and in vivo tumor response results were evaluated for statistical
significance with the Mann-Whitney-U tests with SPSS8.0 for Windows 98.
Mann Whitney U test was used to compare melphalan concentrations in different
groups and Kruskal-Wallis test to compare number of positive cells in different
tumors. A significance level of p<0.05 was used in all analyses.
RESULTS
Tumor Response after Isolated Hepatic Perfusion
The antitumor efficacy of IHP with melphalan with or without TNF was
evaluated for the CC531, ROS-1 and BN-175 tumor. In all groups sham IHP’s
with only perfusion medium were performed. The graphs in figure 2 show the
growth curves of CC531 tumor (A) , ROS-1 (B) and BN-175 (C) after IHP with
melphalan, TNF, both, or after sham perfused rats and untreated control rats.
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Perfusion with melphalan alone significantly reduced tumor growth rates
compared with sham perfused animals in all tumor types. When IHP was
performed in BN-175 bearing rats with the combination of melphalan and TNF a
dramatically enhanced tumor response was observed in all animals. This is a
significant reduction of mean tumor volume compared with in rats perfused with
either TNF only or melphalan alone (p<0.005 and p<0.01 respectively). In the
CC531 or ROS-1 tumors this effect was not observed.
Figure 2. Growth curves of in vivo tumors after isolated hepatic perfusion: (A) CC531,
(B) ROS-1, (C) BN-175. Each group contained at least six animals. Mean values (± SEM)
are shown.
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In vitro Cytotoxicity Assay
The effect of TNF on the growth of tumor cells in vitro was determined to
evaluate whether the synergistic effect of TNF could be related to direct tumor
cell toxicity. The calculated concentration of TNF in the perfusate during IHP in
vivo is about 1.5 µg mL-1. So in vitro tumor cells were exposed to a range of TNF
concentrations varying from 0 to 10 µg mL-1. The growth curves are shown in
figure 3. It is demonstrated that the BN-175 and the CC531 tumor cell line did not
show significant sensitivity to TNF. Only the ROS-1 tumor cells were moderately
sensitive to TNF, a growth inhibition of up to 30% at 10 µg mL-1 was observed.
Figure 3. In vitro growth curves of tumor cells upon exposure to TNF. CC531 (•), ROS-1
(♦), BN-175 ().  Six independent assays were performed in duplicate for each point on
the line. Mean values (± SEM) are shown.
TNF increases melphalan uptake by tumors after IHP
129
Melphalan Concentration in Tumor and Liver Tissue
In this perfusion setting, in which the dose of TNF is 20% of the dose used in
ILP, an enhanced drug accumulation in tumor tissue might take place as well, as
observed after TNF based ILP. In order to investigate this mechanism, melphalan
concentrations were measured in tumor and liver tissues after IHP with melphalan
with and without TNF. In the CC531 and ROS-1 tumors melphalan concentration
did not increase significantly after IHP with melphalan and TNF (figure 4A en
4B). After IHP with melphalan alone in the BN175 tumor bearing rats the
melphalan concentration in tumor and liver tissue was equal (figure 4C). After
IHP with TNF however a more than 5-fold increase of melphalan in tumor tissue
is measured compared to tumor tissue after IHP without TNF; (p<0.05).  So an
augmented drug accumulation can also be achieved in the IHP setting when TNF
is co-administered , which is in correspondence with the tumor response
observed.
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Figure 4. Melphalan concentrations in liver and tumor tissue after IHP with melphalan
with or without TNF. Six IHPs were performed per tumor type (a) CC531, (b) ROS-1, (c)
BN-175. Y-axis: melphalan concentration in ng g-1. X-axis: (1) liver tissue, IHP with
melphalan only, (2) liver tissue, IHP with melphalan + TNF, (3) tumor tissue, IHP with
melphalan only, (4) tumor tissue, IHP with melphalan + TNF. Mean values (±SD) are
shown. ( = p<0.05 versus tumor melphalan concentration after IHP with melphalan
alone).
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Assessment of Tumor Microvessel Density
We already hypothesized that TNF by increasing leakage of tumor vessels
enhances intratumoral concentrations of chemotherapeutics. The increased uptake
of melphalan might therefore be correlated with the microvessel density (MVD)
of the tumor. Quantification of the MVD was performed by
immunohistochemical staining of endothelial cells. The microvessel count of the
colon carcinoma CC531 and the osteosarcoma ROS-1 were equal (figure 5). The
soft tissue sarcoma BN-175 however showed a significantly higher MVD than
CC531 en ROS-1. These results indicate a direct relationship between vascularity
of the tumor and TNF-mediated effects.
Figure 5. Microvessel count of CC531, ROS-1 and BN-175 tumors. Mean values (±SEM)
are shown. ( = p<0.001 versus CC531 and versus ROS-1)
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DISCUSSION
In the present study we demonstrated that addition of TNF in IHP results in
strongly improved response rates of rat liver sarcoma. In vitro no or only minor
sensitivity of tumor cells to TNF was found. Even in ROS-1 tumors, which are
moderately sensitive to TNF in vitro, IHP with TNF alone showed no tumor
response. These data indicate strongly that in vivo indirect mechanisms mediated
by TNF in combination with melphalan determine antitumor effects in IHP. Our
data support the notion that this indirect mechanism is the selectively destructive
effect of TNF on the tumor associated vessels and thereby increasing vascular
permeability [11, 12]. To investigate this hypothesis the melphalan uptake in liver
and tumor tissue was measured after IHP with or without TNF. Tumor melphalan
concentrations were increased in all tumors but  varied significantly in a tumor
type dependent way. Moreover enhanced uptake of melphalan by healthy liver
was not observed. With TNF alone no tumor response was found in any of the
tumor types. Only the combination of TNF and melphalan resulted in a complete
tumor response in the BN175 tumor.  To elucidate this tumor type dependent
response, the MVD of the tumors was determined. We expected a higher tumor
vascularity in this tumor. Indeed a significantly higher MVD compared to the
CC531 and ROS-1 tumors could be demonstrated. So TNF has specific tumor
vascular mediating capacity in this perfusion model, which results in enhanced
tumor responses in highly vascularised tumors. As a result of our findings in ILP
and now also in IHP we know that TNF is able to augment the accumulation of
melphalan. We are of the opinion that this observation is essential in
understanding and explaining the impressive responses observed.
Changes in vascular permeability in patients who underwent IHP with TNF were
studied by Alexander and coworkers [22]. Vascular permeability was measured
by diffusion of radiolabeled I131 albumin in liver and tumor tissue. A significant
increase of the I131 albumin post-perfusion could be demonstrated compared to
levels I131 albumin measured before perfusion. However, this rise was equal in
tumors perfused with or without TNF. A TNF independent mechanism of the
increased endothelial permeability was suggested by the authors. However in the
present study we demonstrated that TNF is effective in increasing vascular
permeability for melphalan selectively in tumor tissue. A more important finding
however, is that this effect could only be found in the highly vascularised BN-175
tumor. The results of Alexander et al. reported on intratumoral I131 albumin
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concentrations were mainly based on colorectal carcinoma liver metastases. In
hypovascular rat colon carcinoma we also could not find an increase of melphalan
intratumorly.  We therefore hypothesize that the usual hypovascularity of
colorectal metastases in patients explains the lack of TNF-benefit in the
experience as described by Alexander in patients, which correlates closely to our
observations in our hypovascular colon cancer liver metastases model in rats.
IHP with melphalan and TNF performed in patients with metastases of ocular
melanoma or leiomyosarcoma showed overall response rates of 50-52% [23, 24].
Both tumor types are highly vascularised. A prolonged duration of response was
found in melanoma patients: 14 months after IHP with TNF versus 6 months after
IHP without TNF [23].  After IHP with melphalan with or without TNF in
patients with colorectal liver metastases the mean duration of response was in
both groups 8-10 months [17, 25]. The data we now present and the first reports
of IHP in melanoma and sarcoma liver metastases strongly indicate that in these
patients TNF has therapeutic potential in IHP. In patients with colorectal liver
metastases however, IHP with melphalan alone may well be just as effective as
combined with TNF. Assessment of the degree of tumor vasculature of liver
metastases would be a way of establishing an indication for the utility of TNF in
this setting.
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INTRODUCTION
Tumor Necrosis Factor α
The American surgeon Coley was the first to observe the spontaneous regression
of cancers in patients with concurrent bacterial infection [1]. These regressions
were acute and a hallmark was rapid hemorrhagic necrosis with bouts of fever.
Many decades later a factor causing hemorrhagic necrosis in experimental tumors
was discovered and called tumor necrosis factor α (TNF) [2, 3].
TNF is a homotrimeric complex of 52 kD which is produced by many cell types
but mainly by activated monocytes/macrophages [4, 5]. Its expression and
regulation is affected by a variety of other cytokines, as interferon-γ (IFNγ),
interleukines (IL-1, IL-2, IL-12), GM-CSF, platelet aggregating factor (PAF) as
well as TNF itself [5]. TNF is directly cytostatic or cytotoxic to only a few cancer
cell lines [6]. On other cell types TNF shows a growth inhibitory or even a
growth stimulatory effect [5, 7]. The effects of TNF are exerted by binding to two
types of receptor with molecular weights of 55 kD (TNF-R1) and 75 kD (TNF-
R2) respectively, which are present on nearly all mammalian cells [4, 8]. The
number of receptors on the cell does not predict the magnitude of response to
TNF, but up-regulation (IFNγ) and down-regulation (IL-1) of TNF receptors have
been reported [7]. TNF has pleiotropic and concentration dependent effects. At
high concentrations, TNF has been shown to have vasculotoxic effects, while at
lower concentrations promotion of angiogenesis and DNA synthesis may be
demonstrated [9, 10].
In vitro, synergism between TNF and a number of cytotoxic agents may be
present [11]. Our group investigated several cell lines on susceptibility of TNF
and certain cytotoxic drugs (e.g. the alkylating agent melphalan or the
topoisomerase-II inhibitor doxorubicin). No direct cytotoxic effects of TNF, nor
synergism with melphalan or doxorubicin were observed in vitro but only
additive antitumor effects were noted [12-14]. Cytotoxic effects of TNF can be
enhanced by a number of other biological response modifiers like IFNγ or IL-1,
by hyperthermia and by irradiation [11, 15-17]. The mechanisms by which TNF
exerts its cytotoxic effects are not yet fully understood. The number of receptors
on the tumor cell is probably of less importance than the role of oxygen free
radicals in TNF cytotoxicity, and activation of lysosomal enzymes [5].
Many animal studies have demonstrated antitumor effects of TNF in vivo, leading
to hemorrhagic necrosis in tumors [2, 11]. Systemic application of TNF in
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humans however, proved to be deleterious to patients and in phase I-II studies
severe toxicity was reported. A variety of side effects were noted, hypotension
being the dose limiting factor [18-20]. The maximal tolerated dose (MTD) varied
between 200 and 400 µg m-2, which was only 1/50 of the effective dose in murine
tumor models [21].
So only low doses could be explored by systemic administration and due to these
low concentrations of TNF negligible response rates were achieved in phase II
studies [22-24]. Addition of IFNγ or IL-2 did not enhance antitumor efficacy but
further increased toxicity [25, 26]. Because of severe toxicity after systemic use
of TNF in clinical trials, other routes (locoregional) of administration were
explored to achieve high local concentration of TNF in tumor tissue. Intratumoral
injection revealed only slightly better responses than intravenous injection with
similar side effects [27-29]. Hepatic artery infusion and intraperitoneal
administration of TNF revealed only modest results [30, 31].
The major breakthrough for TNF was its introduction in isolated limb perfusion
(ILP) as a treatment for patients with irresectable soft tissue sarcoma or in transit
metastases of melanoma [32-36].
The impressive response rates achieved with this treatment modality have
resulted in the approval of the drug in Europe in 1998 for the treatment of
irresectable extremity soft tissue sarcomas and has renewed interest in the
application of TNF in other isolated organ perfusion settings such as isolated
perfusion of lung, kidney, and liver [37-42].
Antitumor effects of TNF
Experimental as well as clinical ILP with TNF and melphalan have demonstrated
that the tumor-associated vasculature (TAV) is the selective target for TNF. The
effects of TNF on this vascular bed are concentration dependent: at high
concentrations mostly vasculotoxic effects have been shown, whereas at lower
concentrations it may promote DNA synthesis and angiogenesis [9]. Renard et al
described the effects of TNF on the TAV as early endothelium activation, up
regulation of adhesion molecules and invasion of polymorphonuclear cells, all
leading to coagulative necrosis with or without hemorrhagic necrosis [43, 44].
However, examination of the melanomas and sarcomas of patients treated by ILP
with TNF, melphalan and IFNγ did not demonstrate differences in expression of
adhesion molecules as ICAM-1, E-selectin (ECAM-1), VCAM-1 or PECAM-1 in
tumors compared with normal tissue [45]. More recently, detachment and
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apoptosis of the integrin αvβ3 positive endothelial cells was demonstrated in
melanoma metastases of patients treated by ILP with TNF, melphalan and IFNγ,
again aiming at the importance of the selective disruption of the TAV [46]. NMR
further indicated this and angiography studies which clearly showed the
disappearance of only TAV after TNF based ILP [47-49].
The antitumor effects of TNF in the isolated perfusion setting are based on
synergism with a cytostatic drug [7, 12, 13, 19]. Probably, TNF is suggested to be
responsible for the disruption and subsequent leakage of the TAV whereas
melphalan (or in theory any other chemotherapeutic drug) causes a non-specific
necrosis of the tumor cells [50, 51].
The TNF induced endothelial damage was demonstrated to occur as early as three
hours after the onset of TNF based ILP [44]. On the other hand, also a delayed
type of TAV hyperpermeability may be present which would explain the fact that
complete tumor regression frequently requires longer periods after TNF based
ILP [52]. The effects of high dose TNF on the TAV lead to an increased
permeability and a significant decrease of the interstitial pressure in the tumor.
Both effects lead to a better penetration of cytotoxic drugs into the tumor tissue
[53-55]. Indeed our group demonstrated a 4 to 6 fold increase of intratumoral
melphalan concentration when TNF was added to the perfusate in ILP with
melphalan [56]. Similarly, an increased uptake of doxorubicin in tumor tissue was
shown after TNF based ILP [14]. Probably these findings are one of the most
important mechanisms behind the successes demonstrated by ILP with TNF and
melphalan [57].
Alexander et al showed an increased capillary leakage during IHP and an
increased uptake of I-131 albumin in tumor tissue compared to liver tissue.
However, the addition of TNF did not affect melphalan concentrations in the
tumor tissue compared to liver tissue [58]. Several reasons for the discrepancy are
possible such as concentrations of TNF used, sampling method and duration of
perfusion. Of more importance however, might be the type of tumor with
associated difference in tumorvasculature since colorectal metastases are
hypovascular and largely necrotic, whereas soft tissue sarcoma are usually
hypervascular. The results from our laboratory implicate that the better the
vascularisation of a specific tumor, the more explicit the effects of TNF on the
TAV and the better the overall response of the tumor to the treatment [14, 56].
This has been proven from experimental as well as clinical results. In the rat, best
response rates after ILP with TNF and melphalan have been demonstrated by our
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group for the highly vascularised BN soft tissue sarcoma bearing rats whereas the
less vascularised rat osteosarcoma (ROS) showed subsequent lower responses
[12, 13, 57]. Similar results have been shown by Van IJken et al in an IHP model
in rats using the same tumors (BN, ROS) but now localized in the liver. In case a
coloncarcinoma was used, only few responses had been shown [59]. In
accordance with these results, best clinical responses have been demonstrated
after ILP with TNF and melphalan in patients with unresectable soft tissue
sarcoma of the extremities [33, 34]. Therefore, the vascularisation of the tumor
seems to be of utmost importance in the treatment with TNF, independent of its
localization (this thesis chapter 7).
Primary and secondary malignant hepatic disease
Patients with unresectable primary and secondary (metastatic) hepatic malignancy
remain a challenging clinical problem. Of the primary hepatic malignancies,
Hepato Cellular Carcinoma (HCC) is the most frequent, although the incidence of
these tumors varies widely worldwide, being most common in the Far East [60].
Recent advances in the early detection of these tumors have improved the
prognosis and long term survival has been reported in patients with small,
encapsulated malignancy [61-63]. Nevertheless, the overall prognosis of HCC
remains poor and usually expressed in months rather than years [64].
In the Western countries the most common hepatic malignancy is metastatic
disease from colorectal cancer. Most frequently, the liver is the site of
dissemination with many other sites in the body (lung, brain, bone). On the other
hand the liver is the sole site of initial cancer recurrence in as many as 30 % of
patients [65]. If left untreated the mean survival rate in these patients is
approximately 6 to 9 months. In contrast, 5-year survival rates up to 35 % have
been reported for patients amendable to resection. Unfortunately in the majority
(75%) of the patients that have been diagnosed with colorectal cancer metastases
confined only to the liver, these metastases are considered unresectable. These
patients are eligible for other therapies.
Systemic chemotherapy
The effect of systemic chemotherapy on hepatic metastases depends on the
primary site of metastatic disease and the dose of agents used. Since certain
tumors (e.g. breast carcinoma) are responsive to chemotherapy, even when
hepatic metastases develop, systemic chemotherapy may be the appropriate
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treatment. The standard therapy for patients with advanced colorectal carcinoma
has been systemic chemotherapy with 5-fluorouracil (5-FU) based protocols.
These therapies produce an average response rate of 20 to 30 % with median
survival times of 6.5 to 13.5 months, if 5-FU plus folonic acid (FA) at
conventional doses is used for systemic (iv) therapy [66-68].
In general, with systemic combination therapy it is not likely to obtain response
rates higher than 30 % with only a minimal effect on survival and in most cases
this is possible at the cost of considerable systemic toxicity, especially with the
use of TNF. Most patients eventually die due to intrahepatic progression and/or
development and progression of extrahepatic disease. In order to achieve a better
control of intrahepatic disease and to reduce systemic toxicity of the applied
therapy, locoregional therapies have been developed.
Locoregional therapy
The main principle for locoregional therapy is the achievement of higher local
drug concentrations and thus higher exposure of tumor tissue to the agents,
resulting in increased response rates, while shielding the patient from systemic
toxicity because of much lower concentrations in the systemic circulation. Since
for most chemotherapeutic steep dose-response curves have been demonstrated,
this should result in a greater tumor response. On the other hand, there is a greater
risk of regional damage to normal cells in the tissues surrounding the tumors. The
most direct mode of locoregional therapy is the injection of drug into the tumor.
TNF has also been used in this treatment modality with only slightly better
responses than iv injection with similar side effects at the same MTD [27-29].
In case of intra-arterial chemotherapy to the liver (hepatic artery infusion, HAI),
depending on the type of drug used, there should be the additional factor of
extraction of a significant amount of the anticancer agents on the first passage
through the organ and thus reduced outflow into the systemic circulation with a
distinctly reduced risk of systemic toxicity.
However, the best approach for regional infusion of the liver is still unknown.
Hepatic artery infusion (HAI), hepatic artery ligation with hepatic artery and
portal vein infusion, or portal vein infusion have all been attempted [69-71]. Of
these modalities, HAI is the single most widely applied form. Only a few
completed randomized studies have been reported in patients with unresectable
colorectal metastases confined to the liver. Although response rates of 50 to 55 %
of HAI using either 5-FU, FUDR, fluoropyrimidines with or without other drug
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have been demonstrated, the median survival time of 11 to 14 months in most of
these studies did not exceed the 11 months of 5-FU iv therapy that showed
response rates of 11 to 20 % [67].
TNF has also been used in HAI in an attempt to improve response rates with
lower systemic toxicity. Mavligit et al treated 22 patients with HAI with
recombinant human TNF (rhTNF) and showed that the MTD was 150 µg m-2,
which is six times the MTD of rhTNF that could be given systemically on the
same schedule. The dose-limiting toxicity, hypophosphatemia and associated
myocardial dysfunction, was severe but transient. However, only modest
responses were demonstrated [30]. In summary, with HAI improved response
rates are achieved but convincing evidence of improved survival is lacking. The
application of TNF in HAI is possible but still limited by systemic toxicity.
For most chemotherapeutic agents steep dose-response curves can be
demonstrated. Therefore, high drug concentrations are important for both
sensitive and resistant tumor cells. For resistant cells extremely high exposure is
needed for adequate cell kill. With HAI higher locoregional drug concentrations
have been demonstrated with subsequent better response rates. However, despite
high extraction ratios in HAI, systemic exposure and toxicity cannot be fully
eliminated and has been reported the dose limiting factor. In order to maximize
locoregional drug concentrations and at the same time completely shielding the
patient from systemic toxicity isolated perfusion techniques have been developed.
Isolated Hepatic Perfusion
The isolated perfusion concept is easy: due to the complete vascular isolation
high local drug concentrations can be achieved whilst minimizing systemic
exposure and thus toxicity. In case of the liver isolated hepatic perfusion (IHP)
has been developed. In IHP the vascular bed of the liver is completely isolated
and perfused with a recirculating circuit. IHP is a means to further improve
selectivity of administration of antitumor agents to the liver as compared with
HAI. IHP with 5-FU in rats and pigs resulted in significantly higher 5-FU
concentrations in liver tissue of animals in the higher dose groups. When
mitomycin C was administered by IHP a 400% higher dose could be safely
administered and resulted in a five times higher tumor tissue concentration as
compared with HAI [72, 73]. These data suggest that, to achieve similar systemic
drug levels, 5 times the HAI dose can be administered with IHP. Therefore, IHP
is a method to improve selective administration of antitumor agents to the liver
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while maintaining very low systemic drug concentrations. As is true in HAI, it is
clear from experimental data that in the IHP setting hepatic rather than systemic
toxicity is dose limiting. Another advantage of the complete vascular isolation of
the liver is the possibility to apply hyperthermia. Hyperthermia has been
demonstrated to synergize with chemotherapeutic and biological agents.
Furthermore, it has direct independent antitumor effects as well [74-76].
Successful clinical experience with IHP is limited but promising. Thus far,
several studies have been published with various chemotherapeutical or biological
agents e.g. Nitrogen Mustard, 5-FU, mitomycin C, and melphalan. Reported
hepatic toxicity is surprisingly mild and transient. Furthermore, data thus far have
made clear that only IHP can bring about 3 – 5 years of disease-free survival [77-
79]. More recently, tumor necrosis factor α (TNF) has come into focus as a result
of the successes achieved in isolated limb perfusions (ILP) with this cytokine in
combination with melphalan.
IHP Technique
Since the liver has a dual blood supply both the hepatic artery (HA) and portal
vein (PV) allow access for IHP. However, the best mode of infusion is not
known. Determination of the most optimal route of infusion involves issues of
vascular variations, technical ease of cannulation, as well as tumor blood supply.
There is no consensus about the route of infusion (HA vs. PV vs. both). Normal
hepatic parenchyma receives most of its blood supply from branches of the portal
vein (PV) and to a much lesser extent from the hepatic artery (HA). In contrast,
the blood supply of hepatic metastases was ascribed to rely almost entirely on the
HA [70, 80, 81]. Consequently, most regional approaches have been using the
HA. More recently, however, attention has been drawn to the PV since very small
liver tumors (< 5 mm), as well as the outer rim of larger hepatic metastases, are
fed mainly by portal branches [81, 82]. In addition, most colorectal tumors drain
via the PV suggesting that spreading tumor cells will first proliferate in the portal
system. Furthermore, the presence of dye in metastatic foci within the liver could
be demonstrated when the color agent had been injected through the portal
system, convincing evidence that blood carrying from the antitumor drug would
reach the same site. Thus, by using the HA as well as the PV, drugs may reach
both established and newly formed (micro) metastases. However, since primarily
the PV supplies most normal hepatic parenchyma tissue, it could be speculated
that infusion via the PV might induce significant hepatotoxicity. Indeed, Boddie
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et al performed IHP via the PV only and demonstrated significant hepatic damage
[83]. Furthermore, Kahky et al demonstrated an increased mortality in rats in case
TNF was delivered via the PV [84]. In contrast, several IHP studies in pigs,
including ours (this thesis, chapter 2) using both vessels could not confirm these
findings [41, 85, 86].
Several studies have demonstrated that liver uptake of various drugs after portal
vein infusion is not significantly different from liver uptake after hepatic artery
infusion [80]. Regardless the route of administration, the drug is delivered to the
sinusoid, where it is extracted by the hepatocyte. Therefore, hepatic uptake of
drugs is not dependent on the route of regional administration. In contrast, the
blood supply of most hepatic metastases is predominantly arterial .
Uptake of drugs by the tumor is dependent both on perfusion of the tumor and
cellular uptake of drug. Most anatomical studies of the blood supply of colorectal
hepatic malignancies are based on bolus injection of dye or radiolabeled
compounds. In a clinical randomized study comparing chronic hepatic artery or
portal vein infusion of FudR for colorectal metastases, the measured uptake of
drug by the tumors correctly predicted the clinical response: 50% of the HAI
group responded, whereas no patient in the portal vein group responded [87].
Therefore, with respect to flow through a tumor, there is a pre for the HA (high
flow through tumor) vs. the PV (low flow through tumor).
Apart from these theoretical considerations there are also some practical ones.
First, the HA is small and local anatomy varies widely whereas the PV is a larger
vessel with limited anatomical variation.  Second, the hepatic venous drainage is
through multiple small veins and meticulous dissection of all these veins is
necessary in order to obtain the desired complete isolation. Although difficult, the
same techniques apply as used in orthotropic liver transplantation. This also
includes the use of a veno-venous bypass in order to shunt blood from the
intestines, kidneys and limbs back to the heart without the risk of intestinal
congestion and subsequent bacterial translocation.
Animal studies
Several groups have been experimenting with IHP and several models have been
developed in rodents, dogs and pigs. The first experimental IHP studies have been
performed in large animal models (pigs and dogs). Since the anatomy of the liver
and its vasculature in these animals resemble those in humans they used to
develop techniques of IHP and study the pharmacokinetics of several
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chemotherapeutics including TNF. Skibba showed that hyperthermic (42°C) IHP
(dual system), without drugs, in dogs with survival (20 out of 26) and with
preservation of good hepatic function was possible [88]. Sindelar et al performed
IHP in pigs with increasing doses of 5-FU with or without hyperthermia (41°C)
and demonstrated temporary hepatic enzyme disturbances without systemic drug
toxicity in all animals. Levels of 5-FU tolerated by the liver in the IHP setting
(500 mg kg-1) were more than 1000-fold greater than maximum levels achieved
by routine systemic, intra-arterial or intraperitoneal administration [85]. Van de
Velde et al performed IHP in pigs with increasing doses of 5-FU (20, 40 and 80
mg kg-1) and demonstrated that at least four times the conventional dose of this
drug can be safely administered [86].
Regarding TNF: In addition to its systemic side effects, TNF is also known to be
cytotoxic for hepatocytes [89-91]. Experience with the use of TNF in IHP in large
animals is scarce. We performed leakage free IHP with melphalan and/or rhTNF
in pigs demonstrating stable perfusate TNF with a cumulative systemic leakage of
rhTNF during IHP of 0.02 %. (this thesis, chapter 2) As to hepatotoxicity, after
IHP a significant but transient rise in hepatic enzymes (ASAT, ALAT, LDH,
Alk.Phosphatase) was observed in all pigs, including the controls, which
normalized within one week. Histologic sections of the liver showed mild
sinusoidal dilatation as well as septal edema with sporadic intraseptal
polymorphonuclear cell infiltration, without apparent hepatocellular damage or
parenchymal necrosis. Since the addition of high dose rhTNF and melphalan to
the perfusate did not lead to additional hepatotoxic side effects, most of the
changes shown are the result of the IHP procedure itself. Similar results have
been reported by Lang who furthermore showed that washout of the liver with a
protein solution reduces systemic rhTNF levels as well as associated lethal
cardiocirculatory and hepatotoxic side effects [92]. Although it is unknown what
the effects of rhTNF on the cytokine release in pigs are, Lang et al demonstrated
that in IHP the addition of rhTNF to the perfusate in pigs led to a statistically
significant release of porcine TNF [92]. In accordance with this study, Pogrebniak
et al showed that i.v. infusion of 80 µg kg-1 BW led to a 100 % mortality due to
cardiocirculatory and pulmonary depression with 24 h in experiments in pigs [92,
93].
From experiments in large animals (pigs and dogs) it is clear that IHP with
hyperthermia is technically feasible and safe, and results in transient
hepatotoxicity. Much higher dosages of chemotherapeutics can be applied since
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with complete vascular isolation systemic exposure and toxicity are and have
been proven to be minimal. With respect to the application of TNF it is important
that isolation is complete and the washout procedure is carried out with protein
solution instead of crystalloids in order to minimize systemic exposure to this
cytokine. Up to date no transplantable tumor cell lines exist in large animals.
Therefore, these models are not suitable for the evaluation of antitumor effects of
IHP. Fortunately tumor models do exist and have been described in rodents (rats
and rabbits) but the obvious technically difficulty of performing hepatic
perfusions in these animals has limited the number. Therefore, contrasting with
the situation for ILP, from animal studies there are limited data available with
respect to IHP for metastases.
Rodent models
In an IHP model in hepatic tumor bearing rats, Marinelli et al and De Brauw et al
demonstrated that when mitomycin C (MMC) resp. melphalan was administered
by IHP a 400 % resp. 200 % higher dose could be safely administered and
resulted in a 5 resp. 4 times higher tumor tissue concentration compared with
HAI. Furthermore, they showed that IHP in a rat coloncancer CC531 liver tumor
model was superior to HAI and allows the administration of a well-tolerated dose
of mitomycin C being high enough to induce marked DNA synthesis inhibition
and even complete tumor remission [72, 73, 94, 95]. Radnell et al demonstrated
that the addition of 5-FU (70 mg kg-1) to the perfusate significantly retarded
tumor growth evaluated 10 days after IHP compared to rats perfused without 5-
FU. There was however also some degree of tumor growth retardation in the
group without 5-FU demonstrating an antitumor effect of the IHP with
hyperthermia also [96]. The influence of hyperthermia on the permeability of
tumor neovasculature has been shown by Gnant et al in a rabbit hepatic
metastases model (VX-2/New Zealand White). They demonstrated that
hyperthermia (41°C) preferentially increased vascular permeability in tumors
compared with liver tissue in a dose-dependent fashion, thus providing a
mechanism for antitumor effects of IHP [97].
We performed IHP with TNF and melphalan in rats bearing BN-175 (soft tissue
sarcoma) hepatic tumors and demonstrated a dramatic increase in regional
concentrations of perfused agents. IHP with only carrier solution resulted in a
significantly diminished growth rate of BN 175 liver tumors compared with the
growth rate of tumors in nonperfused rats. Perfusion with melphalan alone
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resulted in minimal antitumor effects. Perfusion with only TNF had no effect on
tumor growth. When TNF was added to melphalan, a dramatic antitumor effect
was observed. Thus, as in the isolated limb perfusion setting, the antitumor effect
is augmented when TNF is added to IHP with melphalan to treat BN 175 soft-
tissue sarcoma tumor-bearing rats. In contrast, these results could NOT be
extrapolated to the coloncarcinoma (CC531) hepatic metastases model in the rat.
The difference in response rates between BN-175 and CC531 tumors correlated
with the hyper – and hypovascular properties of the respective tumors (this thesis,
chapter 7).
In summary, the experimental IHP in rodents demonstrate that the much higher
drug concentrations used in IHP result in higher tumor tissue concentrations of
the drugs used with subsequent significant better response rates as compared to
HAI. In case the combination TNF and melphalan is used in IHP, similar
response rates have been demonstrated as in ILP. The response rates are,
however, dependent of the vascularity of the tumor: best responses in highly
vascularised tumors.
Clinical experience
Isolated hepatic perfusion (IHP) was first clinically applied almost 40 years ago,
and over the subsequent 20 years a limited number of studies have reported
results indicating its feasibility but also its morbidity and even treatment related
mortality (10% - 25%). Furthermore, it was not clear what drugs had to be to use
since in IHP higher concentrations can be used than in regional or systemic
setting and hepatic rather than systemic toxicity will be the dose limiting factor.
In 1961 Ausman was one of the first to report the results of IHP in patients. Of
the five patients treated with IHP with Nitrogen Mustard there were 2 “long term”
survivors. Furthermore he showed that IHP was accompanied by acceptable
toxicity [98]. After this report a few other reports have followed, describing IHP
in patients with chemotherapeutics and/or hyperthermia alone (Table 1). The
influence of hyperthermia has been demonstrated by Skibba who performed a 4
hour IHP with hyperthermia (42 °C) alone in 8 patients. Two patients died after
surgery but of the surviving six patients five were reported as responders [99].
Several chemotherapeutic agents have been used in IHP, of which 5-FU,
cisplatinum, MMC are the most widely used. The fifty patients treated by
Schwemmle et al with IHP with 5-FU, MMC or cisplatinum had a median
survival of 14 months and showed a 22 % complete and 68 % partial response
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rate [100]. Aigner et al. treated 34 patients with IHP with MMC and/or 5-FU and
described an impressive 34 % CR. Unfortunately, in all patients IHP was
followed by 5 courses of HAI with MMC and 5-FU, such that the impact from the
IHP can not be clearly delineated [77]. Despite the stimulating results of the IHP
studies, results have to be taken with care since there was no standardized
protocol for measurement of responses. In most studies a drop in CEA levels was
used, in others the appearance of central necrosis on CT scans.
As Aigner, MMC was also used in IHP by Oldhafer et al, who reported veno-
occlusive disease (VOD) in 2 out of 6 patients treated by IHP with MMC [101].
The finding of severe VOD has also been described by Marinelli et al. In their
clinical phase I/II study with MMC 30 mg m-2 administered as a bolus in the
isolated circuit, two of nine patients had a complete remission, with a median
survival of 17 months. Four patients developed VOD of the liver, and as a result
one patient died [102]. The same group showed that in IHP experiments in rats
the melphalan MTD of 12 mg kg-1 was even more effective than MMC and did
not cause hepatotoxic side effects. In the following phase I/II dose-findings study
with melphalan in IHP in patients with colorectal metastases confined to the liver,
the MTD in humans was approximately 3.0 mg kg-1. As in the rats, systemic
toxicity was dose-limiting. The median survival of the whole group was 19
months, which is comparable to results after IHP with MMC. However, when
patients were treated with higher doses of at least 1.8 mg kg-1 (dose median),
median survival after IHP was 30 months [102-104]. Their results indicate that
median survival after one IHP treatment is at least comparable to the results
obtained from the most effective (multiple treatments) HAI schedules. After these
promising results they started a phase II study of melphalan in IHP with a fixed
dose of 200 mg melphalan, which is still ongoing [102, 105].
Since the addition of TNF to the isolated circuit in ILP with melphalan has
resulted in a dramatic increase in response rate, trials were started to investigate
the possible application of TNF in IHP. TNF without melphalan or any other
chemotherapeutic agent does not appear to have any significant antitumor activity
when administered in IHP. Fraker et al demonstrated a response rate of only 20%
in 17 patients treated in a study with IFNγ  and escalating doses of TNF
administered in IHP [40]. Similar results have been demonstrated in ILP with
TNF only. Therefore, as was concluded from the ILP experiments in rats, TNF
needs a chemotherapeutic agent to in order to be effective. Alexander et al treated
22 patients with unresectable hepatic metastases of ocular melanoma with IHP: in
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11 patients melphalan was added, in the other 11 melphalan and TNF. There was
one treatment related mortality. Overall response rate was 62 % (2 CR, 11 PR).
More interesting, overall median duration of response was 9 months (range, 5 –
50) and was significantly longer in those treated with TNF (14 vs. 6 months,
respectively). Overall median survival was 11 months [106]. Therefore, TNF
appears to significantly prolong the duration of response at least in ocular
melanoma metastases. Their experience has been extended with other tumor
types. More recently, the same group presented the results of IHP with 1 mg TNF
and 1.5 mg kg-1 melphalan in 50 patients with unresectable hepatic metastases (37
colorectal, 8 ocular melanoma, 5 other). The overall response rate in the 48
surviving patients was 75 % (2 % CR, 73 % PR) and the median time to
recurrence was 6 months with a range of 2 to 50 months [107]. Lindner et al
reported results of 11 patients treated by IHP with 0.5 mg kg-1 melphalan and 30
to 200 µg TNF. Six patients underwent re-operation due to post-operative
bleeding. Two patients died of coagulopathy or multiple organ failure within the
first post-operative month. Three of six patients with hepatic metastases from
malignant melanoma or leiomyosarcoma showed a partial response whereas none
of the patients with liver metastases from colorectal origin showed any response.
The mean survival time in their study was 20 months [108]. In Germany, the
group of Oldhafer treated 12 patients by IHP, of whom 6 received MMC alone
and 6 the combination TNF (200 to 300 µg) with melphalan (80 to 140 mg).
Although there were 3 deaths after treatment, there were no deaths in the patients
treated with TNF and melphalan. Of the 10 evaluable patients, four patients
showed a partial response, three no change and the others progression. We used
the combination of 1 mg kg-1 melphalan with 400 µg (n=8) or 800 µg (n=1) TNF
in patients with irresectable colorectal metastases confined to the liver. Of the
three post-operative deaths, there was probably one TNF related (uncontrollable
coagulopathy). Five of the evaluable patients demonstrated a PR and in one
patient the IHP had no effect on the tumor load [109].
Therefore, concluding from clinical experience, a total of 68 patients with
irresectable metastases confined to the liver have been treated by IHP with TNF
and melphalan. There were 2 CR (2%) and 45 PR (66%) with an overall response
rate of 69 %. The duration of response varied widely from 2 to 50 months.
Toxicity
From our IHP experiments in rats we learned that the MTD of TNF used in the
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perfusate is rat strain dependent: the Brown-Norway (BN) rats tolerated higher
TNF concentrations than the WAG/Rij rats used in the CC531 experiments.
Therefore, it could be speculated that the MTD in the WAG/Rij is too low in
order to be effective. A possibility to further increase the MTD for TNF in our
CC531 model could be the application of TNF mutants with better
chemotherapeutic indices. Nakamoto et al performed IHP with the TNF mutant
TNF-SAM2 in a in a hepatic metastases (syngeneic coloncarcinoma cell line) rat
model. Their group was the first to develop this TNF mutant, the biological
activities of which have been shown to be more beneficial for antitumor therapy
than those of TNF. The chemotherapeutic index of TNF-SAM2 was at least 5
times higher than that of TNF. In addition, the detrimental toxic side effects were
milder than TNF [110, 111]. Despite these results, they also described a rat strain
specific sensitivity to TNF-SAM2 added in the perfusate as demonstrated by us
for TNF. However, in the sensitive rats, they demonstrated that dexametasone (4
mg) administered subcutaneously or low molecular weight lipopolysaccharide
(LPS) (50 mg/rat) administered intradermally could increase the tolerable dose of
TNF significantly to concentrations by which antitumor effects have been
observed in ILP [112].
Apart from strain dependent factors, it has been demonstrated that the intraportal
application of rhTNF results in a significantly higher morbidity and mortality rate
that after intravenous application of this cytokine. This could be shown by Kahky
et al who found 100 % mortality in rats after intraportal perfusion of rhTNF 100
µg kg-1 BW compared to no mortality after infusion of the same dose of rhTNF
into the caval vein [84] Consistently, Tracey et al described that a dosage of 3600
µg kg-1 BW resulted in 100 % mortality after i.v. application of rhTNF in rats and
a mean lethal dosage of 700 µg kg-1 BW  rhTNF  when given as a 5 min bolus via
the tail vein [113]. The data from these studies suggest that intraportal application
of TNF leads to a much stronger activation of macrophages and Kupffer cells
followed by cytokine release (IL-1, IL-6 and TNF) which act synergistically to
TNF (this thesis, chapter 4). We used PV and/or HA as a mode of inflow in IHP
in the rats but could not demonstrate a difference in morbidity or mortality
dependent on route of inflow, besides the rat strain dependent sensitivity (this
thesis, chapter 7) [59]. Concluding, TNF can be used in IHP in rats and the TNF
based toxicity is rat strain dependent. Furthermore, the route of infusion might be
of importance. With respect to TNF induced toxicity, the application of TNF
mutants, like TNF-SAM2, or treatment with dexamethasone or LPS can reduce
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symptoms.
In virtually all patients, temporary elevated hepatic enzymes have been
demonstrated after IHP. These elevations seem more procedure-related than
drug-related and normalize within 2 weeks. In our group we could not
demonstrate a significant difference between hepatic enzyme level patterns of
patients treated with melphalan and patient treated with melphalan and TNF
[114].
When administered systemically, TNF leads to severe side effects mimicking a
septic shock like syndrome with severe hypotension, central nervous system
dysfunction, as well as thromboembolic and cardiopulmonary phenomena.
Despite the isolation of the liver, more toxicity than expected has been described
after IHP with the combination of TNF and melphalan. Linder et al described
considerable toxicity and performed a reoperation in six patients for bleeding and
there were two deaths [108]. Most likely the encountered toxicity was attributable
to systemic exposure to TNF and melphalan. Three of our patients died after IHP,
two of surgical complications, one probably TNF related [114]. Oldhafer et al
demonstrated severe hypotension and capillary leak in one patient [109]. Lans et
al showed that with complete vascular isolation and virtually all other variables
equal, the production of secondary mediators in the liver after IHP with TNF and
melphalan may result in subsequent transient haemodynamic alterations not
observed with melphalan alone [115]. Therefore, most of these side effects can be
minimized by a complete isolation and a thorough washout with colloidal fluids
in order to keep systemic TNF levels during and after IHP as low as possible.
Because of the toxicity of TNF a total isolation of the liver is of utmost
importance in order to minimize systemic toxicity. Since the liver is not an inert
organ like the limbs, hepatic toxicity will be dose-limiting. Indeed Fraker et al
demonstrated that the MTD of TNF in IHP is 1.5 mg, which is far less than the
dose used in ILP, again stressing that local (hepatic) instead of systemic toxicity
is dose limiting [40]. However, this does not implicate that the dose used in IHP
is thus less effective since De Wilt has demonstrated that lower doses of TNF in
ILP can be as affective as the high doses normally used [57].
The systemic toxicity of TNF is related to the systemic concentrations during and
after IHP. As stated, with a meticulous technique, systemic levels during IHP can
be nihil [79, 116]. On the other hand, as has been described in chapter 5 even if
leakage occurs, the effects might be limited. We demonstrated that in complicated
ILP, high leakage of TNF to the systemic circulation led to a ten- to more than
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hundredfold increased levels of TNF, IL-6 and IL-8 in comparison to patients
without leakage. The increase of the APPs was limited. Even when high leakage
occurs, this procedure should not lead to fatal complications. The most prominent
clinical toxicity was hypotension (grade III in 4 patients) which was easily
corrected and no pulmonary or renal toxicity was observed in any patient. It is our
experience that even in the rare event of significant leakage during a TNF-based
ILP postoperative toxicity is usually mild and can be easily managed by use of
fluid and in some case vasopressors [117].
After IHP, all studies describe a brief TNF peak almost immediately after the
restoration of the hepatic vessels. Most probably, the peak consists of remnant
TNF in the liver after washout that flushes out of the liver after release of clamps.
However, this peak varies between groups. In order to minimize the peak
concentration a thorough washout procedure has to be accomplished.
Furthermore, as has been demonstrated by Lang et al, with the use of colloids,
toxicity will be further minimized [92].
In chapter 4 we describe elevated levels of IL-6 and IL-8 after IHP in all patients.
Significantly higher IL-6 and IL-8 levels were shown in those patients with TNF
added to the melphalan in the perfusate [116]. In contrast, we could not
demonstrate significant differences in acute phase response (APR) in those
patients receiving melphalan and TNF compared with those receiving melphalan
only. Presumably, the IHP procedure itself already causes a maximal stimulation
of APR. Similar, Lans et al demonstrated that the addition of TNF to melphalan
in IHP resulted in significant higher systemic levels of both cytokines after
washout with associated changes in mean arterial blood pressure. Contrasting
with our results they also demonstrated greater regional toxicity, as reflected in
higher levels of serum bilirubin levels. However, these measurable differences
were transient and did not lead appear to be major clinical consequence [115].
Similarly to elevated IL-6 and IL-8 levels, we also demonstrated a significant
difference in soluble TNF receptor (sTNFR) level with higher levels in those
patients treated with melphalan and TNF (chapter 6). These receptors do not only
exist as cell surface membrane proteins but also as soluble proteins. Evidence
indicates that these soluble TNF receptors (sTNFRs) are derived by proteolytic
cleavage from the extracellular domain of the corresponding cell surface from a
variety of cells, mostly neutrophils, activated T-cells and monocytes. The
formation of sTNFRs in vitro is triggered by certain immune-stimulating agents
and is enhanced by a number of cytokines, including TNF itself [118, 119]. The
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exact function of sTNFRs is not known yet. The loss of cell surface TNF
receptors may lead to a temporary decrease in sensitivity of the cell to TNF.
Furthermore, by binding to the TNF molecule, soluble receptors could antagonize
TNF function. On the other hand, the same sTNFRs are proposed to augment
TNF activity by the formation of so called ‘slow-release’ complexes, depending
of the relative concentrations of sTNFRs and TNF [120]. TNF induced
hypotension appears to occur when the capacity of released sTNFRs to neutralize
circulating TNF levels is exceeded. Under conditions in which serum TNF levels
are considerably greater than 1.5 ng mL-1 after ILP, refractory hypotension with
associated hematological, hepatic and pulmonary toxicities can occur [121, 122].
In conclusion, IHP with TNF and melphalan leads to transient hepatotoxicity, as
reflected by elevated hepatic enzyme levels. Moreover, most of this local toxicity
seems to be procedure related. Nevertheless, since the liver is not an inert organ,
local MTD of TNF has been demonstrated to be much lower than the MTD in
ILP. Systemic toxicity is dependent of systemic drug levels during and after IHP
and can be minimized by a meticulous isolation technique and a thorough
washout preferably with colloids. Toxicity (clinical, secondary mediators)
encountered in this way will be mild and transient, even when TNF is used.
Future directions
The main disadvantages with the IHP concept in its present form are the
hepatotoxicity of the drug used (TNF), the magnitude of the procedure, and the
non-repeatability of the procedure. In an attempt to further decrease the toxicity
of the drug used, in particular TNF, less toxic TNF mutants have been developed,
aiming at enhancement of cytotoxicity whilst reducing systemic side effects.
Nakamoto et al described their experience with TNF-SAM2, a TNF mutant with a
chemotherapeutic index at least 5 times higher than the index of TNF. The MTD
of TNF-SAM2 administered systemically to a patient was at least twice that of
TNF. In addition, the detrimental side effects such as hypotension were milder
than with TNF [111]. In sarcoma bearing rats, De Wilt et al demonstrated that
ILP with TNF-SAM2 has similar antitumor activity in combination with
melphalan or doxorubicin as rhTNF [123]. In the event of unexpected massive
leakage during ILP it is obvious that the reduced toxicity of TNF-SAM2 can
make ILP a safer procedure. More important, this may lead to the application of
TNF-SAM2 in IHP, as has been described by Nakamoto et al in rats [111].
Systemic tumor progression is the site of initial failure in the majority of patients
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treated with IHP, which is a major drawback of being a locoregional treatment.
Wu et al investigated the possibility that IHP may result in significant
embolization of tumor cells as a potential cause of subsequent systemic tumor
progression. However, using PCR with primers for tyrosinase or
carcinoembryonic antigen with a sensitivity of detecting 1 –10 cells mL-1 of
blood, they were unable to detect any circulating tumor cells systemically or in
the perfusate samples in patients with ocular melanoma or colorectal cancer
during or immediately after IHP [124].
Next to an upgrade of response rates (70 % in IHP with TNF and melphalan) is
the prolongation of the duration of response. Bartlett et al reported the results of
IHP with TNF and melphalan or IHP with melphalan only followed by HAI with
FUDR and leucovorin in patients with unresectable colorectal hepatic metastases.
Twenty-four of 31 patients (77%) had a PR after IHP alone and 14 of 19 (74%)
after IHP followed by HAI. Interestingly, median duration of response was 8.5
months after IHP alone and 14.5 months after IHP and HAI. Median survival was
16 and 27 months, respectively. In their study, HAI appeared to prolong the
duration of response after IHP, and therefore this combined strategy could be a
manner to improve the present results of IHP [125].
Conclusions
In its present form, IHP is a technically demanding procedure and is not
repeatable. One way to overcome these two problems could be the development
of the balloon catheter technique in combination with IHP (IHHP). With this
technique, the procedure is simplified and can be repeated. To apply IHHP, an
inflow catheter is inserted into the proper hepatic artery via the right or left
femoral artery whilst a single or double balloon catheter is inserted at the site of
the femoral artery or vein respectively. Under X-ray the position of the double
balloon catheter is fixed at the upper side just above the hepatic vein and at the
lower side just above the renal vein and the position of the single balloon catheter
in the aorta is above the upper side of the double balloon catheter. The balloons
are inflated and the bloodstream is blocked. In this way, the lower part of the
body under the single balloon enforces the hypoxic condition because the blood
supply is stopped due to blockade of the aorta. Van IJken et al performed IHHP
with TNF, melphalan and MMC in pigs. They demonstrated that a leakage free
isolated IHHP can be performed with a small surgical procedure and is well
tolerated in pigs. Regional drug levels were 20 to 40 times higher than after
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systemic drug injection [126]. Because of the leakage free quality of this
procedure in combination with the efficacy of the washout procedure, TNF may
be used in this setting. After the promising results in pigs, our group started a
phase I-II study on IHHP with melphalan in patients with irresectable hepatic
metastases of colorectal origin [127]. In this study the technique has been further
simplified by replacing the operative placement of the hepatic artery catheter by a
percutaneously inserted and angiographically controlled positioned balloon
infusion catheter in the common hepatic artery. Percutaneously insertable
occlusion catheters for the aorta and caval vein are under development and would
be the next step towards a fully percutaneously managed IHHP. In our first six
patients we have had no serious adverse events. Moreover, antitumor activity has
been demonstrated at the dose level of 1 mg kg-1 melphalan. With further
experience with this technique, TNF may be introduced in order to further
increase antitumor activity.
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Table 1. Overview of literature concerning clinical IHP.
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Summary
In Chapter 1 a general introduction to this thesis is given. An overview is
presented regarding the different treatment options (systemic and locoregional
modalities) for patients with irresectable hepatic malignancy. An introduction to
the isolated perfusion model in general and the isolated hepatic perfusion (IHP) in
particular is described. A summary of the objectives of this thesis concludes this
chapter.
Chapter 2 describes the results of experimental IHP in pigs. This study was
undertaken to assess the feasibility of such an approach by analyzing hepatic and
systemic toxicity of IHP with TNF with and without melphalan in pigs. Ten
healthy pigs underwent IHP. After vascular isolation of the liver, inflow catheters
were placed in the hepatic artery and the portal vein, and an outflow catheter was
placed in the inferior vena cava. An extracorporeal veno-venous bypass was used
to shunt blood from the lower body and intestines to the heart. The liver was
perfused for 60 min with (1) 50 µg kg-1 TNF (n=5), (2) 50 µg kg-1 TNF plus 1 mg
kg-1 melphalan (n=3) or no drugs (n=2). The liver was washed with macrodex
before restoring vascular continuity. All but one pigs survived the procedure well.
A stable perfusion was achieved in all animals with median perfusate TNF levels
of 5.1 ±  0.78 x 106 pg mL-1 (± s.e.m.). Systemic leakage of TNF from the
perfusate was consistently < 0.02%. Following IHP, a transient elevation of
systemic TNF levels was observed in groups 1 and 2 with a median peak-level of
23 ± 3 x 103 pg mL-1 at 10 min after washout, which normalized within 6 h. No
significant systemic toxicity was observed. Mild transient hepatic toxicity was
seen to a similar extent in all animals, including controls. Therefore, IHP with
TNF with(out) melphalan in pigs is technically feasible, results in minimal
systemic drug exposure and causes minor transient disturbances of hepatic
biochemistry and histology.
After the experimental hepatic perfusions with melphalan and TNF, nine patients
with irresectable hepatic metastases of colorectal origin underwent this procedure.
In Chapter 3 the results of this phase I-II study are presented. The technique used
was the same as described in Chapter 2. An extracorporeal veno-venous bypass
was used to shunt blood from the lower body and intestines to the heart. IHP was
performed with inflow catheters in the hepatic artery and portal vein and an
outflow catheter in the caval vein. The liver was perfused for 60 min with 1 mg
kg-1 melphalan plus 0.4 mg TNF (n = 8) or 0.8 mg TNF (n = 1) with hyperthermia
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(> 41 °C). After the perfusion the liver was washed with macrodex before
vascular continuity was restored. During the perfusion, one patient demonstrated
leakage (cumulative leakage 20%) after which the perfusion was ended after 45
minutes. Three patients died in the perioperative period (one possibly drug
related). All patients demonstrated significant but transient hepatotoxicity.
Survival ranged from 6 to 26 months (median 10.3 months). All patients
demonstrated a tumor response (5/6 partial response, 1/6 stable disease) with a
median duration of 18 weeks. In contrast to our experimental program in pigs,
many problems were encountered in the phase I study. By using both the hepatic
artery and portal vein for IHP we encountered more toxicity than expected based
on data from the pig program, resulting in fatal coagulative disturbances in one
patient who received the second rhTNF dose. Furthermore, local control after one
IHP with TNF and melphalan proved to be only temporary.
In Chapter 4 the acute phase response during and after IHP with TNFα and
melphalan is shown. In this study, we have evaluated hepatotoxicity, secondary
cytokine production (interleukin-6, IL-6) and hepatic acute-phase response (APR)
in nine patients, mentioned in Chapter 3, who underwent IHP with TNF and
melphalan for irresectable colorectal liver metastases (IHPTM group). Since we
were interested in the effects of the addition of TNF to the perfusate, results were
compared with those obtained from three patients who underwent IHP with
melphalan only (ongoing Phase 2 study).
After the washout procedure, a TNF peak (169 ± 38 pg mL-1) was demonstrated
in the IHPTM group only. Both groups demonstrated peak levels of IL-6 in
perfusate as well as systemically. These were significantly higher in the IHPTM
group. Acute phase protein (APP) levels followed a similar pattern as has been
demonstrated after major surgery, with no significant differences between both
groups. The addition of TNF to the perfusate did not lead to a significant
difference in APP levels as well as time course between groups. Therefor, IHP
with TNF and melphalan is followed by a transient systemic peak of TNF directly
after liver washout. Secondary IL-6 induction was seen in the present study after
IHP with and without TNF, but IL-6 levels were highest when TNF was added.
This phenomenon could not be extrapolated to APP induction, which appeared
unaffected by the addition of TNF, presumably because the surgical procedure
itself already causes maximal stimulation of APP production.
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In Chapter 5 patients with significant leakage of TNF from the perfusion circuit
into the systemic compartment were investigated. Systemic toxicity in these
patients was studied in detail after an ILP with leakage to the systemic circulation
of 12-65%, and the clinical course of these patients was compared with patients
with uncomplicated (no leakage) ILP. Additionally, cytokine and acute phase
levels were measured in both groups. In four patients, grade III hypotension was
the most prominent clinical toxicity which was corrected with fluid
administration and if necessary dopamine. Hematological toxicity was mild and
no renal or pulmonary toxicity was observed. TNF levels up to 277 ng mL-1 could
be demonstrated in those patients with leakage. Also IL-6, IL-8 and maximum
sPLA2 levels were significantly higher in these patients. In contrast, CRP levels
were lower, suggestive for a higher expenditure of CRP in the removal of injured
cells. Concluding, ILP with high leakage of TNF to the systemic circulation is
accompanied by manageable systemic toxicity and an elevated cytokine and acute
phase protein response.
In Chapter 6 the effects of the addition of TNF to the perfusate in patients (as
described in Chapter 4) with irresectable hepatic colorectal metastases treated by
IHP with melphalan, on the soluble TNFα receptor (sTNFR) p55 and p75 levels
are investigated. After the wash-out procedure a TNFα peak was demonstrated in
the IHPTM group only. In patients with TNFα added to the perfusate, sTNFR-p55
levels were higher than sTNFR-p75 levels, whereas patients in the melphalan
alone group demonstrated the reverse. Furthermore, sTNFR-p55 concentrations
were significantly higher in the IHPTM group and remained so during the
following 2 weeks. In contrast, there were no significant differences in the
sTNFR-p75 levels between groups.
Recently we demonstrated, what we consider a key explanation for the potent
synergy between TNF and chemotherapy, an up to six-fold increased intratumoral
melphalan or doxorubicin concentration in rat sarcomas after ILP when high dose
TNF was co-administrated. Moreover in our pre-clinical ILP model we observed
drastic alterations in tumor microvasculature integrity. These findings led to the
hypothesis that TNF causes specific destruction of tumor endothelial cells and
thereby induces an increased permeability of tumor vasculature. IHP with
melphalan with or without TNF is currently performed in clinical trials in patients
with hepatic metastases. However, whether TNF contributes to the therapeutic
efficacy in IHP still remains unclear. In Chapter 7, we evaluated this efficacy in
IHP in an in vivo hepatic metastases model in rats. We studied three different
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tumors: colon carcinoma CC531, ROS-1 osteosarcoma and BN-175 soft tissue
sarcoma, which exhibit different degrees of vascularisation. IHP was performed
with melphalan with or without addition of TNF. IHP with melphalan alone
resulted in all tumor types in a decreased growth rate. However in the BN-175
tumor addition of TNF resulted in a strong synergistic effect. In the majority of
the BN-175 tumor bearing rats a complete response was achieved. In vitro
cytoxicity studies showed no sensitivity (CC531 and BN-175) or only minor
sensitivity (ROS-1) to TNF, ruling out a direct interaction of TNF with tumor
cells. The response rate in BN-175 tumor bearing rats when TNF was co-
administrated with melphalan was strongly correlated with drug accumulation in
tumor tissue, as only in these rats a 5-fold increased melphalan concentration was
observed. Secondly, immunohistochemical analysis of microvascular density
(MVD) of the tumor showed a significantly higher MVD for BN-175 tumor
compared to CC531 and ROS-1. These results indicate a direct relationship
between vascularity of the tumor and TNF-mediated effects. Assessment of the
tumor vasculature of liver metastases would be a way of establishing an
indication for the utility of TNF in this setting.
In Chapter 8 the results of the presented studies are described in a general
discussion and compared with the available literature.
Conclusions:
- Hyperthermic IHP with TNF and melphalan in pigs is technically feasible,
results in minimal systemic leakage of drugs and causes mild transient
hepatotoxicity.
- After IHP with TNF and melphalan in patients with irresectable hepatic
metastases a temporary tumor response can be demonstrated.
- A transient peak of TNF levels follows IHP with TNF and melphalan in patients
with irresectable hepatic metastases directly after liver wash-out.
- After IHP with melphalan with and without TNF, a secondary IL-6 induction
was seen. Highest IL-6 levels were demonstrated when TNF was added to the
perfusate.
- IHP with melphalan with and without TNF is followed by the induction of acute
phase proteins. This acute phase response appears to be independent of the
addition of TNF, presumably because the surgical procedure itself already causes
maximal stimulation of acute phase protein production.
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- During isolated limb perfusion with melphalan and TNF, high leakage of TNF
to the systemic circulation results in a clear acute phase and cytokine response
with manageable toxicity.
- In IHP with melphalan higher soluble TNF receptor p75 than p55 levels can be
demonstrated, whereas in those patients with TNF added to the melphalan in the
perfusate, a reverse pattern is seen.
- The addition of TNF to IHP with melphalan results in an increased intratumoral
melphalan concentration which is dependent of the tumor vascularity.
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Samenvatting
Hoofdstuk 1 vormt de algemene inleiding tot dit proefschrift. Er wordt een kort
overzicht gegeven van de verschillende behandelingen voor patienten met niet
verwijderbare kwaadaardige levertumoren (meestal uitzaaiingen van darmkanker)
in het algemeen en de geisoleerde lever perfusie (isolated hepatic perfusion, IHP)
in het bijzonder. Aangezien voor de meeste tumoren geldt dat hoe hoger de
concentratie van het werkzame antitumor middel is, hoe sterker het antitumor
effect zal zijn, is het van belang een zo hoog mogelijke dosis van het
desbetreffende middel toe te dienen. Echter: hoe hoger de toegdiende dosis, hoe
meer bijwerkingen de patient daarvan ondervindt. De oplossing van dit dilemma
zou kunnen liggen in de IHP. De geisoleerde lever perfusie is een techniek die het
mogelijk maakt dat alleen de lever (in het lichaam van de patient) wordt
aangesloten aan een hart-long-machiene. De lever wordt dan van zuurstofrijk
bloed voorzien via de hart-long machiene. Als men er zeker van is dat er geen
lekkage vanuit de hart-long-machiene naar de patient optreedt, kan een zeer hoge
dosis van het chemotherapeuticum worden toegediend aan het lever circuit,
zonder dat daarbij de patient dus wordt blootgesteld aan het middel.
Tevens wordt een bondig overzicht gegeven van de geschiedenis van Tumor
Necrosis Factor α  (TNF) alsmede de klinische toepassing van TNF.
Samenvattend blijkt het antitumor effect van TNF vooral te worden veroorzaakt
door de specifieke destructie van tumorbloedvaten. De klinische toepasbaarheid
van TNF wordt echter bemoeilijkt door de ernstige bijwerkingen die reeds
optreden bij doseringen (indien toegdiend aan de bloedbaan) die te laag zijn om
enig antitumor effect waar te nemen. Naast de effecten op de tumorbloedvaten
speelt TNF ook een belangrijke rol bij allerlei systemische processen in het
lichaam. Het hoofstuk besluit met een overzicht van de doelstellingen van dit
proefschrift gegeven.
In Hoofdstuk 2 worden de resultaten beschreven van experimentele IHP in het
varken. Het doel van deze studie was het evalueren van de toepasbaarheid van
deze techniek. Hierbij werd tevens gekeken naar algemene en lever specifieke
bijwerkingen van het gebruik van TNF en melphalan. Tien gezonde varkens
ondergingen IHP. Na het isoleren van alle vaten van en naar de lever werden zgn
in-flow catheters geplaatst in de aanvoerende leverslagader (a. hepatica) en de
aanvoerende ader van de ingewanden naar de lever (poortader, v. portae) en een
out-flow catheter in de naar de lever gaande onderste holle ader. Deze catheters
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werden vervolgens aangesloten op aan hart-long-machiene. Via een buiten het
lichaam verlopend pompsysteem (zgn veno-veneuze bypass, VVB) werd het
bloed afkomstig van de onderste lichaamshelft en de ingewanden, de lever
omzeilend, naar het hart gepompt. Aldus werd de lever na het starten van de
hartlongmachiene en de VVB als het ware buiten de lichaamscirculatie gehouden.
Vervolgens werd de lever gedurende 60 minuten geperfundeerd (1) met  50 µg
kg-1 TNF (n=5), (2) met 50 µg kg-1 TNF plus 1 mg kg-1 melphalan (n=3) of (3)
zonder toevoegingen (n=2). Na de 60 minuten werd de lever gespoeld met
macrodex (plasma), werden de catheters verwijderd, de bloedvaten hersteld en de
lever aldus weer “toegevoegd” aan de lichaamscirculatie.
Met uitzondering van 1 varken overleefden alle varkens de operatie. Lekkage van
TNF (en melphalan) naar het lichaam tijdens de IHP bedroeg < 0.02 %. Tien
minuten na IHP vertoonden de gemeten TNF concentraties een piek waarde in de
groepen (1) en (2), waarbij deze concentraties 6h na de IHP weer genormaliseerd
waren. Geen van de varkens vertoonde systemische bijwerkingen. Wel werden bij
alle varkens tijdelijke tekenen van geringe (reversibele) leverschade
waargenomen. Concluderend is IHP in het varken technisch haalbaar, resulteerd
in zeer geringe blootstelling aan de toegepaste middelen (in dit geval TNF en
melphalan) en leidt tot tijdelijke en reversibele geringe leverschade
Na de experimentele IHP met TNF en melphalan in het varken werd gestart met
een studie naar de toepasbaarheid van TNF in IHP met melphalan als behandeling
van patienten met niet verwijderbare kwaadaardige tumoren (meestal uitzaaiingen
van darmkanker) in de lever. In Hoofdstuk 3 wordt op deze studie nader ingegaan.
Negen patienten met niet verwijderbare uitzaaiingen van darmkanker in de lever
werden behandeld met IHP met melphalan en TNF. De IHP techniek was
dezelfde zoals beschreven in Hoofdstuk 2. De lever werd gedurende 60 min
geperfundeerd met 1 mg kg-1 melphalan en 0.4 mg (n=8) of 0.8 mg (n=1) TNF
waarbij het perfusaat werd verwarmd tot > 41 C. Na de IHP werd de lever, zoals
beschreven, gespoeld met macrodex waarna de vascularisatie weer werd hersteld.
Bij 1 patient werd de perfusie na 45 minuten voortijdig beeindigd in verband met
oncontroleerbare lekkage (totaal 20%). Drie patienten overleden in de post-
operatieve periode waarvan 1 patient mogelijk als gevolg van het toedienen van
TNF. Alle patienten vertoonden tijdelijke maar significante tekenen van
leverbeschadeging. De overleving van de patienten varieerde van 6 tot 26
maanden (mediaan 10.3 maanden). Bij alle evalueerbare patienten werd een
tumor respons waargenomen: bij 5 patienten werden de tumoren kleiner (partiele
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respons) en bij 1 patient vertoonde de levertumoren geen verdere groei (stabiele
ziekte). De duur van deze tumor respons varieerde van 17.5 tot 32.5 weken
(mediaan 18 weken). De bijwerkingen van de IHP met TNF en melphalan waren
ernstiger dan verwacht. Mogelijk dat het gebruik van zowel de a hepatica alsook
de v portae hierbij een rol heeft gespeeld. Daarnaast resulteert IHP met TNF en
melphalan slechts in een tijdelijke tumor respons.
De acute fase reactie (APR) kan omschreven worden als een algemene,
systemische reactie van het lichaam op trauma, ontstekingen, etc. Behalve koorts,
kenmerkt deze APR zich door de productie van zogenaamde acute fase eiwitten
(acute phase proteins, APPs) door de lever waardoor verhoogde concentraties van
deze eiwitten zullen worden aangetroffen in het bloed. Meting van de spiegels
van deze eiwitten, waaronder het C-reactieve proteine (CRP), maken het mogelijk
de duur en omvang van de APR te beschrijven. De laatste jaren is bovendien
duidelijk geworden dat cytokines (waaronder interleukin 6 (IL-6) maar ook TNF)
een centrale rol spelen bij het op gang brengen van de APR. In Hoofdstuk 4 wordt
de APR beschreven na IHP met TNF en melphalan. Hierbij werd bij de patienten
zoals beschreven in Hoofdstuk 3 de hepatotoxicititeit, de secundaire cytokine
productie en de APR van de lever geevalueerd. Omdat TNF zelf ook een rol
speelt bij de inductie van de APR werden de resultaten vergeleken met die zoals
waargenomen bij 3 vergelijkbare patienten die behandeld werden met IHP met
alleen melphalan (lopende studie). De techniek was zoals beschreven in
Hoofdstuk 2 en 3. Na de spoelprocedure werd alleen in de met TNF en melphalan
behandelde groep een piek in TNF concentraties waargenomen (gemiddeld 169 ±
38 pg mL-1). In beide groepen kon een piek van IL-6 concentraties worden
waargenomen maar deze maximale concentraties waren hoger in de groep waar
TNF werd toegegvoegd. De APP concentraties vertoonden eenzelfde patroon
gedurende onderzochte periode zoals ook gezien wordt na grote operaties, waarbij
geen verschillen konden worden aangetoond tussen beide groepen. Concluderend
werden in beide groepen verhoogde IL-6 concentraties (piekwaarden) aangetoond
al waren deze hoger in de groep waar TNF werd toegevoegd aan melphalan. Het
toevoegen van TNF had echter geen effect op de APP productie na IHP aangezien
vergelijkbare waarden en een vergelijkbaar beloop werd gezien in beide groepen.
Een verklaring hiervoor zou kunnen zijn dat de IHP, als chirurgische procedure,
al tot een maximale stimulatie van de APR leidt.
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De APR is ook het onderwerp van Hoofdstuk 5. Hier zijn patienten die een
geisoleerde extremiteits perfusie (isolated limb perfusion, ILP) met TNF en
melphalan ondergingen, gecompliceerd door significante lekkage van TNF naar
de systemische circulatie, onderwerp van de studie. De lekkage percentages
varieerden van 12 tot 65 %. De als gevolg hiervan opgetreden toxiciteit werd
vergeleken met het klinisch beloop bij een groep patienten die een
ongecompliceerde ILP ondergingen (dus zonder meetbare lekkage). Tevens werd
het beloop van de concentraties van cytokines en acute phase eiwitten vergeleken.
De meest prominente bijwerking was hypotensie (te lage bloeddruk), graad 3 bij 4
patienten. Deze hypotensie was echter vrij eenvoudig te corrigeren door extra
vocht toe te dienen en zo nodig bloeddrukverhogende middelen (dopamine).
Hematologische toxiciteit was mild en er waren geen nier of long gerelateerde
bijwerkingen. Hoge TNF concentraties tot 277 ng mL-1 werden aangetoond in de
patienten met lekkage. Ook de concentraties van de cytokines IL-6 en IL-8 waren
in deze groep significant hoger dan in de patienten zonder lekkage. De maximale
concentraties van het acute phase eiwit sPLA2 waren eveneens hoger in de
lekkage groep. De C-reactive protein (CRP), ook een acute phase eiwit,
concentraties waren echter lager in de lekkage groep, waarschijnlijk wijzend op
een hoger verbruik van CRP bij het opruimen van beschadigde cellen.
Concluderend gaat ILP met TNF en melphalan, gecompliceerd door lekkage van
TNF (en melphalan) naar de systemische circulatie, gepaard met behandelbare
bijwerkingen en een verhoogde cytokine en acute fase respons.
De effecten van TNF vinden plaats nadat TNF bindt aan twee receptoren die zich
in de celwand bevinden. Van beide receptoren komen ook zogenaamde oplosbare
varianten voor (sTNFR-p55 en sTNFR-p75), bestaande uit een afgesplitst deel
(dat deel van de receptor dat buiten de celwand uitsteekt) van de receptor. Als een
cel door wat voor reden dan ook veel TNF receptoren afsplitsts zou deze dus
ongevoeliger voor TNF kunnen worden. Daarnaast zijn de oplosbare receptoren
in staat TNF te binden waarbij ze het TNF kunnen verhinderen zich aan een
celgebonden receptor te binden. Aan de andere kant kunnen ze ook fungeren als
een soort buffer waardoor het TNF molekuul beschermd vervoerd kan worden
naar een ander deel van het lichaam om daar vervolgens werkzaam te kunnen
zijn. Bovendien komen grote hoeveelheden oplosbare TNF receptoren voor bij
verschillende, veelal chronische ziekten (rheumatoide arthritis, AIDS, TBC, etc).
In Hoofdstuk 6 worden de oplosbare TNF receptoren nader onderzocht in de
groep patrienten die een IHP met TNF en melphalan ondergingen. De gegevens
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werden weer vergeleken met de groep patienten waarbij alleen melphalan werd
toegevoegd aan het perfusaat. Na de spoelprocedure werd zoals eerder beschreven
een piek in TNF concentraties waargenomen in de IHPTM groep maar niet in de
IHPM groep. Beide sTNFR concentraties waren verhoogd bij alle patienten maar
er waren ook verschillen. Bij de groep met TNF toegevoegd aan de melphalan
waren de p55 concentraties hoger dan de p75 terwijl juist het omgekeerde gezien
werd in bij de IHPM groep. Daarnaast waren de p55 concentraties in de IHPTM
groep hoger dan die in de IHPM groep waarbij de concentraties na 2 weken nog
niet genormaliseerd waren. De p75 concentraties vertoonden echter geen
significante verschillen tussen beide groepen.
Kort geleden hebben wij aangetoond dat toevoeging van TNF aan IHP met
chemotherapie leidt tot een maximaal 6 voudige toename in intra-tumoral
concentraties van het gebruikte chemotherapeuticum. Verder werden drastische
veranderingen waargenomen in de tumor microvascularisatie in ons pre-klinische
ILP model in de rat. Deze waarnemingen kunnen waarschijnlijk een verklaring
vormen voor het antitumor effect van TNF in ILP. De vraag of deze
mechanismen ook gelden in IHP met TNF en melphalan staat centraal in
Hoofdtsuk 7. In dit hoofdstuk wordt experimentele IHP met TNF en melphalan in
een in vivo levermetastasen model in de rat beschreven. Hierbij werden drie
tumoren bestudeerd: CC531 colon carcinoom, ROS-1 osteosarcoom, en BN-175
weke delen sarcoom waarbij elk tumortype een specifieke mate van tumor
vascularisatie vertoont. IHP werd verricht met melphalan waaraan al dan niet
TNF werd toegevoegd. IHP met alleen melphalan resulteerde bij alle tumor
modellen in een afgenomen groeisnelheid van de tumoren. Echter in het BN-175
tumor model resulteerde de toevoeging van TNF tot een zeer sterk synergistisch
effect. Bij de meerderheid van de ratten met het BN-175 levermetastasen model
leidde dit to een complete respons (geen tumor meer aantoonbaar). In vitro
cytotoxiciteits studies (tumor cellen worden hierbij blootgesteld aan verschillende
concentraties chemotherapeuticum) lieten geen gevoeligheid (CC531 en ROS-1)
of alleen lichte gevoeligheid (BN-175) voor TNF zien, zodat een directe interactie
van TNF met tumor cellen onwaarschijnlijk is. De mate van respons in de BN-
175 groep indien TNF werd toegevoegd aan melphalan correleerde met de
concentratie van melphalan in het tumor weefsel, aangezien alleen in deze groep
ratten een 5-voudige toename van de melphalan concentratie in het tumor weefsel
werd aangetoond. Daarnaast toonde immunohistochemische analyse van de
microvasculaire dichtheid (MVD), oftewel de hoeveelheid bloedvaten in de
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tumor, aan dat de MDV in de BN-175 tumoren significant hoger was in
vergelijking met ROS-1 en CC531. Met andere woorden: de BN-175 tumoren
zijn dus het vaatrijkste van de drie onderzochte tumoren. De resultaten van deze
studie tonen een directe relatie tussen de mate van vascularisatie van een tumor en
de door TNF gemedieerde effecten aan. Het bepalen van de mate van
vascularisatie van een tumor kan een manier zijn om de effectiviteit van de
toevoeging van TNF aan een IHP met chemotherapeutica te voorspellen.
Hoofdstuk 8 vormt de discussie van dit proefschrift waarin tevens een overzicht
wordt gegeven van literatuur aangaande IHP.
Conclusies
- Hypertherme IHP met TNF en melphalan in het varken is een technisch
mogelijke ingreep en leidt tot minimale systemische lekkage en geringe, tijdelijke
leverbeschadeging.
- Hypertherme IHP met TNF en melphalan leidt bij patienten met niet
verwijderbare uitzaaiingen in de lever tot een tijdelijke tumor respons.
- Na hypertherme IHP met TNF en melphalan bij patienten met niet
verwijderbare uitzaaiingen in de lever wordt een tijdelijke TNF concentratie piek
waargenomen vlak na de spoel procedure van de lever.
- Na IHP met TNF en/of melphalan werd een tijdelijke IL-6 concentratie piek
waargenomen. Hierbij werden de hoogste concentraties gezien indien TNF was
toegevoegd aan het perfusaat.
- IHP met TNF en/of melphalan leidt tot de productie van acute fase eiwitten.
Deze acute fase reactie lijkt onafhankelijk te zijn van het toevoegen van TNF.
Mogelijk dat de IHP als chirurgische procedure al tot een maximale stimulatie
leidt.
- ILP met TNF en melphalan, gecompliceerd door hoge lekkage van TNF, leidt
tot een evidente acute fase en cytokine respons met behandelbare bijwerkingen;
- Na IHP met melphalan leidt tot hogere sTNFR-p75 concentraties dan sTNF-p55
concentraties, terwijl na toevoeging van TNF aan het perfusaat een omgekeerd
patroon wordt gezien.
- Het toevoegen van TNF aan melphalan tijdens IHP resulteert in een toegenomen
intratumorale melphalan concentratie en is afhankelijk van de mate van
vascularisatie van de tumor.
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